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Thesis Abstract 
Lamins are components of the nuclear lamina and are divided in A and B-types, 
which interact with proteins of the inner nuclear membrane like emerin. 
Mutations in emerin (X-linked) and A-type lamins (Autosomal Dominant) has 
been linked to the Emery-Dreifuss Muscular Dystrophy (EDMD), which conduced 
to the hypothesis that these two proteins might interact in the nucleus. I 
examined the interaction between A and B-type lamins with emerin using a 
panel of deletion mutants of lamin Bl and full-length lamins A, C and Bl in a 
yeast two-hybrid assay, where emerin interacted with all lamins and the 
preferred region of interaction was the globular tail domain of lamin Bl . Ectopic 
expression of tagged proteins in human dermal fibroblasts confirmed that 
emerin remains attached to the inner nuclear envelope through its association 
with lamin B l , as aggregation of tagged A-type lamins did not miss localize 
endogenous emerin or lamin B l . In addition, methanol-acetone fixation showed 
higher number of cells presenting characteristic morphological abnormalities 
called "honeycombs". A-type lamins and their associated protein emerin co-
localized in these structures. Lamin Bl depletion from the honeycombs was 
accompanied by depletion of nuclear pore complexes. In the honeycombs, A-
type lamins segregated from the B-type lamins, forming homo-filaments. 
On the other hand, AD-EDMD cell lines showed a characteristic pattern as a high 
sub-population of cells presented nesprin 1 (amino-terminal) in stress fibres co-
localizing with a-S-Actin fibres, which was enhanced by growth inhibition 
induced by serum starvation. Re-stimulation of fibroblasts by normal serum 
concentrations increased the appearance of honeycombs by up to 2.5 fold in the 
AD-EDMD cell, lines. Late passage cultures of AD-EDMD entered a senescence 
state reminiscent of the induced quiescence state induced by serum starvation. 
Finally, differential allelic expression was evidenced using a specific set of 
ARMS-primers in the cell lines studied, indicative of transcript imbalance, and 
bioinformatics analysis demonstrated the presence of SNPs in the coding region 
of the wild type LMNA gene. The results of these study confirm that lamins 
interact with emerin and suggest that the interacting region is the tail domain of 
lamins; honeycomb structures might have a biological meaning in patient cells; 
other proteins might be involved in EDMD, like nesprins; and heterozygosis is 
presented with transcript imbalance, which might have a negative impact in the 
correct assembly of the nuclear lamina. 
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1 Chapter One: Introduction. 
1.1 Eukaryotic nuclei 
In Nature, two major groups form life's kingdom: the prokaryotes, 
comprising exclusively unicellular organisms, and the eukaryotes, which 
include uni and multicellular organisms, from fungi to plants. In the animal 
kingdom, eukaryotes include two major groups: protozoan and metazoan. 
Evolution of the latter involves cellular entities that are more specialized. 
Prokaryotes and Eukaryotes are very similar in that they contain the basic 
components that characterize self-sufficient living units. However, there are 
few major differences between them, mainly based on the presence or not 
of an organized nucleus. Eukaryotes contain membrane-bound nuclei and 
other organelles, while prokaryotes lack this level of organization. 
The nucleus, being one of the largest sub-cellular compartments, varies in 
diameter from 10 to 20 micrometers under normal conditions, but can be 
larger in disease. Eukaryotic nuclei evolved as a very specialized organelle 
with a high level of compartmentalization. Up to 16 different entities have 
been described inside the eukaryotic nuclei so far including: Nucleoli 
(Carmo-Fonseca et ai., 2000), SAM68/SLM body (Chen et al., 1999), 
Perinucleolar Compartment (PNC) (Ghetti et ai., 1992), OPT Domain 
(Grande et ai., 1997; Spector, 2001), Cleavage Body (Spector, 2001), Cajal 
Body (Gail, 2000), Gem (Hebert et al., 2001), Nuclear Diffuse Body 
(Sutherland et al., 2001a), Nuclear Speckles (Monneron and Bernhard, 
1969), Promyelocitic Leukaemia Body (PML) (Maul et al., 2000), Polycomb 
Body (PcG Body) (Alkema et al., 1997), RNA I I Transcription Sites (Iborra 
et al. , 1996), Chromatin, Heterochromatin, Nuclear Pore Complexes (NPC) 
(Aaronson and Blobel, 1975), and the Nuclear Lamina (Gerace et a!.. 
l978)(Figure 1.1). The growing number of proteins the nucleus contains 
evidences its complexity, as visual gene trap screening revealed more than 
100 new nuclear proteins (Sutherland et al., 2001b). 
The plant nuclear envelope (NE) is very similar to its animal equivalent in 
that it completely dissolves and reassembles during open mitosis, but 
contains obvious differences as for example, the lack of centrosomes 
(Stoppin et al., 1994) and the absence, so far, of lamin polypeptides (Irons 
etal . , 2003). 
1.2 The Nuclear Envelope 
A double membrane forming the nuclear envelope, about 30 nm wide, 
surrounds the cell nucleus (Figure 1.2). This selectively allows molecules to 
enter and leave the nucleus, and physically separates chemical reactions 
taking place in the cytoplasm from reactions happening within the nucleus. 
The inner and outer membranes fuse at regular spaces, forming the nuclear 
pores. A luminal space separates the two membranes, which is continuous 
to the endoplasmic reticulum (ER) and can contain newly synthesized 
proteins as in the ER. I t has been suggested that the luminal space provides 
the aqueous environment that allows signal transduction in both directions: 
to and from the cytoplasm (Sullivan et al., 1993). A growing number of 
nuclear membrane proteins are been discovered as new proteomics 
approaches allow the study of complex protein mixtures in sub-cellular 
organelles (Dreger et al., 2001). 
Higher eukaryotes exhibit the most intriguing characteristic of the NE: its 
ability to disassemble and re-assemble during open mitosis, mediated by a 
wide variety of membrane components and their interaction with other 
binding partners. Proteins of the nuclear envelope play important roles in 
deve lopment and disease, by nnediating a var iety of fundannental processes 
including DNA repl icat ion, gene expression and si lencing, chromat in 
organizat ion cell d iv is ion, apoptosis, sperm nuclear remodel l ing, cell fate 
de te rm ina t ion , nuclear migrat ion and cell polar i ty (Wolfner and Wilson, 
2001). 
1.3 Outer Nuclear Membrane 
Is the outer nuclear membrane (ONM) an extension of the ER, or vice versa? 
Answer 1 would be, yes, it is; the interphase outer envelope is cont inuous 
w i th the rough ER, so it contains r ibosomes. Answer 2 would be, yes, it is; 
the interphase ER comprises a cont inuous network of cisternae and tubular 
membranes extending f r om the ONM into the cytoplasm. During mitosis, 
the ER undergoes disassembly to vesicles and membrane tubules/cisternaes 
to al low the par t i t ion ing of ER membranes to daughter cells (Warren and 
Wickner, 1996). In higher eukaryotes, the NE breaks down during mitot ic 
prophase into a fo rm tha t cannot be dist inguished f rom disassembled 
e lements of the per ipheral ER (Porter and Machado, 1960; Zeligs and 
Wollman, 1979). Associat ion of membrane vesicles and cisternaes during 
late anaphase reassembles the ER and the NE (Porter and Machado, 1960; 
Robbins and Gonatas, 1964). Then NE proteins dif fuse f rom the ER t rough 
the ONM unti l they reach the i r anchor ing sites at the INM by means of their 
in teract ion wi th the lamina and /o r o ther nucleoplasmic proteins (Yang et al. , 
1997). A special subset of proteins can be located specifically at the ONM, 
including a new giant protein connect ing the nucleus with the actin 
cytoskeleton called NUANCE (Zhen et a l . , 2002). 
1.4 Inner Nuclear Membrane 
Proteins located at the inner nuclear membrane ( INM) belong predominant ly 
to the t ype I I integral membrane protein fami ly , and they contain a general 
s t ruc ture wi th a long N-terminal nucleoplasmic domain and a 
t ransmembrane domain (TM) close to the C-terminus (Hartmann et al . , 
1989). Prote in-prote in interact ions between members of the INM and lamins, 
chromat in and o ther nucleoplasmic proteins show the dynamic state of this 
s t ruc ture . The discovery tha t human diseases are associated with mutat ions 
in some type I I integral membrane proteins and /o r interact ing partners has 
brought more a t ten t ion into the biological role of th is fami ly of proteins. 
Dur ing in terphase, INM proteins are embedded into the lipid bi- layer 
t h rough the i r TM doma in , exposing thei r C- terminus to the luminal space, 
and the long N- terminus to the nucleoplasm. During mitosis, when the NE is 
d isassembled, integral membrane proteins of the INM are dispersed 
th roughou t all ER membranes and the NE loses its ident i ty as an ER sub-
compar tmen t . At late anaphase, when membrane vesicles re-organize 
around the surface of the chromosomes, INM proteins diffuse through a 
funct ional ly cont inuous ER to thei r localization into the INM (Yang et al . , 
1997). Other authors consider INM proteins contain specific target ing and 
retent ion signals, fo l lowing a so-cal led d i f fus ion-retent ion model (Furukawa 
et a l . , 1995; Soullam and Worman, 1993; Tsuchiya et al . , 1999). This model 
claims INM proteins di f fuse freely in the interconnected membranes of the 
rough ER and the NE af ter synthesis, move along the lateral channels of the 
Nuclear Pore Complex (NPC) and arr ive at the INM. Binding to thei r 
in teract ing par tners like lamins and /o r chromat in , they achieve thei r 
funct ional local izat ion. Evidence for this model comes f rom chimerical 
studies where putat ive target ing signals in the Lamin B Receptor (LBR) 
mediated ta rget ing of non-nuclear membrane proteins to the INM 
(Ellenberg et a l . , 1997; SouMam and Worman, 1993). On the other hand, 
m o v e m e n t th rough the lateral channels of the NPC is l imited to the protein 
size of ~ 6 7 kDa (Soullam and Worman, 1993). In agreement wi th this fact , 
most INM proteins have a mass less than 60 kDa, wi th the exception of 
Nesprin 1 . 
In p lants, t ransfect ion of N-terminal domains of INM proteins f rom 
mammal ian cel ls, like LBR, fused to Green Fluorescent Protein (GFP), can 
localize t h e m exclusively at the INM ( I rons et al . , 2003). LBR nucleoplasmic 
domain (contains a nuclear localization signal (NLS), the lamin-binding and 
chromat in -b ind ing domains , and ends in the f i rst of eight t ransmembrane 
domains) have shown previously to be suff ic ient for INM target ing in 
mammal ian cells (Ellenberg et al . , 1997; Soullam and Worman, 1993). The 
f inding in plants suggest tha t a target ing and/or retaining mechanism of 
t r ansmembrane proteins is conserved in animals and plants, as proposed by 
the cur rent model for ta rget ing INM proteins (Ellenberg et al . , 1997). 
1.5 Nuclear Pore Complex 
The Nuclear Pore Complex (NPC) has a molecular mass of ~125 mDa in 
ver tebra tes and contains about 50 or more proteins tha t are di f ferent 
(Lyman and Gerace, 2001; Nakielny and Dreyfuss, 1999). NPC spans the 
dual membrane of the NE and acts as a gateway for macromolecular t raf f ic 
between the cytoplasm and the nucleus. The basic f ramework of NPC 
consists of a central core wi th a r ing-spoke st ructure exhibi t ing 8-fold radial 
s y m m e t r y . From th is central r ing , 50 - 100 nm fibres extend into the 
nucleoplasm and the cy top lasm. The NPC is in tu rn anchored in the NE by 
the interact ion of N u p l 5 3 w i th B-type lamins at the nuclear lamina (Smythe 
et a l . , 2000) . A number of proteins (nucleopor ins, Nups) have been localized 
to discrete regions of the NPC and are of ten used as markers for this 
compar tmen t , e.g. N u p l 5 3 (Stoffler et al . , 1999). Approx imate ly half of the 
Nups contain a phenyla lanine-glyc ine repeat mot i f (FG repeat ) , which may 
be diagnost ic for proteins playing a role in nuclear t ranspor t . Protein cargo 
ident i f ies i tself to the nuclei-cytoplasmic t ranspor t machinery by NLSs or 
nuclear expor t signals (NESs), which can be prote in , RNA or consist of a 
composi te of both (Nakielny and Dreyfuss, 1999). A number of nuclear 
t ranspor t receptors exist tha t recognize these signals, variously called 
karyopher ins . Protein Transpor t Associated Complexes (PTACs), import ins 
or t ranspor t ins . These receptors are general ly large acidic proteins that 
share the abi l i ty to bind components of the NPC and contain both an N-
te rmina l RanGTP-binding domain and a C-terminal cargo-binding domain. 
Cargo (p ro te in , RNA or both) can bind its cognate nuclear t ranspor t receptor 
direct ly th rough NLS and NES signals or via adaptor proteins. In part icular, 
prote ins wi th s imple or bipart i te NLSs are impor ted via the p- import in 
receptor indirect ly by association w i th the a- impor t in fami ly of adaptors. 
The progress made in ident i fy ing yeast and mammal ian nucleoporins by 
proteomic approaches (Allen et al . , 2001; Cronshaw et al . , 2002) is 
current ly used to search putat ive homologues in plants, especially in 
Arabidopsis thal iana genome, where some candidates are suggested 
(Altschul et a l . , 1997; Model et a l . , 2002; Schwacke et al . , 2003). 
1.6 Intermediate Filaments 
The cytoskeleton of all metazoan cells contains three major f i laments 
sys tems: 1) microtubules (MTs) , wi th a d iameter of 25 n m , 2) intermediate 
f i laments ( IFs) , w i th a d iameter of 10-12 n m , and 3) actin microf i laments 
(MFs) w i th a d iameter of 7-10 n m . Apart f rom the physical appearance of 
the th ree d i f ferent f i lament sys tems, structural features dist inguishing MFs 
and MTs f rom IFs in tha t the bui lding blocks of the f i rst two are globular 
prote ins, whi le the th i rd ones are assembled f rom elongated and th in 
f i laments . On the o ther hand, MFs and MTs fo rm polar f ibres; IFs have no 
polar i ty , as individual d imers are or ientated in an anti-paral lel fashion 
(Strelkov et a l . , 2003) . The integrated network fo rmed by the three f i lament 
systems is responsible for the mechanical integr i ty of the cel l , and it is 
involved in crit ical cel lular funct ions ranging f rom the cell membrane to the 
nucleoplasm (Goldman et a l . , 1996). Therefore, once af fected, it results in 
several types of d isorders. 
In te rmed ia te f i laments are di f ferent ia l ly expressed in most t issues, and are 
expressed f rom at least 65 d i f ferent genes in humans (Hesse et al . , 2001). 
All IFs share a character ist ic t r ipar t i te s t ruc ture : Head, Coiled-coil and tail 
domain (Fuchs and Weber, 1994), and are grouped in 6 categories 
according to the i r p r imary sequence and structural features (Table 1.1). 
In te rmed ia te Fi laments can assemble into homodimers or heterodimers wi th 
each o ther , even those belonging to d i f ferent sequence homology types. 
According to these character ist ics, there are three assembly groups: 
Kerat ins fo rm assembly Group 1 , fo rming obl igatory heterodimers. Group 2 
is composed by IFs type I I I and IV, and the last one. Group 3, includes the 
lamins, which are only capable of assembl ing into homodimers due to their 
long coil B f ragment . 
Type Protein Tissue KDa Reference 
Acidic Keratins K9 - K20 Epithelia 40-64 (Fuchs and Green, 
Hal 1-4 Trichocytes 42-54 (Fuchs and Green, 
Basic Keratins K1-K8 Epithelia 52-68 (Fuchs and Green, 
Hb 1-4 Trichocytes 58-64 (Fuchs and Green, 
Vimentin Messenchyme 55 (Ramaekers et al . . 
Glial Fibrillary Acidic Prot. Astroglia 51 (Osborn et al . , 1981) 
Desmin Muscle 53 (Gard and Lazarides, 
Peripherin Neuronal 58 (Portier et a l . , 1983) 
Syncoilin Muscle 54 (Newey et al . , 2001) 
Neurofilament Heavy Neurons 220 (Hoffman and Lasek, 
Neurofilament Medium Neurons 110 (Hoffman and Lasek, 
Neurofilament Light Neurons 68 (Hoffman and Lasek, 
a-internexin Neurons 66 (Pachter and Liem, 
A and B-type lamins Nucleated ceils 40-69 (Benavente et al . . 
Nestin Neuro-Epithelia 200 (Niki et a l . , 1999) 
Filensin/CP49 Eye lens 95 (Merdes et al . , 1991) 
Phakinin Eye lens 47 (Merdes et al . , 1993) 
Synemin Avian Muscle 230 (Lazarides, 1982) 
Paranemin Muscle 280 (Lazarides, 1982) 
Septins Nucleated cells 50-60 (Walikonis et al . , 2000) 
Minor lens IFPs Lens 50-60 (Ramaekers et al . . 
Table 1.1 
1.6.1 S t r u c t u r e 
All IFs exhib i t a character ist ic s t ructure tha t includes a highly a-helical 
central doma in , f lanked by the non-hel ical head towards the N-terminus and 
g lobular tai l domain at the C-terminus o f the protein (Fuchs, 1994). 
The central rod domain displays a seven-residue periodicity (abcdefg)n in 
the d is t r ibut ion of apolar residues. Within these repeat posit ions, a and d 
are preferent ia l ly small hydrophobic residues like Leu, He, Met or Va l ; 
posit ions e and g are usually charged, and polar residues are located 
e lsewhere (McLachlan, 1978). There is a charge periodicity of approximately 
9.5 residue interval in th is reg ion, which might contr ibute to the lateral 
electrostat ic interact ions between coiled coils, thereby helping in the 
fo rmat ion of h iger -order o l igomers (Stuurman et a l . , 1998). This heptad 
organizat ion is character ist ic of coiled-coil s t ructures, where two or more a-
helices tw is t on each other in paral le l , unstaggered fashion with the 
hydrophobic chains of one a-hel ice interact ing wi th those of the other one, 
and the hydrophi l ic residues exposed to the aqueous env i ronment , forming 
a super-hel ix (Burkhard P, 2001). The rod domain is in terrupted in several 
places by var iable non-hel ical l inkers, not containing proline in lamins but 
conserved between t h e m . Linkers are responsible for dividing the central 
domain in consecut ive shor t a-helical f ragments : l A and I B ( forming coil 1 ) , 
and 2A and 2B ( fo rming coil 2) (Stuurman et al . , 1998). The length of the 
a-hel ical segments is conserved in ver tebrate cytoplasmic IFs, but nuclear 
lamins rod domain di f fers f rom cytoplasmic IFs by six addit ional heptads 
(Parry et a l . , 1986). A 26 amino acids long segment at the N-terminal end 
and 32 residues s i tuated at the very end of the coil 2B of the rod domain 
play a crit ical role for the association of IFs into higher order complexes, 
where muta t ions appear to be related to human disorders (Coulombe, 
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1993). Another highly conserved feature, st ructural ly and posit ional ly, in 
the rod domain among IFs is a discont inui ty in the heptad repeat pattern 
wi th in coil 2B, called s tu t te r , due to an insert ion of four amino acids 
(Strelkov SV et a l . , 2002) . 
The head domain of IFs is mainly composed of basic residues, and analysis 
of its p r imary sequence shows a highly f lexible conformat ion with low 
content of secondary s t ruc ture. A l though there is not enough 
crystal lographic data to make fur ther analysis as in the rod domain , 
funct ional studies have demonst ra ted its essential role in a te t ramer state, 
as mu tan t v iment ins w i th delet ions in the head domain only fo rm dimers 
(Herrmann, 1996). I t is l ikely tha t the head domain interacts with specific 
sites on the coi led-coi l rod domain and the tail domain , considering the 
basic nature of the head and the acidic propert ies of the others, promot ing 
lateral associat ion of te t ramer ic protof i laments into octameric protof ibr i ls, 
and u l t imate ly into 10 nm f i laments . 
The lack of crystal lographic data of the tai l domain of IFs forced the use of 
funct ional approaches to unravel its role. In lamins, tail less lamin B2 
associated into long f i laments resembl ing the head-to- ta i l f i laments formed 
by fu l l - length lamins. This ta i l -domain delet ion mutan t did not inhibit 
f i lament fo rmat ion but produced increase in f i lament w id th . Not unti l 
recent ly , the crystal s t ruc ture of the tai l domain of IFs was part ial ly 
revealed. A region of the tai l domain of lamins (amino acids 436 - 552 of 
Lamin A) fo rms a compact , g lobular , wel l -def ined domain composed entirely 
of p-st rands, where two large p-sheets fo rm a p-sandwich, an Ig- l ike 
s t ruc ture (Dhe-Paganon et a l . , 2002) , which might control lateral assembly 
of pro to f i laments and mediate IF network format ion (Stuurman et al . , 1998). 
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Apar t f r om size, another feature tha t d i f ferent iates the tai l domain of IFs is 
the unique presence of a NLS in lamins, which contains an invariant lysine, 
fo l lowed by th ree o ther basic residues ( lysine or arg in ine) , a hydrophobic 
residue ( Isoleucine or Leucine), and an acidic residue (Aspartic or Glutamic) 
(Stuurman et a l . , 1998). 
1.6.2 Intermediate Filaments Associated Proteins 
I n te rmed ia te Fi lament Associated Proteins (IFAPs) are a growing group of 
proteins which main ly funct ion to cross-l ink intermediate f i laments to other 
cytoskeletal f i lament sys tems, s t ructur ing the cytoplasm by forming f lexible, 
reversible arrays tha t provide essential resistance to environmental stress 
(Houseweart and Cleveland, 1998). They are grouped in famil ies of proteins 
w i th specific binding partners and most of t hem are at least bivalent wi th 
regards the type of cytoskeletal e lements they interact w i th . Keratin-specif ic 
bundl ing IFAP include Filaggrin and Tr ichohyal in , which are highly charged 
(Lee et a l . , 1993; Mack et al . , 1993). Cytol inkers, the Plakins, are large 
mu l t i -domain proteins and include Plectin, Desmoplakin and Bullous 
Pemphigoid Ant igen 1 (BPAGl ) . Act in-binding proteins include 
Fimbrin/Plast in and Calponin, and a four th group is fo rmed by ap-crystal ins. 
Heat Shock Protein 27 (HSP27) and 14-3-3 proteins (Coulombe et al . , 2000), 
which are specific for d i f ferent in termediate f i laments. Mutations in the gene 
for Plectin are the cause for a kind of muscular dystrophy wi th 
Epidermolysis Bul losa, due to the fai lure to l ink IF cytoskeleton wi th the 
plasma membrane (McLean et a l . , 1996). 
1.6.3 Cytoplasmic Intermediate Filaments and disease 
Disorders related to IFs have been described since the 1 9 * century, but it 
was not unt i l 1991 when mutat ions in the kerat ins were f i rst l inked to 
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Epidermolysis Bullosa Simplex (Ryynanen et al . , 1991). Since then , several 
inher i ted muta t ions affect ing the pr imary s t ructure of cytoplasmic IF 
proteins have been repor ted , and found responsible for a vast number of 
rare, usual ly dominan t inher i ted diseases. The major i ty of the mutat ions are 
missense var iat ions affect ing highly conserved residues in the head and rod 
domains of the f i lament ( Irvine and McLean, 1999). A hot-spot mutat ion 
has been ident i f ied in type I kerat in sequences affect ing the beginning of a-
helix l A , co-re lated wi th a high sever i ty of the disease (Lane et al . , 1992; 
Ma et a l . , 2001) . In mi lder fo rms , mutat ions in th is group of keratins are 
located outside the highly conserved reg ion, do not fo rm hot-spots, and the 
s t ruc ture of the f i laments appear to be normal (McLean and Lane, 1995). 
Other IF proteins have shown structural impa i rment in several human 
diseases. Many card iomyopath ies are due to myosin defects, but some 
others wi th no myosin defects show ul t ra-st ructura l abnormal i t ies in desmin 
f i laments (Pell lssier et al . , 1989). Desmin mutat ions affect ing conserved 
residues cause a fo rm of skeletal myopathy tha t f requent ly has cardiac 
abnormal i t ies associated wi th it. A l though Desmin-nul l -mice develop 
normal ly , it is only a f ter bir th when degenerat ive muscular processes begin, 
leading to aberrant muscle f ibres and cardiovascular lesions (Li et al . , 1997). 
Simi lar ly , massive accumulat ion of neurof i laments in cell bodies and 
prox imal axons in neurons are suff icient to t r igger a neurodegenerat ive 
disorder as is the case in some motor -neuron diseases (Xu et al . , 1993). A 
number of muta t ions in Glial Fibri l lary Acidic Protein (GFAP) have been 
found to be associated wi th Alexander disease, a severe-fatal 
neurodegenerat ive d isorder (Brenner et al . , 2001). Mutat ions appear in 
highly conserved regions of the f i lament , a l though there is no l inkage 
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between muta t ions and sever i ty of the disease as in kerat ins. GFAP null 
mice develop and grow normal ly , but some late-onset abnormal i t ies have 
been descr ibed (Gomi et a l . , 1995; Liedtke et al . , 1996). 
To date no human disease has been l inked to mutat ions in v iment in . 
V iment in -nu l l mice developed and grew normal ly , a l though later produced 
deficiencies in vascular ton ing , mechanotransduct ion and wound healing 
(Eckes et a l . , 2000; Henrion et a l . , 1997; Terzi et al . , 1997). In other cases, 
v iment in over-express ion produced t issue specific a l terat ions, as occurs 
when v iment in is ectopical ly expressed in t ransgenic mice, producing 
cataract (Capetanaki et a l . , 1989). 
A group of human genetic disorders is associated wi th defects in 
neurof i laments (NF) , like Amyot roph ic Lateral Sclerosis (ALS), Infant i le 
Spinal Muscular A t rophy and some other fo rms of Charcot-Marie-Tooth 
Neuropathy. Mutat ions occurr ing in the head and rod domains of the protein 
appear to be responsible for the disrupt ion of self-assembly of human 
neurof i lament l ight (NF-L) (Perez-Olle et al . , 2002). Mutat ions in the 
neurof i lament heavy (NF-H) have been found in ALS (Al-Chalabi et al . , 
1999). NF-L and NF-H nul l -mice have shown reduced axonal d iameter 
(Jacomy et a l . , 1999; Rao et a l . , 1998). 
An emerg ing group of human genet ic diseases involving intermediate 
f i lament proteins is the laminopath ies, where mutat ions in the LMNA gene 
can be associated w i th 6 clearly d i f ferent phenotypes up to date. A more 
detai led descr ipt ion is given in section 1.10. 
1.7 The Nuclear Lamina 
The lamina is a f la t tened , d iscont inuous, open cage-l ike st ructure (Capco et 
a l . , 1982; Hutchison, 2002; Paddy et a!., 1990) subjacent to the inner 
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nuclear membrane and is composed of a wel l -organized meshwork of 
f i laments called lamins (Aebi et al . , 1986). This highly physically and 
chemical ly resistant association of polymers interacts directly (B- type 
lamins) or indi rect ly (A and B-type lamins) wi th the INM, and contr ibutes to 
mainta in the shape and size of the metazoan nucleus (Schirmer et al . , 
2001) . I t s th ickness var ies at d i f ferent areas (Belmont et al . , 1993) and 
lamins can be found fo rming intranuclear foci dur ing G l (Bridger et al . , 
1993; Goldman et a l . , 1992) , reinforcing the idea of mult ip le lamina 
complexes and its funct ional versat i l i ty . 
Lamins are members of the type V intermediate f i lament fami ly (Fisher et 
a l . , 1986; McKeon et a l . , 1986; Parry et al . , 1986). Phylogenetic analysis of 
lamins and cytoplasmic IF sequences f rom invertebrates suggest tha t the 
nuclear lamins were the progeni tor IF and cytoplasmic polypeptides arose 
th rough gene dupl icat ion of the lamin sequence (Riemer et al . , 2000; Stick, 
1992). The rod domain (~ 360 amino acids) of the lamins consists of a 
heptad repeat t ha t is character ist ic of proteins forming a-helices and 
contains six heptads tha t are absent f rom the cytoplasmic IF. Lamins and 
cytoplasmic IF have l inker regions wi th no heptads, but unlike the lat ter 
ones, l inker sequences of lamins do not have prol ine residues, giving a 
cont inuous rod domain (Parry et a l . , 1986; Parry and Steinert, 1999). 
Functional studies demonst ra ted tha t the rod domain drives the 
d imer izat ion of lamin protein chains and higher order interact ions between 
d imers (Stuurman et a l . , 1998). 
A non-hel ical (head) N-terminal (30 - 40 amino acids) and a globular ( ta i l ) 
C- terminal (170 - 265 amino acids) domains f lank the lamin's central rod 
doma in . Here reside the main di f ferences between the lamins and their 
14 
cytoplasmic relat ives. Both , the head and tai l domains in lamins contain 
specific phosphory lat ion si tes, which play a key role in the dynamic 
regulat ion of these proteins dur ing the cell cycle. Mitotic Cell Division Cycle 
2 kinase (CDC2) phosphory lates residues in the head domain which mediate 
lamina assembly-d iassembly (Haas and Jost, 1993; Peter et al . , 1990; 
Thompson et a l . , 1997) , whi le Protein kinase C-a (PKC-a) phosphorylates 
residues near the NLS and regulates its nuclear impor t (Hennekes et al . , 
1993; Shimizu et a l . , 1998). PKC-5 is required to hyperphosphorylate lamins 
dur ing apoptot ic breakdown to faci l i tate access of Caspase 6 to the nuclear 
lamina (Cross et a l . , 2000). Lamins C-terminus domain mediates target ing 
to the nucleus th rough the NLS (Frangioni and Neel, 1993), and as the rod 
domain (Glass et a l . , 1993), contains chromat in-b ind ing sites (Taniura et al . , 
1995) . The very end of the C-terminal region of lamins contains a CaaX 
mot i f tha t undergoes post- t ranslat ional modif icat ions by iso-prenylat ion, 
farnesylat ion and /o r proteol i t ic cleavage (Holtz et al . , 1989; Krohne et al . , 
1989) . 
1.7.1 B-type Lamins 
B-type lamins are di f ferent ia l ly expressed in human tissues (Broers et al . , 
1997) and RNA inter ference of lamin B l has shown to produce cell death 
(Harborth et a l . , 2001) . Taken together , these exper imental evidences 
suggest a re levant role of B-type lamins dur ing embryogenesis and 
deve lopment . There are three B-type lamins in ver tebrates: B l , B2 and B3. 
Lamin B l is encoded by the LMNBl gene (Hoger et al . , 1988), s i tuated on 
the chromosome 5q (Wydner et a l . , 1996), whi le lamins B2 (Hoger et al . , 
1990) and B3 (Furukawa and Hotta, 1993) are splicing var iants of the 
LMNB2 gene, s i tuated on chromosome 1 9 p l 3 . 3 (Biamonti et al . , 1992). In 
human t issues, every cell t ype expresses lamin B2, while lamin B l is 
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expressed preferent ia l ly in prol i ferat ing cells, and is absent f rom skeletal 
muscle and hear t (Broers et a l . , 1997), whi le lamin B3 is expressed only in 
sperm cells (Furukawa and Hotta, 1993). In other ver tebrates, a similar 
pat tern of expression is seen. In chicken for example, there appear to be 
di f ferences between lamin B l and B2 expression. Lamin B2 expression 
appears relat ively constant , whi le Lamin B l expression is high in embryonic 
t issues but drops in adul t t issues (Lehner et a l . , 1986). In lamin B3, the rod 
domain is very shor t and the N-terminal 208 amino acids of lamin B2 are 
replaced by a unique 85 amino acid sequence, giving a molecular st ructure 
apparent ly responsible for the nuclear shape in sperm cells (Furukawa and 
Hotta, 1993). 
All B-type lamins are permanent ly farnesylated at a sequence mot i f CaaX 
(Cyste ine, any al iphat ic am ino acid, X any amino acid) at the very N-
te rm inus of the molecule. This mot i f is ta rge t for farnesyl-modif icat ion of 
the cysteine in the mot i f and appears to anchor B-type lamins to the inner 
nuclear membrane (Farnsworth et al . , 1989; Krohne et al . , 1989). Splicing 
var iants in o ther species show di f ferent modif icat ions. For example, a new 
splicing var iant of the Xenopus laevis lamin B3 (not homologous to 
mammal ian B3) , where the last 12 amino acids are replaced by 12 new 
ones, includes a second cysteine targeted for palmi toy l -modi f icat ion, which 
confers s t ronger association wi th membrane vesicles during nuclear 
breakdown (Hofemeister et a l . , 2000). These modif icat ions may be 
responsible for the behaviour of B-type lamins dur ing open mitosis, when 
the nuclear envelope breaks down but B-type lamins remain associated wi th 
ER vesicles (Gerace and Blobel, 1980), together wi th the interact ion wi th 
specific integral membrane proteins like LBR. Other modif icat ions like 
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phosphory la t ion occur dur ing the S phase (Kill and Hutchison, 1995), when 
B-type lamins are synthesized (Folsy and Bibor-Hardy, 1988). 
There is no repor t in the l i terature which links LMNBl or LMNB2 genes to 
any known disease phenotype. Only one study in FPLD patients wi th no 
muta t ions in the LMNA gene have found novel Single Nucleotide 
Polymorphisms (SNPs) in L M N B l , four intronics and one in the coding 
sequence of lamin B l (A501V) , but they were not l inked to the disease 
phenotype. No genet ic var iat ion was found in the LMNB2 (Hegele et al . , 
2001) , suppor t ing the observat ions made by Broers et al 1997 and Lehner 
et al 1986. 
A large number of genomic clones for ver tebrate lamins have been 
character ized, and analysis of the sequences show tha t intronic posit ions 
are very well conserved among A and B-type lamins of d i f ferent species. 
Since B-type lamins are expressed in all t issues, it has been suggested tha t 
they are the progeni tor ancestor of lamins by exon shuff l ing (Stick, 1992). 
1.7.2 A-type Lamins 
A- type lamins are expressed exclusively in d i f ferent iated tissues (Stick and 
Hausen, 1985). In mouse embryos , lamins A and C do not appear unti l 8 -
11 days post - fer t i l i za t ion, init ial ly in developing muscle (Rober et al . , 1989; 
Stewart and Burke, 1987). Hemopoiet ic and intestinal epithelial cells do not 
express Lamin A/C even in the adul t (Rober et al . , 1989). The induction of 
A - type lamins coincides wi th ma jo r changes in t issue st ructure, but occurs 
well a f ter cells have commi t ted to fo rm a part icular t issue, suggesting tha t 
A - type lamins are involved in mainta in ing a di f ferent iated phenotype rather 
than determin ing the fate of cells dur ing embryogenesis. 
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There are four d i f ferent A- type lamins; all t ranscr ibed as di f ferent splicing 
var iants f r om the LMNA gene, which is located on the chromosome l q 2 1 . 2 . 
Lamins A and C (Fisher et al . , 1986) are somatic lamins expressed in almost 
all d i f ferent ia ted cells (Behavente et al . , 1985), lamin C2 is the specific A-
type lamin of sperm cells (Furukawa et a l . , 1994), whi le Lamin AAlO was 
found in somat ic cells and tumours (Machiels et al . , 1996). Lamin A and C 
are identical in sequence up to the C- terminus, where splicing of exon 10 
produces a unique 98 amino acids C- terminus for Lamin A and a specific 6 
amino acids C- terminus for lamin C (Fisher et a l . , 1986; Lin and Worman, 
1993). Lamin AAlO lacks 30 amino acids f rom the C-terminus specific for 
Lamin A. Lamins A and AAlO contain the specific CaaX mot i f at the very end 
of the globular domain (Holtz et al . , 1989), where the cysteine of the mot i f 
undergoes a series of modi f icat ion by farnesy lat ion, subsequent cleavage of 
the th ree N-terminal residues and carboxy-methy la t ion . 
Other modi f icat ions of lamins are phosphorylat ion of residues in the head 
and tai l doma in , which are responsible for the dynamics of A- type lamins 
dur ing interphase and mitosis (Ottaviano and Gerace, 1985). Early in 
mi tos is , A - type lamins are hyper-phosphory la ted by PKC and CDK2 (Dessev 
et a l . , 1988) and become dispersed th roughout the cytoplasm, most 
probably into ol igomeric complexes (Hutchison et al . , 2001), where they are 
more easily ext ractable (Gerace and Blobel, 1980). But the phosphorylat ion 
and disassembly of A - type lamins is not enough for the NE diassembly 
(Newport and Spann, 1987). At the end of te lophase, the rate of 
dephosphory la t ion by Protein Phosphatase 1 (PP l ) at CDK2 sites modulates 
the init ial rate of lamin f i lament assembly (Thompson et al . , 1997). During 
in terphase, lamins are phosphory lated as wel l , but to a d i f ferent extent , 
which plays d i f ferent roles than the phosphorylat ion event during mitosis 
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(Moir et al., 1995). Phosphorylation at sites adjacent to the NLS by PKC can 
influence nuclear Import of lamins, limiting the availability of lamin subunits 
(Hennekes et al., 1993). On the other hand, phosphorylation by Protein 
Kinase cAMP-dependent (PKA) facilitates the incorporation of new lamin 
subunits into the assembled lamina as the nucleus grows (Peter et al., 
1990). 
The role of A-type lamins in differentiated tissues gained more significance 
following the findings, first, that lamin binding partner Emerin, when 
mutated or absent (Bione et al., 1994), produces a muscular dystrophy 
disorder, and secondly, when mutations in the LMNA gene were linked to 
similar phenotypes (Bonne et al., 1999). Currently near 60 different 
mutations in the LMNA gene have been reported, related to six/seven 
different phenotypes so far, but no hot-spots have been observed. Rather 
mutations are clustered for some phenotypes. For example, Dilated 
Cardiomyopathy with Cardiac Conduction Defects is associated with 
mutations in the rod domain; while Familial Partial Lipodystrophy associated 
mutations are mainly in the globular tail domain. Werner Syndrome, where 
LMNA is involved, seems to cluster the DNA changes in the rod domain of 
the protein. In the case of Autosomal Dominant Emery-Dreifuss Muscular 
Dystrophy, mutations are dispersed along the gene. Progeria disorder 
Hutchison-Gilford presents a deletion in the specific tail domain of Lamin A. 
1.7.3 Lamina Associated Proteins 
As with their cytoplasmic relatives, nuclear intermediate filaments, the 
lamins, have their associated proteins (LAP). Most of them are type I I 
integral membrane proteins with a characteristic protein structure of C-
terminal transmembrane domain (except LAP2a) and a long nucleoplasms 
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N-terminal domain, which are considered to be responsible for the 
association of the nuclear lamina with the INM. LAPl proteins (LAPIA, 
LAPIB and LAPIC) are monovalent due to their apparent unique interaction 
with lamins. LAP2 proteins (LAP2a, (3, 5 , s , y and ^) appear to be bivalent as 
they interact with lamins and chromatin (Foisner and Gerace, 1993; 
Hutchison et al., 2001). 
Specific for B-type lamins is the LBR, the best characterized Lamin 
Associated Protein (Moir et al., 1995). Another LAP is emerin, an INM 
protein that interacts with A and B-type lamins (Vaughan et al., 2001), 
posses a LEM motif (LAP2(3 , Emerin and Man) at the very end of the N-
terminal domain that interact with other nucleoplasmic proteins. Unlike the 
cytoplasmic intermediate filaments, no human diseases have been 
described to involve mutations in LAPs, except emerin (see section 1.10). 
1.7.4 Assembly Models 
Nuclear lamins form 10 nm filaments in vivo (Fuchs and Weber, 1994), but 
the stepwise study of Lamin assembly in vitro results in paracrystal 
formation (> 13nm), through enhanced lateral associations (Quinlan et 
al., 1995). Most of the models for intermediate filament assembly in vitro 
have been developed using cytoplasmic intermediate filaments, particularly 
vimentin and keratins, although it has been suggested that the filament 
assembly pathways may differ between IF types and even between 
individual IF proteins (Strelkov et ai., 2003). I t has been proposed that the 
basic structure of intermediate filaments is two monomers associated in 
parallel via their rod domains in a coiled-coil super helical configuration. 
Dimers associate laterally through three distinct interaction models called 
A l l , A 2 2 and A 1 2 (Steinert et al., 1993). The An mode corresponds to an 
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antiparallel, half-staggered association of two dimers with their coil IB 
segments almost aligned (Herrmann and Aebi, 1998). The A 2 2 mode 
corresponds to a half-staggered anti-parallel association of dimers with the 
coil2B segments aligned (Strelkov SV et al., 2002). The A 1 2 mode is an 
unstaggered anti-parallel association. Mature IFs associate in an ACN mode, 
where the N and C-terminal domains of longitudinally aligned dimers 
overlap (Parry and Steinert, 1999). A linear arrangement of tetramers 
within a mature intermediate filament corresponds to a protofilament, and 
the lateral association of protofilaments assembles protofibrils (Strelkov et 
al., 2003). 
In vitro studies have demonstrated that, as in cytoplasmic IFs, the 
elementary building block of lamins is a parallel, unstaggered two-stranded 
a-helical coiled-coil dimer involving the central rod domain (Heitlinger et a!., 
1991). In contrast with the lateral mode of association of cytoplasmic 
intermediate filaments, nuclear lamins associate longitudinally to form polar 
head-to-tail polymers (Gieffers and Krohne, 1991), which associate laterally 
in an anti-parallel, half-staggered fashion to form IF-like assemblies with a 
periodical 25 nm beading repeat, and eventually forming paracrystals 
(Heitlinger et al., 1991). These lamin specific structures can be 
disassembled in vitro by incubation either in cell-free extracts of mitotic 
cells (Ward and Kirschner, 1990) or with highly purified fractions of p34^'^" 
(Peter et al., 1991), suggesting the predominant role of phosphorylation 
processes in the diassembly of the nuclear lamina in vivo (Moir et al., 1995). 
Accordingly, several models have been developed to explain the steps of 
the lamina assembly in vivo. Because of the basic nuclear lamina must be 
formed around B-type lamins, and, like their cytoplasmic relatives (IFAPs), 
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LAPS influence the formation of a primary nuclear lamina (B-type lamins 
based), lamin dimers are forced to associate with the INM and further form 
a 10 - 13 nm flattened array. At mitosis, the NE disassembles and 
phosphorylation of lamins dissociates the flattened meshwork, keeping B-
type lamins at the mitotic vesicles and A-type lamins into a soluble pool 
(Bridger et al., 1993). B-type lamin subunits retain A-type lamins 
constraining elements (like emerin, LAPIC and others) that recruit lamins A 
and C heterotetramers only after an evident NE is re-assembled (Broers et 
al., 1999). During interphase, phosphorylation of lamins at sites adjacent to 
the NLS regulates the rate of incorporation of new lamins as the nucleus 
grows in preparation for the next M-phase. For more details of this model, 
see (Hutchison et al., 2001). 
1.7.5 Functional Theories 
After the discovery that mutations in the LMNA gene are involved in several 
human diseases, "laminologists" have divided their opinions regarding the 
role of lamins in the cell, in order to explain the tissue-specific effect of the 
mutations. Some support the structural hypothesis, which proposes that 
mutations give rise to weakness of the lamina and lead to fragility of the 
nuclear envelope and its consequent breakage (Hutchison et al., 2001; 
Sullivan et al., 1999). The other group supports the gene expression 
hypothesis which proposes that A-type lamins are involved in the tissue-
specific changes in patterns of gene expression (Cohen et al., 2001). 
As with cytoplasmic intermediate filaments, lamins play a structural role 
maintaining the integrity of the nucleus. Physical depletion of lamins does 
not prevent nuclear assembly, but produces a weak nucleus (Newport et al., 
1990), and lamin deletion mutants alter nuclear morphology (Schirmer et 
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al., 2001). Cultured cells from EDMD patients with different mutations in the 
LMNA gene have an increased number of defective nuclei compared to 
respective controls (Favreau et al., 2003; Novell! et al., 2002; Vigouroux et 
al., 2001). Similarly, nuclei from EDMD patients with mutations in the LMNA 
gene are less resistant to external, artificial stress (Broers et al., (SEB-
Symposia, 2003)). 
I t has been long suggested that lamins should be involved in gene 
expression by early observations that lamins A and C are expressed only in 
differentiated cells (Lehner et al., 1987). A series of experimental evidence 
demonstrated the role of lamins in DNA synthesis. B-type lamins are 
specifically synthesized (Foisy and Bibor-Hardy, 1988), phosphorylated (Kill 
and Hutchison, 1995) and distributed to active sites of DNA replication 
during S phase (Moir et al., 1994). B-type lamins, but not A-type, are 
involved in a lamin^dependent DNA synthesis in Xenopus egg extracts 
(Meier et al., 1991). Nuclei lacking lamins are able to import karyolitic 
proteins involved in DNA replication (Proliferating Cell Nuclear Antigen, 
PCNA), but do not form a resistant nuclear matrix that retains its protein 
composition (Jenkins et al., 1993). B-type lamins interact with cytoplasmic 
intermediate filaments during telophase (Djabali et al., 1991) and a model 
has been developed for the role of an intermediate filament polymer and/or 
the cooperation between cytoplasmic and nucleoplasmic intermediate 
filaments in transporting karyolitic proteins in telophase to the DNA 
replication/elongation/transcription initiation sites (Traub and Shoeman, 
1994). But still the role of A-type lamins in any pathway involving control of 
gene expression has to be demonstrated. 
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1.8 Lamins and Emerin in disease 
1.8.1 X-Linked Emery Dreifuss Muscular Dystrophy (XL-EDMD) 
A typical pattern was first described by (Dreifuss and Hogan, 1961; Emery 
and Dreifuss, 1966) who studied Virginia kindred in which there were 8 
affected males in three generations. Onset of muscle weakness, first 
affecting the lower extremities with a tendency to walk on the toes, was 
noted around the age of 4 or 5 years. In general, the disease was 
characterized by the triad of 1) slowly progressive muscle wasting and 
weakness with humero-peroneal distribution in the early stages; 2) early 
contractures of the elbows, Achilles tendons, and post-cervical muscles; and 
3) cardiomyopathy. The cardiac conduction defect in EDMD patients is the 
most serious and life threatening clinical manifestation of the disease. 
Cardiac defects have been described in female carriers (Emery, 1989) in the 
absence of any skeletal muscle abnormality, suggesting a prominent role of 
emerin in the cardiac conduction system. Studies of the cardiac status in 
three patients with EDMD revealed the effect on the heart in teenage years 
and it was characterized by cardiac conduction defects and infiltration of the 
myocardium by fibrous and adipose tissue (Buckley et al., 1999). I t first 
affected the atria, which resulted in atrial paralysis; treatment with 
ventricular pacing was usually needed. Female carriers developed heart 
problems and were at risk of sudden death, in agreement with Emery's 
work (Emery, 1989). 
The name Rigid Spine Syndrome (RSS) was given to a disorder found in a 
17 years old boy, with a myopathy and stiffness of the back and neck at an 
early age, and progressive scoliosis in his teens (Dubowitz, 1973). For 
several years, the patient had difficulties in extending his elbows. I t was 
then suggested that this may be a X-linked disorder and may be related to 
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the EDMD with contractures (Wettstein, 1983). RSS is distinguished from 
EDMD by lack of cardiac involvement and autosomal recessive inheritance. 
Under the designation Scapulo-Peroneal Syndrome, kindred were described 
with typical X-linked inheritance of a myopathy manifesting as muscular 
weakness and wasting, affecting predominantly the proximal muscles of the 
legs. Accompanying features were contractures of the elbows, pes cavus, 
and, in adulthood, cardiomyopathy (Thomas et al., 1972). The authors 
pointed out similarities to the Emery benign type of muscular dystrophy 
with contractures but thought that the distribution of muscular involvement 
distinguished the two. Later revised opinions concluded that the disorder 
was in fact EDMD (Thomas, 1985). Many studies reached the conclusion 
that X-linked Scapulo-Peroneal Syndrome was the same condition as EDMD 
(Mawatari and Katayama, 1973; Merlini et al., 1986; Rotthauwe et al., 
1972; Rowland et al., 1979; Sulaiman et al., 1981; Thomas, 1985). 
XL-EDMD gene is inherited as a recessive character, with 100% penetrance 
by the second/third decade of life. Heterozygous females show no indication 
of skeletal, muscle disorder, but arrhythmia and bradycardia are observed 
with risk of sudden death (Bialer et al., 1991; Emery, 1987; Fishbein et al., 
1993; Merlini et al., 1986; Pinelli et al., 1987). Molecular analysis of the XL-
EDMD began with the construction of a transcriptional map of the 2 Mb 
region of chromosome Xq28 (Bione et al., 1993). Within this region, the 
STA gene was identified, which encodes a 254 amino acids protein termed 
Emerin. This protein lacks a signal peptide, contains a long N-terminal 
domain, and is hydrophilic, except for a highly hydrophobic 20 amino acids 
sequence at the C-terminal region. In addition, it has several putative 
phosphorylation sites and one potential glycosylation site. Northern blot 
analysis demonstrated ubiquitous expression of a major transcript of 
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approximately 1 kb, with the highest expression in skeletal muscle and 
heart, and abundant expression in other tissues including colon, testis, 
ovary, and placenta. I t was then suggested that Emerin belongs to a class 
of tail-anchored proteins of the secretory pathway involved in vesicular 
transport. 
Among the many genes located in the special part of Xq28, eight transcripts 
expressed at high levels in skeletal muscle, heart and/or brain were 
selected as the best candidates for the site of the mutation causing XL-
EDMD (Bione et al., 1994). Each of the five patients investigated had a 
unique mutation in one of the genes. These mutations resulted in the loss of 
all or part of the protein. In addition, heteroduplex analysis of emerin gene 
exons in 30 unrelated XL- EDMD patients revealed abnormal patterns of 
single exons in seven patients. Direct sequencing of the respective exons 
revealed six novel mutations distributed in the promoter region and exons 3 
- 6. This study identified the first mutations in the promoter region and 
exon 5. With the mutations here described, a total of 25 mutations were 
then known. All of the mutation abolished the synthesis of functional Emerin 
(Wulff et al., 1997). Several mutations have been found in the STA gene, 
and have been classified as: non-sense (34), frame-shift (31 , splice-donor 
(7) , splice acceptor (5) gene deletions (5), missense (3), in-frame (3) 
promoter (1) and large deletions (1) (Yates, 1998). 
Biochemical analysis involving mutations affecting Proline-183 (P183) had 
had demonstrated that the mobility and expression levels of the mutant 
form of Emerin is indistinguishable from those of the wild type form, but 
have weakened interaction with nuclear lartiina components (Ellis et al., 
1999). In comparison with the usual XL-EDMD phenotype, patients with 
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P183 missense mutation had a later age at onset of first symptoms (elbow 
contractures, ankle contractures, and upper and lower limb weakness), but 
there was no difference for the age at onset of cardiac involvement. A 
TCTAC deletion was identified in two brothers with XL-EDMD, spanning 
nucleotides 631 - 635 of the Emerin gene. Both showed an unusual severe 
disease phenotype (Hoeltzenbein et al., 1999). The same mutation had 
been found previously in two brothers with significantly milder phenotype in 
an unrelated family (Manilal et al., 1998). 
A panel of 12 monoclonal antibodies to a large fragment of emerin cDNA 
was prepared by PCR and expressed as a recombinant protein E. coli 
(Manilal et al., 1996). These antibodies detected 4 different epitopes on 
Emerin. All monoclonal antibodies recognized a 34 kDa protein in all tissues 
tested. Immunofluorescence and cell fractionation studies confirmed that 
Emerin is located at the nuclear membrane. Amino acid sequence 
similarities and cellular localization suggested that Emerin is a member of 
the nuclear lamina-associated protein family. 
Monoclonal antibodies showed that Western blotting and immuno-histology 
of a biopsy from an XL-EDMD patient could be simple diagnostic test for this 
disorder (Manilal et al., 1996). Studies in three families with XL-EDMD that 
showed different mutations in the STA gene emphasized the usefulness of 
early diagnosis because insertion of a peacemaker may be life saving (Nevo 
et al., 1999). For example, a case of XL-EDMD in 3 years old boy was 
described with contractures of the Achilles tendons, but without 
characteristic contractures of the elbows and cardiac involvement. 
Immunofluorescence analysis of a muscle biopsy showed no Emerin 
presence at the nuclear membrane. RT-PCR and PCR-based genomic 
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analysis of the STA gene revealed no amplification products in the patient's 
samples (Fujimoto et al., 1999). The authors stressed that Emerin staining 
should be part of the work-up of every unexplained muscular dystrophy, in 
agreement with (Manilal et al., 1996; Nevo et al., 1999). 
Emerin localizes to the INM via its hydrophobic C-terminal domain, but in 
heart and cultured cardiomyocytes it is also associated with the intercalated 
discs. A general role for Emerin was then proposed as a membrane 
anchorage element to the cytoskeleton (Cartegni et al., 1997). In the 
nuclear membrane, Emerin plays a ubiquitous and indispensable role in 
associating the nuclear membrane with the lamina. In heart, it is specifically 
located to desmosomes and fasciae adherents. The role of this complex 
assortment of protein is best demonstrated by the existence of many 
genetic diseases that perturb adhesion, and in the heart, by the dramatic 
consequences of plakoglobin (gamma catenin) knockout (Ruiz et al., 1996): 
plakoglobin - / - mice die at mid-gestation due to rupture of the ventricles. In 
heart, the specific localization of Emerin to desmosomes and fasciae 
adherents could account for the characteristic conduction defects described 
in patients with XL-EDMD. 
Using two antisera against a synthetic peptide predicted form Emerin cDNA, 
a positive nuclear membrane staining was found in skeletal, cardiac and 
smooth muscle in normal controls and in patients with neuromuscular 
diseases other than XL-EDMD (Nagano et at., 1996). In contrast, a 
deficiency in immunofluorescence staining of skeletal and cardiac muscle 
from XL-EDMD patients was observed. In heart, the specific localization of 
Emerin to desmosomes and fasciae adherents could account for the 
characteristic conduction defects described in patients with XL-EDMD 
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(Cartegni et al., 1997). In contrast, other studies found that affinity purified 
antibodies against Emerin gave immuno-staining only in the nuclear 
membrane, casting doubt on the hypothesis that cardiac defects in XL-
EDMD are caused by absence of Emerin from intercalated discs. Although 
Emerin was abundant in the membranes of cardiomyocyte nuclei, it was 
absent from non-myocyte cells in the heart. This distribution of Emerin was 
similar to that of Lamin A, which is mutated in the Autosomal Dominant -
EDMD (AD-EDMD) syndrome. In contrast, Lamin B l was absent from 
cardiomyocyte nuclei, suggesting that Lamin B l is not essential for 
localization of Emerin to the nuclear lamina. Lamin B l was also almost 
completely absent from skeletal muscle nuclei, suggesting that in XL-EDMD 
the additional absence of lamin B l from heart and skeletal muscle that 
already lack Emerin might explain why these tissues are particularly 
affected (Manilal et al., 1999). Studies of ultra-structural localization of 
Emerin in human skeletal muscle and HeLa cells, using ultra-thin cryo-
sections, showed that immune-labelled-colloidal gold particles were 
localized on the nucleoplasmic surface of the INM, but not on the nuclear 
pore likewise demonstrating that Emerin is localized at the INM (Yorifuji et 
al., 1997). 
Other mutation analysis determined that several, but not all disease 
mutations in the STA gene mapped to a central Lamin A-binding domain, 
and that mutations in this region disrupt Emerin-Lamin A interaction. 
Emerin binds directly to Barrier Autointegration Factor (BAF), a DNA-binding 
protein, and this binding requires conserved residues in the N-terminal LEM 
domain of. Emerin (Lee et al., 2001). In addition, Emerin co-localized with 
BAF at the core region of chromosomes during telophase in HeLa cells. Ah 
Emerin mutant deficient in BAF-binding-region mislocalized in vivo to the 
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core of chromosomes and subsequently, failed to localize to the reformed 
nuclear envelope. In HeLa cells expressing a BAF mutant that did not show 
core localization, endogenous Emerin failed to localize to the core region 
during telophase and did not assemble into the nuclear envelope during the 
subsequent interphase (Haraguchi et al., 2001). This BAF mutant also 
dominantly mislocalized LAP2p and Lamin A from the nuclear envelope. This 
finding suggested that BAF is required for the assembly of Emerin and A-
type lamins at the reforming nuclear envelope during telophase and may 
mediate their stability in the subsequent G l . 
Using Fluorescence In-Situ Hybridization (FISH) and immunofluorescence, 
the nuclear organization of every human chromosome was analyzed in 
diploid lymphoblasts and primary fibroblasts. Most gene-rich chromosomes 
were concentrated at the centre of the nucleus, whereas the gene-poor 
chromosomes were located towards the nuclear periphery. There was no 
significant relationship between chromosome size and position within the 
nucleus. The intranuclear organization of chromosomes of a patient with XL-
EDMD was not altered, suggesting that Emerin may not be necessary for 
localizing chromosomes at the nuclear periphery, and that the muscular 
dystrophy phenotype in such individuals may not be due to grossly altered 
chromatin organization (Boyle et al., 2001). 
1.8.2 Autosomal Dominant EDMD 
Studies in two Dutch families, with a seemingly unique form of myopathy, 
revealed features intermediate between Limb-Girdle Muscular Dystrophy 
and Scapulo-Peroneal Atrophy. Onset occurred between 17 and 42 years of 
age and cardiomyopathy was a late feature, with several instances of male-
to-male transmission (Jennekens et al., 1975). Another disorder was 
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described that might be labelled EDMD but was inherited as autosomal 
dominant (Miller et al., 1985). The father and daughter had muscle 
contractures, especially of posterior cervical muscles but also affecting 
elbows and ankles, cardiac involvement with atrial rhythm disturbance and 
slow ventricular rate, slowly progressive weakness mainly of humeral and 
peroneal muscles with some pelvic girdle involvement and tendon areflexia, 
and Electromyography (EMG) and histological evidence of myopathy. 
Hauptmann-Thannhauser eponym was then suggested (Becker, 1972) to be 
attached to autosomal muscular dystrophy with early contractures and 
cardiomyopathy, as Hauptmann reported in 1941 the disorder in a family of 
French-Canadian descent in which nine persons in three generations were 
affected by a form of muscular dystrophy "not heretofore described in tlie 
literature" (Hauptmann, 1941). The disorder was manifested by inability to 
flex the neck and slight webbing due to shortened muscle as well as 
limitation on spinal flexion and elbow extension from the same cause. A 
German family was also described with an autosomal dominant form of 
EDMD. Several affected members died in middle age of sudden cardiac 
death and at least two had a pacemaker implanted. One patient had heart 
transplant and four instances of male-to-male transmission were observed 
(Wittetal., 1988). 
XL-EDMD genetic defects reside in the STA gene. In the AD form, Emerin is 
normal. Distribution of Emerin was found to closely resemble that of Lamins 
A and C (Manilal et al., 1999). A functional interaction between Emerin and 
Lamin A in the nucleus could explain the identical phenotype in the different 
forms of EDMD. Using genetic linkage analysis, the locus for AD-EDMD was 
mapped to an 8cM interval on l q l l - q 2 3 in a large French pedigree, and the 
AD-EDMD phenotype in other four small families was potentially linked to 
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this locus (Bonne et al., 1999). This region contains the LMNA gene, which 
encodes four proteins of the nuclear lamina, lamins A, AAlO, C and C 2 , by 
alternative splicing. Mutations in the LMNA gene co-segregated with the 
disease phenotype in five families: one nonsense and three missense 
mutations. These results represented the first identification of mutations in 
a component of the nuclear lamina as a cause of and inherited muscle 
disorder. 
1.8.3 Autosomal Recessive EDMD 
A mutation in the LMNA gene in a 40 years old man with severe EDMD was 
identified. Both parents, who were first cousins, were heterozygous for the 
mutation. The patient had experienced difficulties when he started walking 
at age 14 months. At age of 5 years, he could not stand because of 
contractures. At age of 40 years, he presented severe and diffuse muscle 
wasting and was confined to a wheelchair. His intelligence was normal; 
careful cardiological examination of the patient and his parents showed that 
they did not present cardiac problems. None of them showed cardiac or 
skeletal muscle abnormities. This study showed that heterozygous 
mutations in LMNA could cause diverse phenotypes ranging from typical 
EDMD to no phenotypic effects. The distribution of mutations in autosomal 
dominant patients suggested that the unique interactions between Lamin 
A/C with other nuclear components exist that have an important role in 
cardiac and skeletal function (Raffaele Di Barletta et al., 2000). 
1.8.4 Familial Partial Lipodystrophy (FPLD) 
Patients with partial lipodystrophy have a normal fat distribution in early 
childhood, but with the onset of puberty, almost all subcutaneous adipose 
tissue from the upper and lower extremities and gluteal and truncal areas 
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gradually disappears, causing prominence of muscles and superficial veins 
in these areas. Simultaneously, adipose tissue accumulates on the face and 
neck, causing a double chin and fat neck. Adipose tissue may also 
accumulate in the axillae, back, labia majora, and intra-abdominal region. 
Affected patients are insulin-resistant and may develop glucose intolerance 
and diabetes mellitus after the age of 20 years, with hypertriglycideridemia, 
and low levels of high density lipoprotein (HDL). The phenotype is readily 
discernible in females. Affected males, however, are more difficult to 
recognize due to relative muscularity and reduced body fat in normal 
individuals, accounting for the past suggestion of X-Linked dominant 
inheritance of this disorder. 
A dominantly inherited disorder in six females in four generations was 
described, where clinical features were symmetric lipoatrophy of the trunk 
and limbs with rounded, full face, tuberoeruptive xanthomata, acanthosis 
nigricans and insulin-resistant hyperinsulinism (Dunnigan et al., 1974). In a 
second family, six females in three generations were affected. This 
syndrome was distinct from congenital lipodystrophy, a recessive form with 
progressive partial lipodystrophy. It was then concluded that there are two 
types of familial lipodystrophies: type 1, with loss of subcutaneous fat 
confined to the limbs; and type 2, in which the trunk is also affected with 
the exception of the vulva, giving an appearance of labial hypertrophy 
(Kobberling and Dunnigan, 1986). Diabetes mellitus, hyperlipoproteinemia, 
and acanthosis nigricans were present to a variable degree in some but not 
all patients. Both types, occurring either as a familial disorder or 
sporadically, had been observed only in females. The pedigrees suggested 
to the authors X-linked dominant inheritance with lethality in the 
hemizygous XY conceptus. I t was suggested as a one possibility that the 
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two types were allelic. Other pedigrees showed clear autosomal dominant 
inheritance (Jackson et al., 1997; Peters et al., 1998; Robbins et al., 1982). 
I t was uncertain whether there was a distinct Kobberling variety of familial 
lipodystrophy, which had been characterized as having loss of subcutaneous 
adipose tissue limited to the limbs without involvement of the trunk and 
with normal facial fat (Kobberling and Dunnigan, 1986; Kobberling et al., 
1975). 
To investigate whether there was a unique pattern of fat distribution in men 
and women with FPLD, whole-body magnetic resonance imaging in one 
male and three female patients from two pedigrees confirmed the clinical 
findings of near-total absence of subcutaneous fat from all extremities. 
Reduction in subcutaneous adipose tissue from the truncal area was more 
prominent anteriorly than posteriorly. Increased fat stores were observed in 
the neck and face. I t was then concluded that FPLD results in a 
characteristic absence of subcutaneous fat from the extremities, with 
preservation of intermuscular fat stores (Garg et al., 1999). Anthropometric 
variables and prevalence of diabetes mellitus, dyslipidemia, hypertension, 
and atherosclerotic vascular disease were assessed among 17 post-pubertal 
males and 22 females with FPLD from eight pedigrees. All individuals were 
analyzed for glucose, insulin and lipoprotein concentrations and presented 
similar patterns of fat loss. Compared with the affected men, women had a 
higher prevalence of diabetes (50% women vs. 18% men) and 
atherosclerotic vascular disease (45% women vs. 12% men), and had 
higher serum triglycerides and lower HDL cholesterol concentrations. The 
prevalence of hypertension and fasting serum insulin concentrations were 
similar, suggesting that females with FPLD are more severely affected with 
metabolic complications of insulin resistance than males (Garg, 2000). 
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Genomewide scan studies w i th a set of higfi iy polymorphic short tandem 
repeats (STRs) in indiv iduals f rom f ive wel l -character ized pedigrees mapped 
the genet ic locus to I q 2 1 - q 2 2 , wi th no evidence for genetic heterogeneity 
(Peters et a l . , 1998). Linkage and haplotype analysis wi th highly 
po lymorphic microsatel l i te markers on large, mul t igenerat ional Caucasian 
k indred of German ancestry w i th the Dunnigan's fo rm of FPLD l inked FPLD 
gene near marker D1S2721 (Anderson et al . , 1999), support ing the minimal 
region previously repor ted (Jackson et a l . , 1998; Peters et a l . , 1998). A 
genomewide l inkage search using microsatel l i te markers provided 
conclusive evidence of l inkage to l a 2 1 (D1S498) , w i th no evidence of 
heterogenei ty . Addi t ional haplotype and mul t ipo in t analysis supported the 
locat ion of the FPLD locus wi th in a 21.2 cM chromosomal region tha t is 
f lanked by markers D1S2881 and D1S484. The LMNA gene was considered 
to be a candidate for FPLD for several reasons: FPLD maps to the same 
region of ch romosome 1 as the LMNA gene; mutat ions in LMNA gene cause 
muscle wast ing in AD-EDMD; and' regional muscle wast ing in AD-EDMD is 
analogous to the regional adipocyte degenerat ion in FPLD. DNA sequencing 
of the LMNA gene in f ive Canadian fami l ies affected by FPLD showed an 
R482G missense muta t ion (Cao and Hegele, 2000). 
In a th ree generat ion Canadian k indred, in w h o m four members had 
autosomal dominan t fami l ia l l ipodystrophy and normal LMNA gene sequence, 
a muta t ion was ident i f ied in the Peroxisome Proliferator Act ivated Receptor 
y (PPARG) gene. All fou r af fected members were heterozygous for an 1164 
T-A t ransvers ion in exon 5, predict ing a F388L subst i tu t ion. The mutat ion 
a l tered a highly conserved residue wi th in helix 8 of the predicted l igand-
binding pocket of PPARG, and was not found in normal fami ly members or 
normal unre lated subjects . The mu tan t receptor had signif icantly decreased 
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basal t ranscr ip t ional levels, and impaired st imulat ion by a synthet ic l igand. 
Cl inical ly, the pat ient phenotype was simi lar to tha t seen in the Canadian 
FPLD probands wi th missense mutat ions in LfANA gene (Hegele et al . , 2002). 
In another f o rm of FPLD, l ipoatrophy wi th diabetes was described by in a 27 
years old male pat ient whose phenotype was characterized by acquired 
general ized l ipoatrophy w i th metabol ic a l terat ions, massive l iver steatosis, 
d ist inct ive subcutaneous mani festat ions, and cardiac abnormal i t ies involving 
both endocard ium and myocard ium. Generalized at rophy of subcutaneous 
fa t resul ted in sunken cheeks and muscular pseudo-hyper t rophy of the four 
l imbs. Mult iple whi t ish papules on p igmented skin were present on the neck, 
t r unk , and upper l imbs and to a lesser extent on the lower l imbs. Muscular 
s t reng th was no rma l , and no neurological defects were detected. Cardiac 
invo lvement included concentr ic hyper t rophy of the left ventr ic le w i thout 
cavi ty d i latat ion associated wi th thickness and regurgi tant valves, aort ic 
f ibrot ic nodules, and calcif ication of the poster ior annulus. Doppler 
echocardiographical f indings were simi lar to dose described in aged patients. 
Abdomina l Magnetic Resonance Imag ing (MRI) revealed an absence of body 
at bo th , the subcutaneous and visceral levels. Family members were 
unaf fec ted , and no consanguini ty was repor ted. Mutat ion analysis of the 
LMNA gene found a heterozygous 398 G-T t ransvers ion in exon 2. This 
muta t ion resul ted in amino acid change R133L in the rod domain of lamins 
A and C. Argin ine 133 is located in a charged peptide s t re tch , which is 
highly conserved in A and B-type lamins in ver tebrates. The switch f rom 
posi t ively charged Argin ine to hydrophobic Leucine in the Lamin A/C 
d imer izat ion domain may severely impair its polymer izat ion and fur ther 
f i lament assembly. Accordingly, nuclear abnormal i t ies in pr imary cultures of 
pat ient f ibroblasts were observed (Caux et al . , 2003). 
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1.8.5 Di la ted C a r d i o m y o p a t h y w i t h Conduct ion De fec ts ( D C M - C D ) 
I n a fami ly where 10 members were suffer ing or had died f rom 
card iomyopa thy , and six others were probably af fected, transmission 
seemed to occur only th rough the female , a l though both males and females 
were af fected (Whitfield, 1961). In a d i f ferent fami ly , two sisters presented 
w i th Famil ial Id iopath ic Cardiomegaly (Schrader et a l . , 1961). Based on 
s imi lar clinical phenotypes, card iomyopath ies were classified in : type 1 , wi th 
p redominant f ibros is ; type 2, wi th predominant ventr icu lar hyper t rophy, 
hered i ta ry ; and type 3, w i th deposits of a nonmetachromat ic polysaccharide 
(Boyd e t a l . , 1965). 
Studies in k indred in which 12 members had Cardiomegaly wi th poor 
vent r icu la r funct ion and /o r dys rhy thmia , the disorder was evident by 
echocard iogram in a 6 mon th old infant. Skeletal muscle biopsies showed 
subt le myopath ic a l terat ions. The pedigree, spanning 5 generat ions, was 
consis tent w i th autosomal dominan t inher i tance (Gardner et al . , 1985). I n a 
d i f ferent fami ly , mul t ip le members in three generat ions had di lated 
card iomyopathy w i th over t clinical onset between the four th and seventh 
decades. I t was then concluded tha t there may be an associated skeletal 
myopa thy mani fested by very mi ld prox imal weakness or detectable only on 
biopsy (Gardner et a l . , 1987). Further studies found in eight individuals, 
four of w h o m were males in three generat ions, showed var iat ion in muscle 
f ibre size and interst i t ia l f ibrosis. Average t ime to death f rom onset of 
s y m p t o m s suggest ive of card iomyopathy was 16 months . One member died 
suddenly af ter being asymptomat ic (MacLennan et al . , 1987). 
Linkage studies demonst ra ted the disease locus was near the centromere of 
ch romosome 1 , between D1S305 and D1S176 (Kass et a l . , 1994). Based on 
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t he disease phenotype and the map locat ion, it was speculated tha t the 
gap- junc t ion prote in connex in-40 was a candidate for mutat ions tha t result 
in conduct ion sys tem disease and di lated card iomyopathy. PCR-based 
studies and Southern blot analysis of the dystrophin gene (DMD) in 27 
males w i th id iopathic di lated card iomyopathy showed no defects. None of 
the pat ients had clinical evidence of skeletal muscle disease or any systemic 
illness tha t could cause hear t disease (Michels, 1993). Genetic studies 
excluded l inkage between the disease phenotype and a 21 cM region 
spanning the Human Leukocyte Ant igen (HLA) cluster in at least 6 0 % of the 
fami l ies studied (Olson et a l . , 1995). Another study compared 31 famil ial 
and 209 non- fami l ia l cases of di lated card iomyopathy, concluding tha t 
fami l ia l f o rm was more mal ignant : it occurred at an earl ier age and 
progresses more rapidly than the non-fami l ia l fo rm (Csanady et al . , 1995). 
Dilated card iomyopathy , a disorder character ized by cardiac dilation and 
reduced systol ic func t ion , represents an outcome of heterogeneous group of 
inher i ted and acquired disorders. Causes include myocardi t is , coronary 
ar te ry disease, systemic diseases, and myocardial tox ins ; idiopathic di lated 
card iomyopathy in which these causes are excluded, represents 
approx imate ly one-hal f of the cases (Olson and Keating, 1996). Among 
pat ients w i th idiopathic di lated card iomyopathy , famil ial occurrence 
accounts for 2 0 - 2 5 % , wi th the except ion of rare cases result ing f rom 
muta t ions in dys t roph in of mi tochondr ia l genes. Familial di lated 
card iomyopathy is character ized by an autosomal dominant pat tern of 
inher i tance w i th age-re lated penetrance. I t presents wi th development of 
vent r icu lar di lat ion and systol ic dysfunct ion usually in the second or th i rd 
decade of l ife. 
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Several loci for fami l ia l di lated card iomyopathy have been mapped. In 
addi t ion to the CMDIA locus on chromosome I p l l - q l l , these include 
C M D I B on 9 q l 3 ; CMDIC on 1 0 q 2 1 ; CMDID on l q 3 2 ; CMDIE on 3p ; CMDIF 
on 6 q ; CMDIG on 2 q 3 1 ; CMDIH on 2 q l 4 - q 2 2 ; C M D I I , which results f rom 
muta t ions in Desmin (DES) on 2q35 ; CMDIJ on 6q23 -q24 ; CMDIK on 6 q l 2 -
q l 6 ; C M D I L , which results f rom mutat ions in the Sarcoglycan (SGCD) gene 
on 5q33 ; C M D I M , f rom mutat ions in Cysteine and Glycine Rich Protein 
(CSRP3) gene on l l p l S . l ; and CMDIN f rom mutat ion in Tit in (TCAP) on 
1 7 q l 2 . Another f o rm of CMD is caused by mutat ion in actin (ACTC). 
Mutat ion in the cardiac beta-myos in-b ind ing protein C (MYBPC3) can cause 
CMD or hyper t rophic card iomyopathy . Another fo rm of autosomal dominant 
d i lated card iomyopathy and heart fai lure is caused by missense mutat ions 
in the phospholamban gene. For a review of the genetic and clinical 
heterogenei ty of fami l ia l di lated card iomyopathy see (Semsarian and 
Seidman, 2001). 
The region to which the CMDIA locus had been mapped, namely l p l - q 2 1 , 
over laps wi th the region where the nuclear lamins A and C are encoded by 
the LMNA gene. Mutat ions in the head, rod and tai l domain of this gene are 
known to cause autosomal dominant Emery-Drei fuss muscular dyst rophy. A 
s tudy of eleven fami l ies wi th autosomal dominant card iomyopathy and 
conduct ion sys tem defects showed f ive novel mutat ions in the heterozygous 
s ta te : four in the a-hel ical rod domain of the LMNA gene, and one in the 
lamin C specific tai l domain . Each muta t ion caused her i table, progressive 
conduct ion sys tem disease (sinus bradycardia, at roventr icu lar conduction 
block, or atr ia l a r rhy thmias ) and di lated card iomyopathy. Heart fai lure and 
sudden death occurred f requent ly wi th in these fami l ies. No fami ly members 
wi th muta t ions had ei ther jo in contractures or skeletal muscle myopathy. 
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Fur thermore , serum creat ine kinase levels were normal in fami ly members 
w i th muta t ions in the lamin rod doma in , but mi ldly elevated in some fami ly 
members wi th a defect in the tai l domain of lamin C. The f indings indicated 
tha t the Lamin A/C in termediate f i lament protein plays an impor tant role in 
cardiac conduct ion and contract i l i ty (Fatkin et al . , 1999). In a di f ferent 
s tudy, a large fami ly presented a severe autosomal dominant dilated 
card iomyopathy w i th a t rovent r icu lar conduct ion defect in some af fected 
members . In add i t ion , some affected fami ly members had skeletal muscle 
s y m p t o m s vary ing f r om min imal weakness to a mild l imb-gird le muscular 
dys t rophy . Af fected individuals were heterozygous for a single nucleotide 
delet ion in the LMNA gene, increasing the range of phenotype arising f rom 
th is muta t ion (Brodsky et a!., 2000). For a review of the chromosomal 
locat ions of the known loci responsible for inheri ted forms of di lated 
card iomyopathy see (Fatkin et al . , 1999). 
Another fo rm of di lated card iomyopathy presented quadriceps myopathy in 
a large fami ly (Charniot et a l . , 2003). Cardiac invo lvement preceded 
neuromuscular disease in all af fected pat ients, whereas in previously 
repor ted cases wi th both cardiac and neuromuscular invo lvement , the 
neuromuscular disorders had preceded cardiac abnormal i t ies. Twenty-n ine 
members of the fami ly were examined , of whom eleven classified as 
a f fec ted , and four had both cardiac and peripheral muscle symptoms. 
Average age at onset of cardiac symptoms was 40 years. Bilateral motor 
def ic i t of the quadr iceps deter iorated progressively, w i thou t involvement of 
o ther muscles. A muta t ion in the LMNA gene (R377H) was found , similar to 
a muta t ion found in a French fami ly causing l imb-gi rd le muscular dystrophy 
w i th age-re la ted at rovent r icu lar cardiac conduct ion disturbances and the 
absence of early cont ractures (Muchir et al . , 2000) , and it was suggested 
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t he presence of factors o ther than the R377H mutat ion influencing the 
phenotyp ic expression in the i r fami ly . 
Ano ther genet ic cardiac disorder is Atr ial Fibr i l lat ion, characterized by rapid 
and i r regular act ivat ion of the a t r iu rn . The prevalence of Atr ial Fibri l lation in 
the general populat ion rises wi th increasing age, ranging f rom less than 1 % 
in young adul ts to greater than 5 % in those older than 65 years. Atrial 
Fibri l lat ion causes t h romboembo l i sm, tachycard ia-mediated card iomyopathy, 
hear t fai lure and ventr icu lar a r rhy thmia . Within a crit ical region on 
ch romosome l l p l 5 . 5 , muta t ion S140G was found in a Potassium Channel, 
Vol tage-Gated ( K C N Q l ) gene in all af fected members of a four generat ion 
Chinese fami ly w i th autosomal dominant heredi tary atr ial f ibr i l lat ion (Chen 
et a l . , 2003) . Screening of the coding region of the LMNA gene in DNA 
samples f rom 66 cases of di lated card iomyopathy wi th or w i thout associated 
features ident i f ied a muta t ion E161K in one fami ly wi th early onset of Atr ial 
Fibri l lat ion (Sebillon et a l . , 2003) . 
1.8.6 L i m b - G i r d l e M u s c u l a r D y s t r o p h y I B ( L G M D I B ) 
The clinical p icture of th ree fami l ies w i th autosomal dominant Limb-Girdle 
Muscular Dyst rophy (LGMD) associated wi th cardiac involvement showed 
af fected individuals wi th symmet r i c weakness in the proximal lower- l imb 
muscles before the age of 20 years (van der Kooi et a!., 1996; van der Kooi 
et a l . , 1997). In the th i rd and four th decades, upper- l imb muscles gradual ly 
became af fected as wel l . Early contractures of the spine were absent, and 
cont ractures of e lbows and Achil les tendons were ei ther minimal or late, 
d is t inguishing th is d isorder f rom EDMD. Electromyography (EMG) and 
muscle biopsy were consistent w i th mi ld muscular dyst rophy. Cardiological 
abnormal i t ies were found in 6 2 . 5 % of the pat ients, including atroventr icular 
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conduct ion d isturbances and dysrhy thmias , present ing as bradycardia; 
syncopal a t tacks needed pacemaker implanta t ion , and sudden cardiac death 
occurred at age of approx imate ly 50 years. Linkage studies found 
associat ion w i th ch romosome l q l l - q 2 1 , and suggested connexin 40 as a 
potent ia l candidate gene (van der Kooi et al . , 1997). A l though the clinical 
descr ipt ion of t he LGMDIB pat ients di f fered f r om those w i th AD-EDMD by 
the absence of s igni f icant contractures, predominance of proximal l imb 
weakness, and occasional presence of calf hyper t rophy, the two phenotypes 
could resul t f rom d i f ferent alleles of the same locus. 
In th ree LGMDIB famil ies l inked to markers on chromosome l q l l - q 2 1 , 
muta t ions in the LMNA gene were ident i f ied: a missense muta t ion , a 
delet ion of a codon, and a spl ice-donor site var iant (Muchir et al. , 2000). 
The th ree muta t ions were identi f ied in all af fected members of the 
corresponding fami l ies and were absent in 100 unrelated control subjects, 
demonst ra t ing tha t LGMDIB and AD-EDMD are allelic disorders. Al though 
the repor t by Bonne 1999 was the f i rst l inking a specific disease to a 
mu ta t ion in the lamin fami ly , they found t ha t the gene encoding lamin B l 
mapped to the same region, 5q23 .3 -q31 .3 , in another dominant ly inherited 
myopa thy , LGMDIA. 
1.8.7 Autosomal Recessive Charcot-Marie-Tooth type 2 (AR-CMT2) 
(CMT2B1) 
Charcot -Mar ie-Tooth disease const i tutes a clinically and genetical ly 
heterogeneous group of heredi tary motor and sensory neuropathies. On the 
basis of electrophysiological cr i ter ia, CMT is divided into two major types: 
t ype 1 , the demyel inat ing f o r m , character ized by a motor median nerve 
conduct ion veloci ty less ' than 3 8 m / s ; and type 2, the axonal f o r m , wi th a 
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normal or s l ight ly reduced nerve conduct ion veloci ty. CMT2B2 is clinically 
s imi lar to CMT2B1 but maps to 19q. 
In a large consanguineous Moroccan fami ly wi th autosomal recessive CMT2, 
nine af fected sibs presented the onset of the clinical features in the second 
decade of l i fe. All af fected individuals had weakness and wast ing of the 
distal lower l imb muscles and lower l imb aref lex ia; pes cavus was present in 
seven pat ients , and there was a proximal muscle involvement in six. Motor 
nerve conduct ion velocit ies were normal or sl ightly reduced in all pat ients, 
ref lect ing an axonal process (Bouhouche et al . , 1999; Leal et al . , 2001). A 
genome-w ide search showed l inkage of the disorder to marker on 
chromosome I q , specif ically I q 2 1 . 2 - q 2 1 . 3 . Myelin protein zero gene (MPZ) 
was excluded as a candidate for mutat ions by physical mapping and direct 
sequencing (Bouhouche et a l . , 1999). 
In a separate s tudy, th ree consanguineous Algerian famil ies wi th autosomal 
recessive CMT2 were l inked to chromosome l q 2 1 . A homozygous mutat ion 
was found in the LMNA gene (R298C). An animal model has revealed tha t 
LMNA null mice presented wi th axonal clinical and pathological phenotype 
highly s imi lar to pat ients wi th autosomal recessive CMT2 (De Sandre-
Giovannoli et a l . , 2002) . 
1.8.8 Mandibuloacral Dysplasia (MAD) 
Two teenaged males wi th hypoplast ic mandible producing severe dental 
c rowd ing , acroosteolysis, st i f f jo ins , and at rophy of the skin over hands and 
feet were descr ibed. The clavicles were hypoplast ic and persistently wide 
cranial sutures and mu l t iwormian bones were noted. Alopecia and short 
s ta ture were o ther features of this proger ia- l ike syndrome (Young et al . , 
1971). The di f ferent ia l diagnosis also included pycnodysostosis, Hajdu-
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Cheney synd rome, cleidocranial dysplasia, and acrogeria. Patients wi th MAD 
have been mis taken ly diagnosed as having Werner syndrome (Cohen et a!., 
1973). 
Partial l ipodyst rophy, ex t reme insulin resistance and marked 
hypermetabo l i sm have been observed in MAD pat ients. Studies of body fat 
d is t r ibut ion in two male and two female patients wi th MAD by 
an th ropomet ry , dual energy X-ray absorpt iometry , and magnet ic resonance 
imaging found tha t th ree of the four subjects had loss of subcutaneous fat 
f rom the ex t remi t ies wi th normal or sl ight excess in the neck and t runcal 
regions (Pattern A ) . In contrast , one pat ient had general ized loss of 
subcutaneous fat involv ing the face, t runk , and extremi t ies (Pattern B). All 
of the pat ients had normal glucose tolerance but fasting and postprandial 
hyper insul inemia were suggest ive of insulin resistance. Therefore, there are 
t w o types of body fa t d is t r ibut ion pat terns, both of which are associated 
w i th insulin resistance and its metabol ic compl icat ions (Cutler et al . , 1991; 
Freidenberg et a l . , 1992; Simha and Garg, 2002). 
By analysis of f ive consanguineous I ta l ian fami l ies, a l inkage of MAD to 
l q 2 1 was found . DNA sequencing of the LMNA gene identif ied a 
homozygous muta t ion (R527H) in the famil ies (Novelli et al . , 2002). 
Mutat ional analysis of the LMNA gene in pat ients wi th MAD f rom six 
pedigrees found tha t pat ients f rom two pedigrees wi th type A l ipodystrophy 
had the homozygous R527H hnutation, whereas the other four affected 
sub jec ts , who had type B l ipodystrophy, did not have any mutat ion in the 
exons or splice junc t ions of the LMNA gene. RNA extracted f rom 
lymphoblas ts of t w o of t he pat ients also revealed normal sequence. I n these 
four sub jects , sequencing of o ther genes impl icated in l ipodystrophies, i.e. 
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alpha acylglycerol 3 phosphate o acyl transferase 2 (AGPAT2), seipin and 
PPARG revealed no substant ial a l terat ions (Simha et al . , 2003). These 
au thors no ted t ha t pat ients repor ted by (Novell! et al . , 2002) had type A 
l ipodyst rophy, and concluded tha t MAD is a genetical ly heterogeneous 
disorder, w i th defects at locus other than LMNA being responsible for the 
MAD wi th type B l ipodystrophy phenotype. According to the lat ter, a study 
described a 13 years old gir l w i th mandibuloacral dysplasia who had absent 
breast deve lopment , a l though pubic and axi l lary hair was normal . Hormone 
studies revealed no abnormal i t ies (Cogulu, 2003). 
1.8.9 Others 
1.8.9.1 Hutchinson-Gilford Progeria Syndrome 
Hutchinson-Gi l ford Progeria Syndrome (HGPS) is an exceedingly rare 
disorder character ized by precocious senil i ty of a str ik ing degree. Death 
f r om coronary ar tery disease is f requent and may occur before 10 years of 
age. The name Progeria was given to this disorder in an article where the 
t e r m ateleiosis was assigned to a p i tu i tary g rowth hormone deficiency 
(Gilford, 1904). Earl ier reports about th is disorder had been wr i t ten 
(Hutchinson, 1886) and recorded cases of two possible affected brothers 
whose parents were f i rst cousins were described as: "A boy, aged 8 years. 
Condit ion has been present since b i r th . There are four children in the fami ly : 
the girls are una f fec ted ; both boys are af fected. The senile condit ion of the 
skin and fades should be no ted. The vessels show arteriosclerosis. There is 
a lmost complete absence of subcutaneous fa t " (Paterson, 1922). 
A Japanese pat ient w i th Progeria surv ived the age of 45 years and died of 
myocardia l in farct ion. Clinically he seemed typical except for the unusual 
long surv ival (Ogihara et a l . , 1986). According to reviews of the l i terature, 
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the age at death ranges between 7 and 27.5 years, wi th a median age of 
13.4 years. Ident ica l tw ins wi th Progeria, who developed heart fai lure at the 
age of 8 , died wi th in one month of each other. Cytogenetical analysis 
showed an inver ted insert ion in the long a rm of chromosome 1 in 7 0 % of 
the cells, suggest ing tha t a gene for Progeria might be located on 
ch romosome 1 (Brown, 1990). In a 9 years old pat ient wi th a classic picture 
of Hutchinson-Gi l ford Progeria, an interst i t ial delet ion on region l q 2 3 was 
found . I t was then suggested tha t the genetic defect might reside in the p-
1,4-Galactosyl t ransferase polypept ide 3 (B4GALT3) gene, which maps to 
l q 2 3 , as per turbat ion of glycosylat ion in connect ive t issue had been 
demons t ra ted in pat ients wi th th is condit ion (Delgado Luengo et al . , 2002). 
A later s tudy suggested t ha t t he defect causing Progeria migh t reside in the 
pro l ine/arg in ine-r ich end leucine-r ich repeat protein gene (PRELP), which 
maps to region l q 3 2 and is a small leucine-r ich proteoglycan that binds 
type I col lagen to basement membrane and type I I collagen to cart i lage 
(Lewis , 2003). 
A recent s tudy repor ted de novo point mutat ions in Lamin A causing 
Hutchinson-Gi l ford Progeria Syndrome. The HGPS gene was initially 
localized on chromosome I q by observing two cases of uniparental 
isodisomy of I q , and one case wi th a 6 Mb paternal intersti t ial delet ion. 
Eighteen out of twen ty classic cases of HGPS harboured the identical de 
novo single-base subst i tu t ion , a C-T t ransi t ion (C-T 2036) result ing in a 
si lent G-G change at codon 608 wi th in exon 11 (G608G). One addit ional 
case was ident i f ied w i th a d i f fe rent subst i tut ion wi th in the same codon. Both 
of these muta t ions were shown to result in act ivat ion of a crypt ic splice site 
wi th in exon 11 of the LMNA gene, result ing in the product ion of a protein 
product t ha t deletes 50 amino acids near the C-terminus. This pre-Lamin A 
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sti l l retains the CaaX box but lacks the site for endoproteolyt ic cleavage. 
Immunof luorescence of HGPS f ibroblasts wi th ant ibodies directed against 
Lamin A revealed tha t many cells showed visible abnormal i t ies of the 
nuclear membrane (Eriksson et al . , 2003). 
Other studies w i th cells lines f rom HPGS probands showed tha t f ive carr ied 
the common muta t ion wi th in exon 11 of the LMNA gene (C-T 2036) (Cao 
and Hegele, 2003) ; one of the seven pat ients carried the mutat ions G608S, 
and conf i rmed the f indings made by (Eriksson et al . , 2003) using the same 
cell l ines. One of the pat ients wi th an apparent ly typical HGPS, who was 28 
years old at the t ime of DNA analysis, presented compound heterozygosity 
for two missense muta t ions , R471C in exon 8 and R527C in exon 9. 
Unfor tunate ly , parental DNA samples were not available for analysis. In a 
separate s tudy, t he exon crypt ic spl ice-site act ivat ion mutat ion (1824C-T = 
1819-1968de l ) in two HGPS pat ients was found. Immunocytochemica l 
analysis of lymphoblasts f rom one pat ient using specific antibodies against 
Lamin A /C , Lamin A and Lamin B l showed tha t most cells had str ik ingly 
a l tered nuclear sizes and shapes, wi th nuclear envelope interrupt ions 
accompanied by chromat in ext rus ion. Lamin A was detected in 1 0 - 2 0 % of 
HPGS cells. Only Lamin C was present in most cells, and Lamin B l was 
found in the nuc leoplasm, suggest ing tha t it had dissociated f rom the 
nuclear envelope. Western blot analysis showed 2 5 % of normal Lamin A 
levels and no t runcated fo rm was detected (De Sandre-Giovannoli et al . , 
2003) . 
1.8.9.2 Werner Syndrome 
The clinical features of Werner Syndrome are scleroderma-l ike skin changes, 
especial ly in the ex t remi t ies , cataract , subcutaneous calcif ication, 
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prematu re arter iosclerosis, diabetes mel l i tus, and wizened-premature ly 
aged faces. A part icular instruct ive pedigree was reported were the habitus 
was character is t ic : shor t s ta ture , slender l imbs, and stocky t runk (McKusick, 
1963). Werner Syndrome has been found to be caused by mutat ions in the 
DNA Hel icase- l ike (RECQL2) gene, which encodes a homolog of the E. coli 
RecQ helicase. Patients whose phenotype was classified as "atypical Werner 
Synd rome" , w i th a more severe phenotype than tha t observed wi th 
muta t ions in the RECQL2 gene, were found to have mutat ions in the LMNA 
gene. 
An extended s tudy of 129 indexed pat ients referred to the internat ional 
regist ry for molecular diagnosis of Werner Syndrome, 26 ( 2 0 % ) had wild 
t ype WRN prote in coding regions and were categorized as having atypical 
Werner Syndrome on the basis of molecular cr i ter ia. In these individuals, 
DNA sequencing of all exons of the LMNA gene revealed tha t four pat ients 
( 1 5 % ) were heterozygous for novel missense mutat ions in this gene, 
specif ically A57P, R133L and L140R. These mutat ions altered relatively 
conserved residues wi th in Lamin A/C. Fibroblasts f rom the pat ient wi th 
muta t ion L140R had a substant ia l ly enhanced proport ion of nuclei wi th 
al tered morpho logy and mislocalized lamins. Indiv iduals wi th atypical 
Werner Syndrome w i th mutat ions in the LMNA gene had a more severe 
phenotype than did those wi th the disorder due to mutant RECQL2. 
Typical Werner Syndrome is autosomal recessive; atypical Werner 
Syndrome due to muta t ions in the LMNA gene is a heterozygous disorder 
(Autosomal Dominan t ) . A report by Hegele et al 2003 states tha t the clinical 
designat ion of Werner Syndrome for each of the four pat ients described by 
Chen et al 2003 , appeared somewhat insecure. The author noted tha t the 
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comparat ive ly young ages of onset in the pat ients wi th mutant LMNA would 
be j u s t as consistent wi th late onset HGPS as wi th early onset Werner 
Syndrome. Patients wi th so-called atypical Werner Syndrome and mutan t 
LMNA also expressed componen t typical of non-progero id laminopathies. I t 
was then suggested tha t DNA analysis could help draw a diagnostic line tha t 
clarif ies potent ia l over lap between older pat ients wi th Hutchinson-Gil ford 
Progeria Syndrome and younger pat ients wi th Werner Syndrome, and tha t 
therapies may depend on a precise molecular classif ication. 
1.9 The yeast two-hybrid system (YTHS) 
The yeast two hybr id sys tem (YTHS) has probed to be one of the most 
popular methods in b iochemist ry to tes t for prote in-prote in interact ion, 
which combined wi th o ther biochemical approaches, produces a powerful 
tool for b iochemists and cell biologists. 
In yeast , the genes required for galactose metabol ism are control led by two 
regulatory prote ins, GAL4 and GAL80, as well as by the carbon source in the 
med ium. When galactose is present, the GAL4 protein binds to GAL4-
responsive e lements wi th in the UAS upst ream of several genes involved in 
galactose metabo l ism and act ivates t ranscr ip t ion. I n the absence of 
galactose, GAL80 binds to GAL4 and blocks transcr ipt ional act ivat ion. 
Fur thermore , in the presence of glucose, t ranscr ipt ion of the galactose 
genes is immedia te ly repressed. The t ight regulat ion of the GAL UASs by 
GAL4 makes it a valuable tool for manipulat ing expression of reporter genes 
in two -hyb r i d sys tems t ha t are dependent on the GAL4 DNA-Binding 
Domain (BD) . However , in such sys tems, the yeast host strains must carry 
delet ions of the GAL4 and GAL80 genes to avoid interference by 
endogenous gal4 and gal80 proteins. I f this is the case, no significant 
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glucose repression is observed in these strains and no induction is produced 
unless a two -hyb r i d interact ion is occurr ing. Therefore, nutr i t ional regulat ion 
of GAL4 UASs is not a feature of the GAL4 based two-hybr id systems. 
The nat ive yeast HIS3 promoter contains a UAS site recognized by the 
t ranscr ip t ional act ivator GCN4, and two TATA boxes. GCN4 regulates one of 
the TATA boxes (TR), whi le the other TATA box (TC) drives low-level 
const i tu t ive expression of HIS3. TC is not regulated by the nat ive GCN4-
binding UAS, the G A L l UAS, or the art i f icial UASG constructs. HIS3 reporter 
gene in the yeast strain Y190 is unusual ly st rong among the GAL4 two -
hybr id repor ter genes in t ha t it is under the control of the G A L l UAS and a 
min imal p romote r contain ing both HIS3 TATA boxes. The result is high level 
of expression (due to GAL l UAS) when induced by a posit ive two-hybr id 
in terac t ion ; th is strain also exhibi ts a signif icant level of const i tut ive leaky 
expression (due to HIS3 TC). In contrast , in other yeast strains (HF7c, 
PJ69-2A or AH 109) the ent i re HIS3 promoter ( including both TATA boxes) is 
replaced by the ent i re G A L l p romoter , leading to a t ight regulat ion of the 
HIS3 repor ter in these strains. 
Recently, systemat ic two-hybr id system approaches have been used in 
bacter ia, yeast and nematodes to construct impressive large-scale prote in-
prote in in teract ion maps involv ing complex processes f rom DNA-damaging 
responses to vulval deve lopment . Yeast two-hybr id assays have proven to 
be very useful when coupled to other prote in-prote in interaction tests , 
a l lowing the ass ignment of putat ive funct ion categories to novel proteins. 
But on its o w n , as any exper imenta l approach, it has disadvantages. First, 
t he vo lume of exper imenta l work required and contradictory results. For 
example , in yeast , a genome-wide prote in-prote in interact ion map gave 
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a r o u n d 4 5 0 0 p u t a t i v e i n t e r a c t i o n s . Even t h e w e l l - c h a r a c t e r i z e d p r o t e i n s 
I n t e r a c t e d w i t h 5 - 7 o t h e r p r o t e i n s . S o , c o n s i d e r i n g t h e a m o u n t o f p o t e n t i a l 
c o d i n g s e q u e n c e s d e r i v e d f r o m t h e y e a s t g e n o m e , t h e n u m b e r o f 
i n t e r a c t i o n s is e s t i m a t e d in 3 0 - 4 0 0 0 0 , c o m p a r e d t o t h e a c t u a l 4 5 0 0 
i n t e r a c t i o n s f o u n d . S e c o n d l y , a p p r o x i m a t e l y 5 0 % o f t h e i n t e r a c t i o n s a r e 
f a l s e , d u e t o s p u r i o u s i n t e r a c t i o n s b e t w e e n p r o t e i n s t h a t do n o t i n t e r a c t in 
v i v o . T h i r d , a c o n v e n t i o n a l t w o - h y b r i d i n t e r a c t i o n o c c u r s in t h e n u c l e u s , a n d 
u s e s a t r a n s c r i p t i o n a l s y s t e m , l i m i t i n g t h e s t u d y o f i n t e r a c t i o n o f cel l 
m e m b r a n e p r o t e i n s a n d t r a n s c r i p t i o n f a c t o r s . 
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1.10 Aim of this thesis. 
T h e e m e r g e n c e o f n e w c l in i ca l d i a g n o s i s o f o l d - r a r e h u m a n d i seases 
i n v o l v i n g n u c l e a r m e m b r a n e f i l a m e n t s has r e v o l u t i o n i z e d t h e L a m i n o l o g y 
f i e l d a n d h a s p r o v i d e d a p o w e r f u l t o o l t o a d d r e s s t h e u n r e s o l v e d issue o f t h e 
ro le o f l a m i n s A a n d C in n u c l e a r m e t a b o l i s m . M o r e i m p o r t a n t l y , t h e 
e x i s t e n c e o f s i m i l a r d i s o r d e r s ( A D a n d X L - l i n k e d E D M D ) i n v o l v i n g n u c l e a r 
l a m i n s ( A - t y p e ) a n d t h e i r a s s o c i a t e d p r o t e i n s ( e m e r i n ) has g i v e n k e y c lues 
o f t h e i m p o r t a n c e o f t h e i n t e r a c t i o n b e t w e e n l a m i n s a n d t h e i r i n t e r a c t i n g 
p a r t n e r s . 
C h a p t e r 3 o f t h i s t h e s i s a d d r e s s e d t h e q u e s t i o n w h e t h e r l a m i n s i n t e r a c t w i t h 
e m e r i n , a t y p e I I i n t e g r a l m e m b r a n e p r o t e i n o f t h e n u c l e a r m e m b r a n e . 
Us ing a Y T H S a p p r o a c h , n o t o n l y d e m o n s t r a t e d t h a t al l l a m i n s i n t e r a c t w i t h 
e m e r i n , b u t a f u r t h e r s t e p p r o v e d t h a t t h e i n t e r a c t i o n occu rs p r e f e r e n t i a l l y 
w i t h t h e g l o b u l a r t a i l d o m a i n . T r a n s f e c t i o n e x p e r i m e n t s s u p p o r t e d t h e 
p r o t e i n - p r o t e i n i n t e r a c t i o n s in v i t r o , c o n f i r m i n g t h a t e m e r i n a n d l a m i n B 
r e m a i n a t t a c h e d t o t h e n u c l e a r w h e n A - t y p e l a m i n s a re e x p r e s s e d 
e c t o p i c a l l y a n d f o r m n u c l e o p l a s m i c a g g r e g a t e s . 
I n C h a p t e r 4 , t h e s e s t u d i e s s h o w t h a t m u t a t i o n s in t h e A D - E D M D a re n o t 
i n v o l v e d in a n y m o l e c u l a r c r o s s - l i n k i n g , e v e n in t h e case w h e n a n e w 
c y s t e i n e a p p e a r s in t h e A - t y p e f i l a m e n t s . I n v i v o ana l ys i s c o n f i r m e d t h a t a 
n u c l e a r c h e c k - p o i n t in G O ^ G l e x i s t , w h e r e t h e r e - a r r a n g e m e n t o f n u c l e a r 
p r o t e i n s o c c u r s w i t h a h i g h e r f r e q u e n c y in ce l ls l ines w i t h m u t a t i o n s in t h e 
L M N A g e n e . T h i s e v e n t o c c u r s i n d e p e n d e n t l y o f t h e l o c a t i o n o f t h e 
m u t a t i o n s . I n a d d i t i o n , t h i s s t u d y p r o v i d e d a n in v i t r o m o d e l t o assess t h e 
b e h a v i o u r o f m u t a n t l a m i n s in l a m i n o p a t h i e s , as t y p i c a l h o n e y c o m b 
s t r u c t u r e s w e r e i n d u c e d b y s e r u m s t a r v a t i o n . I n p a r a l l e l , i t has b e e n 
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d e m o n s t r a t e d t h e ro le o f N e s p r i n s in t h e cel l cyc le a n d in s e n e s c e n c e , a n d 
t h e i r p o s s i b l e I n v o l v e m e n t in m u s c u l a r d y s t r o p h i e s . 
F i na l l y , c h a p t e r 5 c o m p i l e s s u f f i c i e n t e v i d e n c e t o j u s t i f y f u r t h e r s t u d i e s t o 
f i r s t , d e s c r i b e a p o s s i b l e c o m m o n h a p l o t y p e t h a t e x p l a i n s t h e d i f f e r e n t 
l a m i n o p a t h i e s b a s e d o n SNPs p a t t e r n s ; s e c o n d , t h e poss ib le d i f f e r e n t i a l 
a l le l i c e x p r e s s i o n o f l a m i n s in A D - E D M D ; t h i r d , t o s t u d y r e g u l a t o r y 
m e c h a n i s m s o f l a m i n s a t d i f f e r e n t l eve ls ( t r a n s c r i p t i o n a n d t r a n s l a t i o n ) ; a n d 
las t b u t n o t l e a s t , t h e p o s s i b l e ro le o f s u b t l e s t o i c h i o m e t r i c c h a n g e s in t h e 
c o m p o s i t i o n o f t h e n u c l e a r l a m i n a . 
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Figures Chapter 1. 
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Figure 1.1. 
D i a g r a m s h o w i n g t h e s t r u c t u r e o f t h e n u c l e u s w i t h al l t h e s u b -
c o m p a r t m e n t s d e s c r i b e d u p t o d a t e , w i t h spec ia l e m p h a s i s on t h e n u c l e a r 
l a m i n a . 
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Nuclea 
Lamm 
Figure 1.2 
E l e c t r o n m i c r o g r a p h s h o w i n g t h e u l t r a s t r u c t u r e o f t h e n u c l e u s . A r r o w s s h o w : 
NE ( n u c l e a r e n v e l o p e ) , M i t ( m i t o c o n d r i a ) , ER ( e n d o p l a s m i c r e t i c u l u m ) , N u , 
( n u c l e o l i ) . 
56 
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2. Chapter T w o - Materials and Methods 
2.1. Cloning 
2.1.1. Media 
For d rug select ion of t r ans fo rmed E. coli, LB-agar plates (10 g /L Tr ip tone, 5 g /L 
Yeast Ext rac t , 10 g /L NaCI, pH 7.2) were supp lemented w i th 100 ng/ml Ampici l l in 
or 50 \ig/m\ Kanamicin where it corresponded (J. Sambrook, 1989). 
2.1.2. Bacterial strains 
E. coli s t ra in DH5-a [F - , r e c A l , e n d A l , hsdR17, supE44, t h i l , gyrA, r e c A l ] and 
JM109 [ e l 4 - ( M c r A - ) r e c A l e n d A l gy rA96 t h i - 1 hsdR17 (rK- m K + ) supE44 re lA l 
D( lac-proAB) [F ' t raD36proABIac l ' 'ZDM15] ] was used as the bacterial t rans fo rmat ion 
rec ip ien t fo r all p lasmid cons t ruc ts . 
2.1.3. Sub-Cloning the emerin gene into pASl-CYH2 
For c loning Emerin into p lasmid pASl -CYH2 (GAL4 Binding Domain) , a full length 
cDNA of h u m a n Emer in in pEGFP-Cl was prov ided by Dr. Will Whi t f ie ld . This 
p lasmid was d igested w i th 30 uni ts of Hindll l (AVAGCTT) ( in Buffer E, Promega) 
per 1 ^g of p lasmid DNA for 2 hours at 37°C, and pur i f ied w i th the Promega's DNA 
Clean-up Sys tem. The Hindl l l ends were t reated w i th 1 uni t of DNA Polymerase 
Large F ragment (K lenow) per 1 ng of p lasmid DNA in Klenow buffer (SOmM Tris-
HCI (pH 7.2 at 25 °C) , l O m M MgS04, 0 .1 mM DTT) at 25°C for 10 minutes and 
pur i f ied w i th Clean-Up Sys tem, fo l lowing digest ion w i th 30 units of BamHI 
(GTGATCC) (in buf fer E, Promega) per 1 ^g of p lasmid DNA for 2 hours at 37°C. 
The f r a g m e n t genera ted was t rea ted w i th 1 uni t of DNA Polymerase Large 
F ragment (K lenow) per 1 i^ g of p lasmid DNA in Klenow buf fer at 25°C for 10 
m i n u t e s , and pur i f ied by the Clean-Up S y s t e m . The DNA products were separated 
by e lec t rophores is on 1 % Low Melt ing Point Agarose Gel in TAE buf fer . The band 
of a round 700 bp was excised f r o m the gel and purif ied by using the Wizard® SV 
Gel and PCR Clean-Up Sys tem. 
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The p A S l - C Y H 2 vec to r was d igested wi th 40 uni ts of Smal (CCCTGGG) (in Buf fer 
J, P romega) per i^ g of p lasmid DNA for 2 hours at 25°C, pur i f ied by the DNA c lean-
up sys tem (Promega) and then d igested wi th 30 uni ts of BamHI (GTGATCC) (in 
bu f fe r E, Promega) per 1 ng of p lasmid DNA for 2 hours at 37°C (Figure l a ) . Once 
the l inear vec to r (Sma l - B a m H I ) was pur i f ied w i th the Clean-Up Sys tem, the 
emer i n f r a g m e n t was l igated using 1 unit of T4 DNA Ligase (in T4 DNA Ligase buffer 
[ 3 0 m M Tris-HCL (pH 7.8 at 25°C) , lOmM MgClz, lOmM DTT and I m M ATP] per 
l igat ion react ion and incubated at 22°C for 16 hours (opt imal temperature for blunt 
end c loning) (J . Sambrook, 1989). Two vector- inser t rat ios where used, 1:3 and 
1:6, to increase the probabi l i ty of c loning the insert a t the b lunt end . 
Trans format ion react ions where set up using 2.5 \i\ of the l igation reactions and 80 nl 
of JM109 competent cells prepared by Rubidium Chloride method (Ano and Shoda, 
1992). The m ix tu res were incubated on ice for 30 m inu tes ; heat shocked at 42°C 
fo r 1 m inu te and cooled down on ice for 2 m inu tes . Growing media (800 nl LB 
m e d i u m w i t hou t ant ib io t ics) was added and bacteria were al lowed to recover by 
gent le shaking a t 37°C for 1 hour. The whole cu l ture was centr i fuged at 5000 x g 
fo r 5 m inu tes and resuspended in 200 ^1 of LB med ium. Two 90 m m LB/Agar plates 
(conta in ing 25 ^1 of X-Gal ( 5 0 m g / m l ) and 50 n of IPTG O. IM, f reshly p lated, but 
d r y ) were p lated w i th 100 \i\ of t he bacter ia suspens ion, air dr ied and incubated at 
37 °C unt i l colonies appeared ( 1 4 - 1 8 hours ) . 
Ten colonies whe re picked up fo r each t rans fo rmat ion react ion, and were 
inocu la ted in LB m e d i u m conta in ing 100 ng/ml ampic i l l in . Bacteria were incubated 
a t 37°C and shacked a t 250 rpm for 16 hours. Glycerol stocks were prepared using 
0.2 ml of the cu l tu re , and the rest of the cu l tures were used to pur i fy plasmid DNA 
using Promega's W i z a r d ® Plus Minipreps DNA Puri f icat ion Sys tem. 
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2.1.4. Confirmation of the insert cloned. 
Plasmid DNAs were analyzed by restr ic t ion enzymes to conf i rm tha t the insert w i th 
the expected size was c loned. Plasmid DNA recovered f rom p A S l + emer in l igat ion 
react ions was d igested w i th 20 uni ts Ncol (CTCATG G) and BamHI (in Mult icore 
Reaction Buf fer , Promega) per 0.5 ^g of p lasmid DNA at 37°C for 2 hours and the 
products were analyzed by electrophoresis on 1 % agarose gel in TAE buffer. A band 
around 700 bp was considered as a posit ive clone. The construct was called p A S l -
Emer in . 
2.1.5. Other DNA constructs 
Al l l a m i n const ructs for yeast exper iments were kindly provided by Dr. Howard J. 
Worman Universi ty of Columbia, USA) (Ye and Worman, 1995) (Table 3.2). EGFP-
Lamin A full length was a gi f t f r o m Dr. Masako Ozumi ( Ins t i tu te of Physical and 
Chemica l Research, Sa i t ama , Japan) . EGFP-Emerin was a g i f t f r om Dr. Will 
Wh i t f i e ld . DS-Red2-Lamin C was produced in our laboratory by Maria Choleza. 
2.1.6. Sequence analysis 
The p A S l - E m e r i n DNA plasmid was pur i f ied using the Promega's Wizard® Plus 
Min ipreps DNA Puri f icat ion Sys tem. Prior to DNA sequenc ing, 100 nl of plasmid 
DNA was prec ip i ta ted w i th 50 ^1 of 7.5M A m m o n i u m Acetate and 375 nl of 
Abso lu te Ethano l , m ixed by vo r tex and cent r i fuged at 14000 x g for 15 minutes at 
r oom t e m p e r a t u r e . The pel let was washed w i th 7 0 % cold Ethanol and centr i fuged 
aga in . Superna tan t was removed carefu l ly , pel let air d r ied , and resuspended in 50 
nl of ddH20. Samples were quant i f ied by reading OD260 and 2 ^1 checked by 
e lect rophoresis on 1 % agarose gel compared to a DNA s tandard . 
Samples were sequenced tw ice by the cycle sequencing method using dye -
t e r m i n a t o r chemistry (Rosenblum et al., 1997) (Applied Biosystems) at the DNA 
Sequencing Service, D e p a r t m e n t of B iochemis t ry , Univers i ty of Dundee, using an 
A B I 377 Au toma t i c DNA Sequencer (Appl ied B iosystems) . 
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2.2. Allelic specific RT-PCR 
2.2.1. RNA isolation 
Cells were g rown on 9 0 m m dishes unt i l 80 % conf luence, and total RNA was 
isolated using 1 ml of TRI reagent (Sigma) per dish and i ncuba ted fo r 5 m i n u t e s a t 
r o o m t e m p e r a t u r e . D ishes w e r e s c r a p e d , t h e lysates t r ans fe r red to a 1.5 m l 
c e n t r i f u g e t u b e and 2 0 0 ^1 o f C h l o r o f o r m was a d d e d . Samp les we re m i x e d by 
v o r t e x f o r 15 seconds , i n c u b a t e d 3 m i n u t e s a t r o o m t e m p e r a t u r e and 
c e n t r i f u g e d a t 1 2 0 0 0 x g f o r 15 m i n u t e s a t 4 ° C . The s u p e r n a t a n t s w e r e 
co l lec ted ( t o t a l RNA) , t r a n s f e r r e d to a f resh cent r i fuge tube and 500 ^1 of 
I sopropano l was added . Samples were then vor texed for 15 seconds, incubated for 
10 m inu tes at room t e m p e r a t u r e and then cent r i fuged for 10 minutes at 4°C. 
Superna tan t was removed and the RNA pel lets were washed wi th 1 ml of 7 5 % 
Ethanol (d i lu ted w i th DEPC-treated w a t e r ) . The tubes were brief ly vor texed and 
cen t r i fuged for 5 m inu tes at 12000 x g at 4 °C. Pellets were air dr ied for 10 
m inu tes , resuspended in 20 ^1 of DEPC-treated ddH20 and heated at 50°C for 5 
m inu tes . An a l iquot was taken to read absorbance at 260nm to assess RNA 
concen t ra t ion . 
2.2.2. DNase treatment of RNA samples 
Twen ty i^ g of to ta l RNA were t rea ted w i th 0.075 uni ts of R Q l RNase-Free DNase 
(Moore, 1981) (Promega) per ng of RNA for 30 minutes at room temperature in IX 
reaction buffer ( 40mM Tris-HCI [pH 8.0 at 25 °C ] , lOmM MgS04, I m M CaCb). The 
react ion was stopped by add ing 1 ^1 of 20mM EGTA, pH 8.0 , and incubat ing the 
samples a t 65°C for 10 m inu tes . The RNA was precip i tated wi th 1/10 of the 
react ion v o l u m e of 3M NaOAC, pH 5.2 and 2 vo lumes of 1 0 0 % Ethanol and 
incubated ove rn igh t at - 20 °C . To recover the RNA, tubes were centr i fuged at 
12000 X g at 4 °C for 15 m inu tes , the superna tan t r emoved , pellets washed wi th 
300 ^l of 7 0 % Ethanol ( in DEPC t reated ddH20) and vacuum dried for 5 minutes at 
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r o o m t e m p e r a t u r e . Final ly, to ta l RNA was d i lu ted in 20 |il of, DEPC-treated ddH20 
and RNA concentra t ion assessed by reading the absorbance at 260 nm. 
2.2.3. Primer design 
Al le le-speci f ic RT-PCR depends on the synthes is of a PCR o l igonucleot ide p r imer 
t h a t precisely matches w i th one of the alleles but mismatches wi th the other 
(Newton et a l . , 1989; Wu et a l . , 1989). When the mismatch occurs near the 3' end of 
the PCR pr imer, ampli f icat ion is inefficient (Sommer et al . , 1989). Based on this 
evidence, specific pr imers were designed for the wi ld t ype and m u t a n t al leles of the 
LMNA gene d i f fe r ing in on ly one base. 
Pr imers were des igned using NetPr imer PCR onl ine so f tware which combines the 
la tes t p r ime r design a lgo r i t hms w i th a web-based in ter face a l lowing analysis of 
p r ime rs ove r the I n te rne t . Al l p r imers were analyzed for mel t ing t empera tu re 
using the neares t ne ighbour t h e r m o d y n a m i c theo ry to ensure accurate Tm 
pred ic t ion . Pr imers were ana lyzed for secondary s t ruc tu res including hai rp ins, 
se l f -d imers , and c ross -d imers in p r imer pairs. This ensured the o p t i m u m pr imer 
for the RT-PCR reac t ions , m in im iz ing the f o rma t i on of unspecif ic products . To 
fac i l i ta te the select ion of an op t ima l o l igonuc leot ide , each pr imer was given a 
rat ing based on the stabi l i ty of its secondary s t ructures. Only the best pr imers are 
tabu la ted here (See Table 5.1) 
2.2.4. RT-PCR reactions 
All react ions were downscaled f r o m the or ig inal vo lumes (50^1) considered by the 
Access- Quick RT-PCR System (Promega) to a final volume of 25 
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The react ions con ta ined : 
Final Concentrat ion in RT-PCR (25 ul) 
Access Quick RT-PCR Master Mix I X 
Total RNA 0.004 ng/^l 
Forward Primer 0.1875 pmol/nl 
Reverse Primer 0,1875 pmol/nl 
Avian Myeloblastosis Virus Reverse Transcriptase (AMV-RT) 0.125 u/\i\ 
For all t he react ions , Access Quick RT-PCR Master Mix (Tfl DNA po lymerase, 
dNTPs, and m a g n e s i u m chlor ide and react ion bu f f e r ) , reverse p r imers , Total RNA, 
and DEPC-t reated ddHaO were, m ixed in a general Master Mix. Equal vo lumes were 
d is t r ibu ted in th in wal l PCR tubes conta in ing fo rward pr imers specific for each 
al lele and heated up a t 70°C for 5 minu tes to denature the mRNA secondary 
s t ruc tu res . Samples were cooled down on ice, the AMV-RT was added, and af ter 
m ix ing gen t l y , t he tubes were spun down to col lect the contents of the tubes 
before set t ing up the thermocyc le r . D i f ferent anneal ing tempera tu re gradients 
were des igned to establ ish the op t ima l condi t ions for the set of pr imers used. All 
s teps we re carr ied ou t in a Safety Cabinet p re - t rea ted w i th UV l ight. 
2.2.5. Fragment analysis 
All ampl i f ied f r agmen ts were separated on 2 % agarose gels in I X TAE buf fer a t 70 
Vol ts . 100 bp DNA ladder (Promega) was used to assess the size of the RT-PCR 
produc ts . DNA products were stained w i th Eth id ium Bromide and visualized on an 
UV t rans i l um ina to r . 
A p i lot t r ia l was set up in the Au toma t i c DNA Sequencer CEQ-8000 (Beckman-
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Coul te r ) to analyze t he RT-PCR f ragmen ts using the l ight emi t ted by the 
f luorescence probes a t tached to the 5' end of the pr imers . CEQ-8000 was in the 
se t t ing up process, so we did not manage to use the size s tandards in the t r ia l run . 
My a im was basical ly to assess whe the r the ARMS-PCR pr imers were able to work 
in a one step mu l t ip lex RT-PCR react ion. Two ^ 1 of cleaned up products were mixed 
wi th 40 )il of d i -methy l fo rmamide , vor texed for 1 minute and centr i fuged. This 
m ix tu re was in jected into the capi l la ry system and ana lyzed. 
2.3. Bioinformatics 
I ana lyzed all t he regu la to ry e lements conta ined in the genomic sequence of LMNA 
gene and its f lank ing reg ions, and compi led all the SNPs reported unt i l the 20'^ 
November 2003 in the NCBI Database. The posit ion of each regulatory e lement 
and SNP was re lated to its actual base pair on Chromosome 1 , which contains 
7 8 6 4 9 4 5 base pairs in t o t a l . 
First , to a l locate the regu la tory e lements , a LMNA gene sequence including 32kb 
ups t ream f r o m the ATG and 14.5 Kb downs t ream f rom the TAA (57.5 Kb in to ta l ) 
was obta ined using t he OMIM Database at the Nat ional Centre for Biotechnology 
I n f o r m a t i o n webs i t e ( N C B I , USA, w w w . n c b i . n l m . n i h . g o v ) . The DNA sequence 
w a s sen t on - l i ne t o t h e Human Genome Mapping Project (HGMP) computa t iona l 
fac i l i t ies in Cambr i dge , UK, fo r NIX analys is , which searched for d i f fe rent 
regu la to ry e lemen ts l ike CpG is lands, p romo te rs and t ranscr ip t iona l sites using 
d i f f e ren t a l go r i t hms (Table 5 .5 ) . A f t e r 2 days , a not ice was given by email tha t the 
resul ts were ready, A s u m m a r y of the predicted regulatory e lements was g iven in a 
char t t ha t can only be ana lyzed by logging in the HGMP's websi te . By cl icking on 
each fea tu re on the compu te r ' s screen (Figure 5 .9 ) , detai ls of the specif ic 
regu la to ry e lemen ts are t a b u l a t e d , including the posi t ion re lated to the sequence 
p rov i ded , s ta t is t ica l scor ing and qua l i ty of predic t ion (Table 5 .4 ) . But the number 
g i ven to the region where the regu la tory e lements are in the NIX analysis is 
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re la ted to t he LMNA gene sequence p rov ided , so it does not correspond to the 
actua l posi t ion on ch romosome 1 . This inconvenience makes it a lmost impossible 
to f ind the regu la to ry e lements in the Chromosome 1 sequence (7864945 bp) and 
over lap t h e m w i th the SNPs by hand or any known sof tware . A way to avoid th is 
p rob lem is to send the who le ch romosome 1 sequence for NIX analys is, but th is 
p roved to be imposs ib le to do on- l ine because of the size of the electronic f i le . 
Ch romosome 1 ful l sequence (NT079487) was searched in the OMIM database and 
used to assign the actual posi t ion for each base of the genomic sequence of the 
LMNA gene ana lyzed , inc luding i ts regu la tory e lements . The whole ch romosome 1 
sequence was saved in Fasta f o r m a t , and impor ted into BioEdit Sequence 
A l i g n m e n t Edi tor , vers ion 5.0.9 (Hall, 1999), which automat ical ly assigned a 
number to each base f rom 1 to 7864945 . But BioEdit does not give page numbers 
for the a r ray , so it is ve ry d i f f icu l t to keep t rack of the posit ion of several SNPs in 
the 7 8 6 4 9 4 5 bases of ch romosome 1 . The ar ray was then saved in tex t f o rma t in 
Microsof t W o r d ® and pag ina ted , g iv ing a map where each bp of ch romosome 1 
can be assigned to a page number . This approach demanded the m a x i m u m power 
o f the c o m p u t e r used (DELL Pent ium 4 , 2.00 GHz, 512 MB RAM) and the m a x i m u m 
processing capaci ty of Microsof t W o r d ® since the fi le generated contained 11001 
pages of bases a r ranged in g roups of 10 w i th the corresponding number ing . This 
gave t he r ight coord inates to f ind any base pair on the ch romosome 1 sequence in 
f u t u r e analys is . 
Having now both sequences in BioEdit f o rma t ( the genomic sequence for LMNA 
gene plus its f lank ing reg ions, and Chromosome 1 ) , the f i rst step was to locate the 
actua l posi t ion ing of the genomic sequence of the LMNA gene on chromosome 1 . 
To do th i s , both f i les were opened s imul taneous ly . The f i rs t 100 bp of the LMNA 
genomic sequence were copied and pasted in the BioEdit 's searching engine to 
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look for this region on chromosome 1, finding the actual starting position 
(2502182). Then the same methodology was followed to find the end of LMNA 
genomic sequence (2559742). Both regions were easily found in the chromosome 
1 file (text format) in Microsoft Word® on pages 3513 and 3594 respectively. 
Following the same methodology (cut, paste and BioEdit search engine), each 
regulatory element predicted in the NIX analysis can be mapped accurately. 
Once the actual boundaries of the genomic sequence of the LMNA gene on 
chromosome 1 were defined and the regulatory elements allocated on it, then the 
compilation of SNPs from the NCBI website can be mapped onto the LMNA 
genomic sequence and its flanking regions to find whether they overlap or not 
with the areas of interest. To do this, two complementary approaches were used. 
First, the chromosome 1 file in Microsoft Word® was opened and the genomic 
sequence for LMNA gene was printed in hard copy (pages 3513 to 3594). All 
regulatory elements and SNPs were precisely located in the text. The second 
approach was to draw a diagram to scale in Microsoft PowerPoint®, where 
genomic regions containing all the features located in the text could be 
graphically represented (Figures 5.10 and 5.11). 
2.4. Yeast Two-Hybrid Experiments 
2.4.1. Media 
For yeast culture, YPD (20 g/L Difco Peptone, lOg/L Yeast Extract, 20 g/L 
Glucose, 20 g/L Agar [for plates], pH 5.8) and SC (6.7 g/L Yeast Nitrogen Base 
Without Amino acids, 20 g/L glucose, 20 g/L Agar [for plates]) were used with 
0.003% Adenine Hemisulfate supplement. Dropout supplements where added as 
required: 0.69 g/L -Leu, 0.74 g/L -Trp, 0.64 g/L -Leu/Trp, 0.62 g/L -Leu/-Trp/-
His, 0.60 g/L -Leu/-Trp/-His/-Leu (Parchaliuk, 1999b; Parchaliuk, 1999a). 
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2.4.2. Yeast Strains 
Yeast strain Y190 [MATa, ade2-101, ga!80, his3-200, leu2-3, 112 t r p l - 9 0 1 , 
ura3-52, URA3: :GALl- lacZ, Iys2: :GAL1-HIS3] was obtained from Dr. Emma 
Warbrick (Department of Biociiemistry, University of Dundee, UK), and was used 
as the recipient for all yeast transformations. 
2.4.3. Yeast Transformation using the Lithium Acetate Method 
S, cerevisiae strain Y190 was inoculated into 5 ml of YPD + Adenine medium and 
incubated overnight at 30°C on a shaker at 250 rpm. The titre of the overnight 
culture was determined by measuring the ODeoo of a 1:10 dilution in YPD medium. 
2.5 X 10^ cells were added to pre-warmed (30°C) YPAD medium, to give a total 
volume of 50 ml in a 250 ml flask, giving a starting cell titre of about 5 x 10^ cells / 
ml (For most yeast strains an ODeoo of , 0.1 corresponds to approximately 1 x 10^ 
cells/ml). The culture was incubated at 30°C on a shaker at 250 rpm until the cells 
went through two divisions (2 x 10^ cells/ml, approximately 3 - 4 hours). 
Cells were harvested in a sterile 50 ml disposable centrifuge tube by centrifugation 
at 3000 X g for 5 min, the supernatant removed, and cells washed in 25 ml of 
sterile ddH20, centrifuged, and the supernatant removed. The cell pellet was 
resuspended in approximately 900 nl of sterile dH20 and transferred to a 1.5 ml 
microcentrifuge tube. Cells were centrifuged at 14000 x g for 1 minute, 
resuspended in 0.1 M LiAc to a final volume of 1 ml, and incubated at 30°C for 10 
minutes. For each 1 X transformation reaction, 100 nl aliquot of the LiAc cell 
suspension was transferred to a new 1.5 ml microcentrifuge tube. Cells were 
pelleted at top speed in a microcentrifuge for 1 minute and the supernatant 
removed. 
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Transformation mix was prepared by adding the following reagents: 
50 % polyethylenglycol 240 i^l 
1.0 M LiAc 36 i^l 
ss-DNA (2 mg/ml) ,50.^1 
Plasmid DNA (0.5 ^g) X nl 
Sterile H2O X ^1 
Total volume 360 ^\ 
Transformation mix was added to the cell pellet, vortexed vigorously until the 
pellet was fully resuspended and the transformation mixture incubated at 30°C for 
30 minutes with no shaking. Cells were heat shocked at 42°C in a water bath for 
30 minutes, and then pelleted at top speed in a microcentrifuge for 1 minute and 
then the transformation mix was removed carefully. 
Cells were washed with 1.0 ml of sterile ddH20 by gently pipetting the suspension 
up and down (to much pipetting washes away transformants), and 100 |il of each 
sample was plated onto the appropriate SC-dropout medium. Plates were 
incubated at 30°C for 2-4 days until colonies appeared. 
2.4.4. Testing the DNA-BD/bait protein for transcriptional 
activation 
S. cerevisiae Y190 was transformed with 0.5 |ig of the pASl-Emerin (BD) construct 
using the small-scale yeast transformation protocol (Agatep, 1998). Transformants 
were plated on SD/-Leu/X-a-Gal, SD/-Trp/X-a-Gal, SD/-His/-Trp X-a-Gal, SD/-
Ade/-Trp/ X-a-Gal and SD/-Trip/-His/40mM SAT, and grown for 2 - 4 days at 
30°C until colonies appeared. A negative control including the "empty" DNA-BD 
vector (pASl ) was used under the same growth conditions. 
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2.4.5. p-Galactosidase lift assay 
The yeast two-hybrid system was prepared as described (Fields and Song, 1989). S. 
cerevisiae Y190 was grown in YPAD (20g/L peptone, 10 g/L Yeast Extract, 2% 
Glucose and 0.003% Adenine Hemisulfate, and 40 mM 3AT, pH 5.8) to mid log 
phase at 30°C in liquid cultures agitated at 250 rpm and then transformed with 
plasmid DNA using the modified lithium acetate procedure (Agatep, 1998). After 
transformation, yeasts were plated on SDA medium (6.7 g/L Yeast Nitrogen Base 
without Amino acids, 2 % Agar and 0.003% Adenine Hemisulfate, and 40 mM 
3AT, pH 5.8) and incubated at 30°C for 2 - 4 days (colonies 1-3 mm in diameter). 
Once colonies appeared, they were streaked in a "radial fashion" onto 90 mm 
master plates containing SD medium (5.7 g/L Yeast Nitrogen Base without Amino 
acids, 2 % Agar and 0.003% Adenine Hemisulfate, and 40 mM 3AT, pH 5.8) and 
grown for another 2 days at 30°C. 
For each plate of transformants, a sterile Whatman filter was pre-soaked in 2ml of 
Z-buffer (16.1 g/L Na2HP04x7H20, 5.50 g/L NaH2P04xH20, 0.75 g/L KCI and 0.246 
g/L MgS04x7H20, pH 7.00, plus 0.039 M (3-mercaptoethanol and 0.33 mg/ml X-
gal) (fresh solution) in a 90mm plate. Using forceps, a clean and sterile 
nitrocellulose filter was placed carefully over the surface of the plate of the 
colonies to be assayed, and gently rubbed to help colonies cling to the filter. After 
the nitrocellulose filter was properly marked for orientation on the original plate, 
and left to get properly wetted, it was carefully lifted off the agar plate and 
transferred, with the colonies facing up, to a pool of liquid nitrogen and completely 
submerged for 30 seconds. After the filter was completely frozen, it was removed 
from the liquid nitrogen and allowed to thaw at room temperature, then placed 
carefully, colonies side up, on the pre-soaked filter, avoiding any air bubbles under 
or between the filters. Finally, the filters were incubated at 30°C and checked 
periodically for the appearance of the blue colour. 
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2.4.6. Liquid Culture Assay 
Transformants were grown at 30°C with shaking (250 rpm) overnight in 5 ml SD 
medium supplemented with -Ade/-Trp/-His and 40 mM 3-AT. Cultures were 
vortexed vigorously for 1 minute to disperse the yeast clumps and 2 ml were 
immediately transferred to 8 ml of YPDA medium. The cultures were incubated at 
30°C for 3 - 5 hours, until the OD50O of 1 ml (culture vortexed for 1 minute to 
disperse the clumps) was 0.5 - 0.8 (mid-log phase). The culture was divided into 3 
replicate aliquots of 1.5 ml each and centrifuged at 14000 x g for 30 seconds to 
pellet the cells. After the supernatant was removed, 1.0 ml of Buffer 1 (0.01 M 
HEPES, 0.154 M NaCI, 0.0045 M L-Aspartate [hemi-Mg salt ] , lOg/L BSA and 0.05 
% Tween 20, pH 7.25) was added, vortexed until cells were thoroughly 
resuspended and centrifuged 14000 x g for 30 seconds. Supernatant was 
carefully removed, 0.3 ml of Buffer 1 was added (concentration factor 1.5/0.3 = 5 
fold) and 0.1 ml (in triplicate) of the yeast suspension was transferred to fresh 
micro-centrifuge tubes. Samples were frozen in liquid nitrogen for 2 minutes and 
thawed in a water bath at 37°C for 1 minute. This freeze/thaw cycle was repeated 3 
times to ensure that the cells were completely broken open. 0.7 ml of Buffer 2 
(2.23 mM chlorophenol red-p-D-galactopyranoside, CPRG) was then added to the 
samples and mixed thoroughly by vortexing (very critical step for the assay). 
Time was recorded as soon as Buffer 2 was added to the samples. A blank 
consisted of 1 ml of Buffer 2, and a positive control consisted of 0.1 units of a 
commercial p-galactosidase enzyme in Buffer 2. Once the colour of the samples 
was yellow/grey to red, 0.5 ml of 0.003 M ZnCl2 was added to each sample and 
vortexed vigorously to stop colour development. Time was recorded as reaction 
t ime. Samples were centrifuged at 14000 x g for 1 minute at room temperature to 
pellet the cell debris and the clear supernatant was transferred to a fresh cuvette. 
The spectrophotometer was set up to zero using the blank at O.D 578 and the O.D of 
the samples recorded (an OD578 between 0.25 - 1.8 is in the linear range of the 
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assay). 
One unit of (p-galactosidase is defined as the amount of enzyme that hydrolyzes 1 
^mol of CPRG to chlorophenol red and D-galactose per minute per cell (Miller, 1972; 
Miller, 1992). The units of |3-galactosidases were calculated using the following 
formula: 
p-galactosidase units = 100 x OD578 / (t x V x ODeoo) 
Where: 
t = Elapsed time (in minutes) 
V = 0.1 X concentration factor 
ODeoo = Absorbance of 1 ml of culture 
2.5. Mammalian Cell Culture and Transfection 
2.5.1. Media 
Dulbecco's modified Eagle's medium (DMEM) supplemented with 10 units/ml 
penicillin, 50 ng/ml streptomycin and 10% newborn, calf serum (NCS, v/v) was used 
to routinely maintain the cell cultures. For transfection experiments, DMEM without 
phenol red (supplemented as above) was used to reduce the toxic effects of this 
chemical in the transfected cells. 
2.5.2. Cell Lines 
Human Dermal Fibroblasts (HDF) from a control and EDMD patients were established 
by needle biopsy from the inner forearm. The cultures were routinely maintained at 
37°C in a humidified atmosphere containing 5% CO2 until 70 - 80 % confluence. Serial 
passage was performed in the presence of Trypsin and 0.5% EDTA. 
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For the experiments including transfection and nuclear deformities studies, cultures 
were used between passage 4 and 12 and seeded at 0.02xl0^cell/ml in 90 mm dishes 
containing 13 mm glass coverslips. For experiments involving nesprins and HSPs, 
cultures were used at later passages. Old cell cultures (up to passage 45) were used to 
assess the behaviour of fibroblasts from normal donors and from patients. 
Cells were made quiescent by serum starvation. Primary cultures were seeded 
at 0.02xl0^cel l /ml in 90 m m dishes containing 13mm glass coverslips. After 24 
hours in culture, the medium was removed, cells washed IX with 10 ml of 
DMEM medium containing 0.5 % NCS. Cultures were maintained at 37°C in a 
humidif ied atmosphere containing 5% CO2 for 5 days in DMEM supplemented 
with 0.5 % NCS, and coverslips collected and treated for indirect 
immunofluorescence. Re-stimulated cultures were obtained by removing the 
starvation medium at day f ive, washing cells IX with 10 ml of DMEM 
supplemented with 10 % NCS and adding fresh medium containing the 
standard concentration of serum ( 1 0 % NCS). 
Rat dermal f ibroblasts were a kind gift f rom Dr. Colin Jahoda (School of 
Biological and Biomedical Sciences, University of Durham, UK) and were 
maintained in DMEM supplemented with 10 % FBS. 
2.5.3. Transfection of Human Fibroblasts by electroporation 
Cells were grown until 90 % confluence, harvested by Trypsin treatment and 
washed IX in DMEM (Gibco) without phenol red. Cells were resuspended in 
Hyposmolar buffer (Eppendorf, 0.025 M KCI, 0.003 M KH2PO4, 0.085 M K2HPO4, 90 
mOsmol/kg myo-inositol, pH 7.2, conductivity at 25°C 3.5 mC/cm ± 10%), and 
the concentration assessed by counting in a haemocytometer. Cells were 
collected at 300 x g for 5 min at room temperature, and resuspended to 
Ix lO^cel l /ml . Four hundred i^l of the 1x10^ cells/ml cell suspension was added to 
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an electroporation cuvette (Eppendorf) (gap width 2 mm) containing 20 ng/ml of 
each construct (GFP-LamA, DSRed2-LamC or GFP-Emerin) and pulsed in a 
Multiporator ® (Eppendorf, Soft Pulse™ Technology) at 400 V for 200 ^S, 1 pulse, 
at room temperature. Cells were allowed to recover for 7 minutes after pulse, 
washed IX in 5ml of outgrowth medium (DMEM without Phenol Red/10% NCS) at 
room temperature and collected at 250 x g for 10 min. Finally, cells were 
resuspended in 1ml outgrowth medium and grown on 13mm coverslips at 37°C in 
5% CO2 for 36 - 60 hours. 
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2.6. Biochemistry 
2.6.1. Antibody reagents 
A list of the primary antibodies used in this study is given below: 
Antibody Target Assay Source Dil 
Jol2 Lamin A and C tail Immunofluoresc. 
Western Blot 
Prof.C.J. Hutchison 1:25 
1:600 
Jol4 Lamin A tail Immunofluoresc. Prof.C.J. Hutchison 1:10 
Lamin CI Lamin C tail Immunofluoresc. 
Western Blot 
Prof.C.J. Hutchison 1:25 
1:800 
Emerin Emerin Immunofluoresc. Novocastra 1:30 
414 Nucieoporins Immunofluoresc. Boehringer 1:75 
Lamin Bl Lamin Bl Immunofluoresc. Santa Cruz 1:20 
Lamin B2 Lamin B2 Immunofluoresc. Dr. B Lane 1:1 0 
PDI PDI Western Blot Dr. A. Benham 1:800 
Nesprin 1 CI Nesprin 1 C 
terminus 
Immunofluoresc. Dr. C. Shanahan 1:75 
Nesprin 1 N5 Nesprin 1 N 
terminus 
Immunofluoresc. Dr. C. Shanahan 1:75 
Nesprin 2 N2 Nesprin 2 N 
terminus 
Immunofluoresc. Dr. C. Shanahan 1:1 00 
Nesprin 2 CHS Nesprin 2 C 
terminus 
Immunofluoresc. Dr. C. Shanahan 1: 100 
HSP27 HSP27 Immunofluoresc. Prof Roy Quinlan 1:200 
HSP70 HSP70 Immunofluoresc. 
Western Blot 
Prof Roy Quinlan 1:100 
1:1000 
a-S-actin a-S-actin Immunofluoresc. Sigma 1:400 
p-Actin 3-actin Western Blot Sigma 1:1600 
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A list of the secondary antibodies used in this study is given below: 
Antibody Assay Dilution 
FITC-Donkey-anti-mouse Immunofluoresc. 1:50 
TRITC-Donkey anti-mouse Immunofluoresc. 1:50 
TRITC-Donkey anti-goat Immunofluoresc. 1:50 
TRITC-Donkey anti-rabbit Immunofluoresc. 1:50 
Donkey-anti-mouse HRP Western Blot 1:8000 
Donkey-anti-rabbit HRP Western Blot 1:8000 
2.6.2. Cell fractionation 
Cells were grown on 75 cm'^ flasks and were washed twice with Versene Buffer (137 
mM NaCI, 2.7 mM KCI, 8 mM Na2HP04, 1.5 mM KH2PO4) EDTA, pH 7.4) and then 
treated with Trypsin for 1 minute at 37°C in a humidified atmosphere containing 
5% CO2 and collected in DMEM plus 10 % NCS. Cells were transferred to a 
centrifuge tube and recovered by centrifugation at 300 x g for 5 minutes in a 
Sigma centrifuge. After centrifugation,. cell pellets were washed IX with DMEM -1-
10 % NCS and centrifuged to recover the cells. Cell concentration was assessed by 
counting in a haemocytometer, and 5x10^ cells were collected per tube. Finally, 
cells were washed with IX PBS. After centrifugation at 300 x g for 5 minutes, cell 
lysis occurred after incubation in Ripa Buffer (50 mM Tris, pH 8.00, 150 mM NaCI, 
1 % NP-40, 0.5 % Deoxycholic Acid (DOC) and 0.1 % SDS) containing 20 mM N-
ethylmaleimide (NEM) to trap disulphide bonds and IX Protein Inhibitor Cocktail 
(Sigma) for 10 minutes on ice. Protein concentration was assessed by the Bradford 
method. 
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2.6.3. Gel electrophoresis and immunoblotting 
Five ^g of total protein were, loaded per well in the SDS-PAGE. Samples were mixed 
with the same volume of 2X Sample Buffer Reducing (125 mM Tris-HCL, pH 6.8, 
2% SDS, lOOmM DTT, 5% Glycerol and traces of BromoPhenolBlue) or Non-
Reducing (125 mM Tris-HCL, pH 6.8, 2% SDS, 5% Glycerol and traces of 
BromoPhenolBlue). Proteins samples were incubated at 95°C for 3 minutes and 
pelleted at 15,000 g for Im in . Samples were resolved on SDS-PAGE at 70V in 
Tank Buffer (25 mM Tris, 192 mM Glycine and 0.1 % SDS) and transferred to 
nitrocellulose membrane (Protean) overnight at 4°C in Transfer Buffer (25 mM 
Tris, 192 mM Glycine, pH 9.2 plus 20 % Methanol). Nitrocellulose membranes 
were washed IX in blot rinse buffer (BRB) (10 mM Tris, pH 7.4, 150mM NaCI and 1 
mM EDTA) containing 0.1 % Tween 20 and incubated in blocking buffer (4% milk 
powder (w/v ) , 0 . 1 % Tween-20 in BRB) for 16 hour at 4°C with constant shaking. 
Cell culture supernatant containing mAb Jol2 (1:600) was used to detect lamins 
A/C. Primary antibodies were incubated with membranes for 1 hour with constant 
agitation at room temperature. Membranes were rinsed with BRB-0.1 % Tween 20 
3X for 5 minutes at room temperature and then incubated with appropriate HRP-
conjugated secondary antibodies for 1 hour at room temperature. ECL reagents 
(1 :1 v/v) (Amersham Life Science) were used for the immunological detection of 
proteins using ECL films (Amersham Life Science). 
2.7. Immunofluorescence 
2.7.1. Cell staining 
Control and EDMD fibroblasts were grown on 13 mm glass coverslips until 70 -
80 % confluence, or until the t ime lapse pre-determined. Para-formaldehyde 
fixation was performed after 5 minutes incubation in hypotonic buffer (10 mM 
Tris, pH 7.4, 10 mM KCI and 3mM MgCl2). Cells were fixed in 3.5 % Para-
formaldehyde for 10 minutes, permeabilized by incubation in 0.5 % Triton X-100 
75 
in PBS for 5 minutes at 4°C and washed twice in IX PBS for five minutes at room 
temperature. Methanol : Acetone (1:1) fixation was performed by incubating cells 
with methanol: acetone (1 :1 v/v chilled to - 20°C) at 4°C for 10 minutes, without 
permeabil ization, and washed twice in IX PBS for 5 minutes at room 
temperature. 
A blocking step was performed with IX PBS/1 % NCS for 30 minutes, and then 
coverslips were washed twice with IX PBS and allowed to air dry for 10 minutes. 
Primary antibodies were incubated at room temperature for 1 hour in a wet 
chamber, and coverslips washed 5 times in IX PBS. Secondary antibodies were 
incubated 1 hour at room temperature in wet chamber, and then coverslips were 
washed five times in IX PBS. After washes in PBS, coverslips were mounted face 
down on Mowiol (12% Mowiol (Calbiochem), 30 % glycerol, 120mM Tris-HCI, pH 
8.5, 2.5 % DABCO, 1 ng/ml DAPI). 
2.8. Microscopy 
A BioRad Radiance 2000 confocal laser scanning system fitted to a Zeiss Axiovert 
microscope and equipped with a 40X and a 63X/1.40 oil immersion lens was used 
for imaging the cells. For imaging the honeycombs, a dynamic range adjustment 
was used to optimize the signal of the fluorophores, and Z-series were collected 
in Sequential Mode through individual nuclei using Kalman (4 times) averaging 
program at a scan speed of 500 lines per minute and a resolution of 1024 x 768 
pixels. 
For imaging the cells prepared for proliferating studies, a confocal microscope LMS 
510 META (Zeiss) equipped with 40X and 63X/1.10 lens was used. A dynamic 
range adjustment was set up to optimize the signal, and images were collected in 
Multi-track Mode (similar to Sequential Mode in BioRad's software) averaging the 
background 4 times (similar to Kalman in the BioRad system) at a scan speed of 
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500 lines per minute and a resolution of 1024 x 1024. 
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3. Chapter Three- Protein-Protein interactions in vitro: emerin and 
lamins. 
3.1. Introduction 
The aim of this chapter was to assess the interaction in vitro between emerin and 
lamins, and to map the domain of Lamins involved in their interaction with emerin 
using the yeast two-hybrid assay. 
EDMD is a rare neuromuscular disorder, characterized by slowly progressive 
skeletal muscle wasting of the shoulder girdle and distal leg muscles, early 
contractures of the joints (Achilles tendons, neck and elbows) and 
cardiomyopathy with conduction defects which often is presented as atrial 
ventricular block requiring a cardiac pacemaker implant. This disease is inherited 
as an autosomal dominant (Fenichel et al., 1982; Miller et al., 1985), autosomal 
recessive (Takamoto et al., 1984; Taylor et al., 1998) or an X-linked disorder (Hodgson 
et al., 1986; Thomas et al., 1986). 
The disease gene for the X-ljnked form of Emery-Dreifuss Muscular Dystrophy 
(XL - EDMD) has been identified and it was mapped to distal Xq28. The STA gene, 
coding for emerin, a serine-rich inner nuclear membrane protein (Manilal et al., 1996; 
Yorifuji et al., 1997) consisting of 254 amino acids and with a carboxy-terminus 
transmembrane domain, was first described to contain mutations in all five patients 
studied (Bione et al., 1994). 
Genetic studies in five French families with AD-EDMD linked locus l q l l - q 2 3 to 
the disease phenotype, identifying four mutations in the LMNA gene that co-
segregated with the disease phenotype (Bonne et al., 1999). Other studies have 
shown that mutations in the same gene are present in the Autosomal Recessive 
form of the disease, or have no phenotypic effect (Raffaele Di Barletta et al., 2000). 
The LMNA gene encodes for the A-type lamins, key components of the nuclear 
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lamina, by alternative splicing mechanisms at the 3'end of the mRNA (Lin and 
Worman, 1993). 
Several studies have addressed the question of whether emerin and lamins 
interact at the protein level. Using bio-molecular interaction analysis (BIA) 
combined with the use of monoclonal antibodies, direct interaction between 
recombinant emerin and Lamin A molecules was demonstrated (Clements et al., 
2000). By immuno-precipitation assay, it has been reported that emerin interacts 
specifically with Lamin A (Sakaki et al., 2001). The functional domain in A-type 
lamins that binds emerin has been localized in the globular tail domain, between 
amino acids 384 and 566 (Clements et al., 2000; Sakaki et al., 2001). Other studies in 
our laboratory have shown that using competition assays and immuno-precipitation 
with specific antibodies, emerin interacts preferentially with Lamin C (Vaughan et 
al. , 2001). Not many studies have been undertaken using Lamin B l , probably 
because of the technical obstacles in producing high amounts of the recombinant 
protein for in vitro assays (Clements et al., 2000). The yeast two-hybrid system has 
been used to demonstrate that the tail domain of Lamin A and C is essential for the 
interaction with emerin. Evidence for the interaction between inner nuclear 
membrane proteins and the members of the lamins family has been established 
previously using similar approaches to the study by (Sakaki et al., 2001) mine. The 
a-helical rod domain of lamins B l and B2, but not lamin B3 was shown to be 
involved in the interaction with LAP2p, an inner nuclear membrane protein, by 
biochemical assays and yeast two-hybrid system (Furukawa and Kondo, 1998). 
The functional domains of emerin have been defined (Lee et al. , 2001). The 
product of the STA gene interacts with the Barrier Auto-Integrat ion Factor 
(BAF) throughout its amino acids 1 - 56, which includes the LEM domain (a 
conserved region between LAP-2P, Emerin.and Manl (Laguri et al., 2001; Wolff et 
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al., 2001), W01G7.5 (Laguri et al., 2001; Wolff et al., 2001), otefin and M01D7.6 
(Wolff et al. , 2001) and F42H11.2 (Laguri et al., 2001). Emerin domain extending 
f rom amino acids 70 and 178 is responsible for the interaction with A-type 
lamins, and a th i rd domain not required to bind either BAF or Lamin A extends 
f rom amino acids 179-222 (Lee et al . , 2001). Recently, new binding partners for 
emerin have been discovered by using different experimental approaches. 
Transcriptional repressor germ line-less (Holaska et al . , 2003), YT521-B 
(Wilkinson et a l . , 2003), nuclear and cytoplasmic actin (Lattanzi et al., 2003), and 
Nesprin l a interact with emerin (Mislow et al . , 2002). 
The yeast two-hybr id system offers a number of advantages over many 
biochemical methods historically used in protein biochemistry to test for 
putat ive protein-protein interactions. I t is relatively inexpensive; cDNA 
libraries can be easily screened, putative new-interacting partner subcloned 
and fur ther features of novel interactions described; the system is often more 
sensitive than in vi tro techniques to test for weak or transient interactions and 
post-translat ional modif ications and correct folding of many proteins is not a 
practical problem. Other two-hybr id technologies have been developed to 
study other complex protein-protein interactions. This is the case of the 
hSos/Ras recrui tment system (cytoplasm-based yeast two-hybrid system 
using Ras signalling and rescue of a CDC25 temperature sensitive mutant) 
(Broder et a l . , 1998), Split-ubiquitin system (to study protein-protein interaction 
in transcription factors) (Johnsson and Varshavsky, 1994), three-protein system 
(study of ternary protein complexes, uses the classical two-hybrid approach 
plus the third protein fused to a nuclear localisation signal (Zhang and Lautar, 
1996) , Small ligand-dependent system, (original two-hybr id approach modified 
in the case of interactions dependent on non-protein ligands (Brent and Finley, 
1997) , dual bait system (based on two sets of reporter genes bound to different DNA-
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binding domains (Serebriiskii et al., 1999), reverse-two-hybrid system (uses toxic 
reporter genes to dissect protein-protein interactions) (Vidal et al., 1996) and the 
mammalian and bacterial two-hybrid systems (Joung et al., 2000; Luo et al., 1997). 
Applying the information above, a classical yeast two-hybrid experiment was set 
up using a series of deletion mutants of Lamin Bl constructs, including full length, 
and lamins A and C full length. In this chapter I confirm that emerin interacts with 
A and B-type lamins in the yeast two-hybrid system, and that the preferential 
domain in this interaction is the tail domain. A transfection assay in primary 
cultures of human skin fibroblasts (HDF) from healthy donor and from XL-EDMD 
patients (emerin null by indirect immuno-fluorescence) was used to confirm this 
result. GFP-Lamin A and DSRed2-Lamin C were individually transfected in these 
cells. Lamin C tagged with DSRedZ was excluded from the emerin defective 
nuclear envelope in a higher proportion of the transfected cells. 
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3.2. Results 
3.2.1. Emerin is cloned in p A S l . 
After cloning ennerin in pASl, colonies were picked and plasmid DNA was purified 
using Promega's Wizard® Plus Minipreps DNA Purification System. Restriction 
enzyme analysis was set up using Nco I and BamH I with Multicore buffer. The 
presence of a band of around 700 base pairs was used as criteria to consider 
positive clones for DNA sequencing (Figure 3.1A). 
Positive clones were sequenced twice (forward and reverse) (Figure 3.1 B) and the 
sequence obtained was analyzed. BLAST® (Basic Local Alignment Search Tool, 
(http://www.ncbi.nlm.nih.qov/BI-AST) algorithm confirmed the results, showing 
that the sequence submitted belonged to the STA gene (Figure 3.1 C). This 
analysis showed that the emerin gene was successfully cloned. The fusion protein 
contained the respective domains of GAL4 fused in-frame to full length human 
Emerin. 
3.2.2. Emerin-BD construct does not auto-activate RNA 
polymerase in yeast . 
The first step in setting up any yeast two-hybrid experiment consists of assessing 
the transcriptional activation risk conferred by the bait protein cloned downstream 
of the GAL4 Binding Domain (BD) as a fusion polypeptide. To determine whether 
pASl-emerin construct was able to auto-activate RNA polymerase in the Yeast 
Two-Hybrid System (Y2HS), Y190 yeast strain was transformed with 0.5 ^g of the 
"empty" pASl vector and the pASl-BD-emerin using the Lithium Acetate method 
described in Chapter 2. Water was used in the transformation mix instead of the 
plasmid DNA as a negative control. Plates containing selective media SD/-leu, 
SD/-Trp plates, SD/-Trp/-His, SD/-Trp/-His/3AT 40mM, and SD/-Ade/-Trp/-His 
were plated with 100 lal of transformed cells by duplicate and incubated at 30°C 
for 2 - 4 days (Figure 3.2). Y190 yeast strain did not grow on any of the selective 
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medium, but grew on SD/-Trp when transformed either with pASl vector or with 
pASl-emerin. 3-AT, a competitive inhibitor of the yeast HIS3 protein (His3p), was 
used to inhibit low levels of HisSp expressed in a leaky manner in some reporter 
strains like in Y190 yeast strain, where the basal levels are relatively high. With this 
result, I confirmed that the emerin construct in pASl does not exhibit any auto-
activation properties, showing that this construct it is suitable to set up the lift 
and liquid assays to assess (p-galactosidase activity upon any putative interaction 
in the Yeast Two-Hybrid assays. 
3.2.3. Lift assay A: Emerin interacts with full length A and B-
type lamins in the Yeast Two-Hybrid System. 
To determine whether emerin interacts with lamins in a yeast two-hybrid system 
assay, the BD-emerin (in pASl) construct was co-transformed with the AD-lamin 
constructs (in pGAD424) in the Y190 yeast strain. In the first instance, p-
galactosidase lift assay, a qualitative assay to assess the strength of interaction 
between two proteins, was used. All the full length Lamin AD-constructs 
interacted with emerin, but Lamin Bl was the strongest one. A summary of the 
strength of the interactions is given in Table 3.1. 
3.2.4. Lift assay B: Emerin interacts with lamin's tail domain in 
the Yeast Two-Hybrid System. 
Using other fragments of Lamin B l , the region of interaction of lamins with emerin 
was determined. Five additional Lamin Bl fragments were used. Fragment 5 
(region HClalb2), fragment 6 (region HClalb), fragment 7 (region Cla lb) , and 
fragment 8 (region Clb2) (Table 3.2). None of the constructs gave a very strong 
interaction, as the time of appearance of the colour on the plates was around 1 
hour. Strong interactions in p-galactosidase lift assay usually develops colour in 20 -
30 minutes (Clontech, 2000). The strongest interaction of pASlBD-emerin was with 
the Lamin Bl full length and fragment 4, which consisted of the tail domain of 
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Lamin B l . The high levels of p-galactosidase activity suggested that emerin 
interacts preferentially with the tail domain of lamins in the yeast two-hybrid assay 
(Figure 3.4). 
3.2.5. Emerin interaction with the tail domain of lamins is 
confirmed by the semi-quantitative liquid Yeast Two-Hybrid assay. 
In order to semi-quantify the interaction between emerin and lamins, a Liquid 
Culture Assay was set up using chlorophenol red-p-D-galactopyranoside (CPRG) 
as substrate to assess the activity of p-galactosidase enzyme released by the 
interacting partners (Figure 3.5). The same constructs as in the lift assay A (see 
above) were used, plus the Lamin B l -a lb , Lamin B1-C2 and Lamin Bl-tail 
deletion mutants. The strongest values for p-galactosidase activity were obtained 
for the constructs containing the tail domain and full length of Lamin B l . The 
interaction with Lamin C produced higher activity than with Lamin A, supporting 
the former results published by our laboratory (Vaughan et al., 2001). 
Combining these results with the lift assays A and B (see above), the Y2H data 
suggests that emerin interacts preferentially with Lamin Bl through its tail 
domain. These results suggest that emerin interacts with A and B-type lamins in 
the yeast two-hybrid, assay, and confirm that the functional domain for this 
interaction is through the tail domain of lamins (Clements et al., 2000; Sakaki et 
al., 2001). 
3.2.6. Transfection efficiency 
In order to confirm that emerin interacts with lamins, and to assess the 
distribution of the different lamin subtypes in emerin deficient cell lines, I set up in 
vivo experiments using human dermal fibroblasts from a healthy donor and from 
XL-EDMD patients. Cells were transfected with 20 ng/ml of GFP-Lamin A (wild 
type), GFP-Emerin (wild type) and DSRed2-Lamin C (wild type), and after 48 
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hours in culture, 300 cells were counted to assess the efficiency of transfection of 
the assay. A consistent efficiency transfection rate of 6 - 9 % was achieved. The 
percentage of cells transfected with the DSRed2-^Lamin C construct was always 
higher than with the GFP-Lamin A construct, but it is not clear whether the 
differences in the transfection efficiency can be related to any preference in the 
rate of transfection of the different constructs due to differences in the DNA 
sequences (between the tag proteins, the tail domain of lamins A and C, or both) 
or just to the variability intrinsic to the transfection method. 
3.2.7. GFP-Lamin A and DSRed2-Lamin C form aggregates in 
human primary cultures. 
Human Skin Dermal Fibroblasts (from a healthy donor and from a patient with XL-
EDMD) were used at early passages. After 48 hours of transfection with 20 ng/ml 
of DNA fusion constructs, confocal images showed different patterns of distribution 
of the endogenous tagged proteins: 1) normal nuclear rim and 2) intra-nuclear 
aggregates for both fusion proteins. 
Replicate experiments were set up and three hundred cells were counted for each 
cell line per each fusion construct transfected. In the normal fibroblasts, 4.76% 
and 11.33 % of the cells presented aggregates after transfection with the GFP-
Lamin A or DSRed2-laminC, respectively. The patient fibroblasts showed 14.33 % 
and 26% of the cells with intranuclear aggregates when transfected with the 
same constructs (Figure 3.6). 
In the case of GFP-Lamin A, an increase of 3.1 fold (Z= -5.657; p=0.0001) in 
the amount of aggregates in the X-linked cell line as compared to the control may 
indicate that the absence of emerin in these cells causes less GFP-Lamin A to be 
targeted to the nuclear lamina. DSRed2-Lamin C produces an increase of 2.3 fold 
(Z= -6.782; p=0.0001) in the amount of aggregates in the patient cell line when 
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compared to the control. The overall increase of A-type lamin's aggregates in the 
X-linked fibroblasts was 2.5 fold (Z= -6.455; p=0.0001) compared to the control. 
3.2.8. GFP-Lamin A transfection and staining with anti-
Emerin, anti-Lamin C and anti-Lamin B l antibodies in 
control and XL- EDMD cell lines. 
In GFP-Lamin A transfected cells stained with anti-emerin antibody (Figure 3.7), 
when the exogenous protein was localized to the nuclear rim (GFP-Lamin A i), 
endogenous emerin showed normal rim localisation in control fibroblasts (Emerin 
i). Aggregation of the reporter protein (GFP-Lamin A ii) did not cause significant 
miss-localisation of endogenous emerin (Emerin ii) into aggregates. GFP-Lamin A 
wild type formed "honeycomb"-like structures in the patient fibroblasts (GFP-
Lamin A v). The lack of emerin in these cell lines is shown in the red channel 
(Figure 3.7 panel iii -vi). 
GFP-Lamin A transfected cells stained with anti-Lamin C antibody (Figure 3.8) 
showed different patterns of distribution of the exogenous protein. In control and 
X-L EDMD fibroblasts, when GFP-Lamin A was localized to the nuclear rim (GFP-
Lamin A i, iii and v), endogenous Lamin C had a normal distribution (Lamin C i, iii 
and v). Aggregation of the reporter protein (GFP-Lamin A ii, iv and vi) caused mis-
localisation of the endogenous Lamin C into aggregates in control fibroblasts 
(Lamin C ii), but only partial mis-localisation in the patient cell lines (Lamin C iv 
and vi). 
Cells transfected with GFP-Lamin A and stained with anti-Lamin Bl antibody 
(Figure 3.9), both in control and X-L EDMD fibroblasts, presented GFP-Lamin A 
localized to the nuclear rim (GFP-Lamin A i, iii and v), and into aggregates (GFP-
Lamin A ii, iv and vi). Endogenous Lamin Bl localisation at the nuclear rim was 
never affected by the distribution adopted by the reporter protein (Lamin Bl i -
vi). Absence of Lamin Bl from one pole of the nucleus corresponded with the 
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absence of GFP-Lamin A aggregates from the same area. 
3.2.9. DSRed2-Lamin C transfection and staining with anti-
Emerin, anti-Lamin A and anti-Lamin B l antibodies in 
control and XL- EDMD cell lines. 
Fibroblasts from a healthy donor and X-L EDMD cell lines were transfected with 
DSRed2-LaminC (wild type) and stained with anti-emerin antibody (Figure 3.10). 
In control fibroblasts, DSRed2-LaminC was localized to the nuclear rim (DSRed2-
LaminC i, iii and v), and into aggregates (DSRed2-LaminC ii, iv and vi). 
Endogenous emerin localisation at the nuclear rim was not affected by the 
distribution adopted by the reporter protein in the control fibroblasts (Emerin i -
ii). As expected, emerin was not expressed in the patient cell lines (Figure 3.10 iii 
- vi). 
All cell lines were transfected with DSRed2-LaminC (wild type) and stained with 
anti-lamin A antibody (Figure 3.11). In control and X-L EDMD fibroblasts, 
DSRed2-LaminC localized to the nuclear rim (DSRed2-LaminC i, iii and v), and into 
aggregates (DSRed2-LaminC ii, iv and vi). Endogenous lamin A localisation at the 
nuclear rim was not affected by the distribution adopted by the reporter protein 
(Lamin A i -vi). 
Transfections with DSRed2-LaminC (wild type) were followed by staining with anti-
laminBl antibody (Figure 3.12). Different patterns of distribution of the 
exogenous protein were observed. In control and X-L EDMD fibroblasts, DSRed2-
LaminC was localized to the nuclear rim (DSRed2-LaminC i, iii and v), and into 
aggregates (DSRed2-LaminC ii, iv and vi). Endogenous lamin Bl localisation at 
the nuclear rim was not affected by the distribution adopted by the reporter 
protein neither in the control nor the patient fibroblasts (lamin B l i - vi). 
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3.2.10. GFP-Emerin transfection and staining with anti-Lamin 
A, anti-Lamin C and anti-Lamin B l antibodies in control 
and XL-EDMD cell lines. 
After GFP-Emerin (wild type) DNA transfection, cells were stained with anti-lamin 
A antibody (Figure 3.13). In control and X-L EDMD fibroblasts, when GFP-Emerin 
was localized to the nuclear rim (GFP-Emerin i, iii and v), endogenous lamin A 
showed a normal distribution (lamin A i, iii and v). GFP-Emerin was often localized 
in the cytoplasm, either in a smooth distribution (GFP-Emerin ii, iii and vi) or into 
aggregates (GFP-Emerin iii and iv). Aggregation of the reporter protein in control 
and patient fibroblasts did not cause mis-localisation of endogenous lamin A (lamin 
A ii, iv and vi) into aggregates. 
Fibroblasts from a healthy donor and X-L EDMD cell lines were transfected with 
GFP-Emerin (wild type) and stained with anti-lamin C antibody (Figure 3.14). 
Different distribution patterns of the exogenous protein were observed. In control 
fibroblasts, when GFP-Emerin was localized to the nuclear rim (GFP-Emerin i, iii 
and v), endogenous lamin C showed a normal distribution (lamin C i, iii and v). 
Aggregation of the reporter protein in control cells caused mis-localisation of 
endogenous lamin C (lamin, C ii) into the nucleoplasm. In the patient's cell lines, 
aggregation of the GFP-Emerin did not cause mis-localisation of the endogenous 
lamin C, but in this case, GFP-Emerin aggregates were localized mainly to the 
perinuclear space (GFP-Emerin iv and vi, lamin C iv and vi). 
Cell lines were transfected with GFP-Emerin (wild type) and stained with anti-lamin 
Bl antibody (Figure 3.15). The exogenous protein assumed different distribution 
patterns. In control and X-L EDMD fibroblasts, GFP-Emerin was localized to the 
nuclear rim (GFP-Emerin i, iii and v), and into aggregates (GFP-Emerin ii, iv and 
vi). Endogenous lamin Bl localisation at the nuclear rim was never affected by the 
distribution adopted by the reporter protein (LaminBl i - vi). 
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3.3. Discussion 
3.3.1. The tail domain of lamins as a target for the interaction 
with emerin. 
Understanding the biochemical nature of the interaction between emerin and 
lamins became an important objective after it was confirmed by genetic studies 
that the protein involved in XL- EDMD was emerin (Bione et al., 1994), and AD-
EDMD was linked to locus lq l l -q23 (Bonne et al., 1999), where the LMNA gene was 
mutated. Since these initial reports, additional disease causing mutations have been 
characterized in the STA gene (68 reported until 1998) (Yates, 1998) and in LMNA 
gene (58 reported until 2003). 
At the time I established the yeast two -hybrid experiments in February 2000, 
there was no data available regarding the interaction of emerin and lamins using 
this approach. Using different deletions mutants of Lamins Bl (a kind gift of Dr. 
Howard Worman), I have demonstrated that emerin interacts with lamins in the 
yeast two-hybrid system, and that the region of interaction is mainly through the 
tail domain. 
The interaction of emerin with the head and rod domains of Lamin Bl appeared to 
be weak, but not absent. The growth of yeast transformed with the deletion 
mutants lacking the tail domain could be due to the "leak" of His3 protein 
characteristic of Y190 yeast strain which was not inhibited by the concentration of 
3-AT used (0.040 M). But considering that the reporter gene (p-galactosidase) 
was weakly expressed in both, the lift and the liquid assays (the linear range of 
the assay is between 0.25 and 1.8 O.D 578); I conclude that these interactions 
were not relevant to the experiment. Alternatively, weak interactions between 
the mutant constructs lacking the tail domain of Lamin Bl and emerin could be 
produced by the "sticky" biochemical nature of the rod domain (a-helical 
structure), allowing the assembly of the GAL4 transcription factor in the yeast 
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system. 
In contrast, a strong p-galactosidase activity was generated by the interaction 
between emerin and lamins (A and B-type) constructs containing the tail 
domain (globular domain, Ig-like structure in the case of Lamin A (Krimm et al., 
2002)) in both of the Y2HS approaches used (p-galactosidase lift and liquid 
assays). In the qualitative lift p-galactosidase assay, the constructs containing 
the tail domain of Lamin B l produced a blue colour which developed within the 
first 30 minutes of reaction, with the strongest point at 2 - 3 hours, after 
which the colour did not develop any further. The semi-quantitative liquid 
assay (using CPRG as substrate) with the same mutant and the full length 
protein rendered values of O.D578 = 0.265 for the full length Lamin Bl and 
0.292 for the tail domain (395-586 amino acids) (linear range for this assay is 
between 0.25 and 1.8 (Clontech, 2000). 
Considering the Y2HS is an in vitro assay (some researchers consider it an in 
vivo assay) under "ideal" physiological conditions in the yeast, artefacts 
generated by other in vitro assays (overlay, immuno-precipitation, column 
binding) may be minimized. However, some false positive interactions can 
arise, as the p-galactosidase activity in the yeast two-hybrid system results 
from a number of factors such as plasmid copy number, the level of protein 
expression, the stability of the chimerical fusion proteins, conformational 
effects, and the possible interaction of the fusion proteins with endogenous 
yeast proteins (Ye and Worman, 1995). 
Additional in vitro experiments with a different approach are needed in order to 
confirm the results of Y2HS. No studies reported in the literature so far have 
addressed alternative biochemical approaches to define more precisely the minimal 
sequence(s) required for the interaction of lamins with emerin, since only one 
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additional study has mapped the interaction of emerin with the tail domain of 
Lamin A using the same approach as described here (Sakaki et al., 2001). 
Interestingly, one study using lamin Bl tail domain-vimentin chimeras in human 
breast adenocarcinoma (MCF7) and human adrenal cortex carcinoma cell lines 
demonstrated that the vimentin chimera was able to recruit LBR and emerin to 
nuclear vimentin-bodies (Dreger et al., 2002). 
3.3.2. Over-expressing nuclear envelope proteins in emerin 
deficient cell l ines. 
Cell lines derived from patients, "naturally" deficient in one or more proteins, are 
excellent models to study the function of a particular protein, as most of the 
cellular pathways remain "unaffected" by experimental manipulations. Here we 
have used human dermal fibroblasts derived from XL- EDMD patients to further 
investigate the interaction between emerin and lamins, which are affected in 
different forms of EDMD. 
Additionally, fluorescent proteins have proved to be useful tools to study the 
distribution of polypeptides in the cell, or to monitor cell migration in animal models 
(Lu et al., 2003). Some studies have shown that the distribution of fluorescent 
tagged proteins can be affected by the tag (Soling et al., 2002; Zhang et al., 2003) 
and due to over-expression (Bechert et al., 2003). However, the general approach is 
still useful for unravelling or confirming some biological and biochemical properties 
of proteins in living cells. With this in mind, transfection experiments were carried 
"out to investigate the behaviour of lamins and emerin in cell lines lacking emerin. 
Ectopic expression of GPF-Lamin A and DSRed2-Lamin C induced the formation of 
either normal nuclear rim localisation or intranuclear aggregates of these tagged 
proteins. Although the results of transfection into normal fibroblasts suggest that 
the aggregates can arise either through the nature of the fluorescent protein, due 
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to over-expression, or both, some valuable data can be conclusive. In the case of 
the patient cell line, the data might reflect a combination of the effect of over-
expression of tagged proteins and the biochemical effect induced by the lack of 
emerin. Nevertheless, the differences between the control and the patient in the 
case of GFP-Lamin A (Z= -5.657; p=0.0001) and DSRed2-lamin C (Z= -6.782; 
p=0.0001) were highly significant. These results suggest that with a very high 
probability (> 99%), the absence of emerin in the patient cell line leads to the 
accumulation of A-type lamins in intranuclear aggregates, confirming the 
molecular interaction between emerin and,lamins (Clements et al., 2000; Sakaki et al., 
2001). When pooled all together, GFP-Lamin A and DSRed2-lamin C as A-type 
lamins, the difference between the control and the patient cell line (Z= -6.455; 
p=0.0001) was still highly significant. This is evidence for the interaction of 
emerin with Jamins as has been demonstrated in other studies using other 
approaches (Clements et al., 2000; Sakaki et al., 2001; Vaughan et al., 2001). 
Transfected cells stained with different antibody combinations showed that the 
aggregation of A-type lamins did not affect the distribution of endogenous Emerin. 
Neither GFP-Lamin A nor DSRed2-Lamin C over-expression produced any re-
distribution of the endogenous Emerin from the nuclear rim, suggesting that 
emerin remains attached to the nuclear envelope through its carboxy-terminus 
transmembrane domain, the interaction with its hinging partners (Lamin Bl?) or 
both. As expected, Lamin Bl remained more stable at the nuclear rim since its 
localisation was never affected by any of the over-expressed fusion proteins. 
It has been shown that A-type lamins are disassembled when the cell enters 
mitosis by reversible phosphorylation (Heald and McKeon, 1990; Ottaviano and 
Gerace, 1985; Peter et al., 1990), but B-type lamins remain attached to the nuclear 
vesicles and associated to the LBR (Chaudhary and Courvalin, 1993; Meier and 
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Georgatos, 1994). Live imaging experiments have shown emerin and LBR are 
recruited early to reforming nuclear envelopes during mitosis as patches, and 
become more homogeneous at later stages (Haraguchi et al., 2000). Other live 
imaging studies have shown different pathways of assembly of A and B-type lamins 
into the "novo" nuclear envelope following mitosis. Immediately after mitosis and 
until early G l , Lamin A is distributed homogenously throughout the nucleoplasm, 
but Lamin Bl is targeted directly to the periphery of the chromosomes before any 
de-condensation begins, and remains attached to the nuclear boundaries (Moir et 
al., 2000). As A-type lamins are soluble during mitosis, they are automatically 
excluded as interacting partners for emerin, at least at this stage of the cell cycle. 
Our results show that lamin Bl is stably localized with emerin at the NE when A-
type lamins are mislocalized to aggregates, which suggest that the retention of 
emerin at the NE in fibroblasts may be due to its stable interaction with B-type 
lamins. This observation is distinctively different from what happens in HeLa cells, 
where mis-localisation of A-type lamins to aggregates causes retraction of emerin to 
the ER (Vaughan et al., 2001). Perhaps there are other factors in fibroblast 
responsible for retaining emerin in the NE, e.g. low level of retention of A-type 
lamins at the lamina. However, during mitosis, emerin and Lamin Bl co-localize 
with LBR, so it is possible that emerin remains attached to the surface of the 
chromosomes through its direct association with Lamin B l , or indirectly through 
the formation of a transient complex that involves the Lamin Bl and other 
interacting partners yet to be discovered. Most probably, the ubiquitous interaction 
of emerin with all lamin subtypes may warranty that emerin remains stable 
attached to the NE during the cell cycle. 
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Figures Chapter 3 
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Figure 3.1 
Emerin was cloned in pASl vector. A) Plasmid DNA digestion with restriction 
enzymes produced a band of approximately 700 bp as expected for the emerin 
gene. B) pASl-Emerin was sequenced using the Big Dye terminator technology 
and the data acquired in an ABI377DNA Sequencer (Applied Biosystems). The ATG 
initiation codon is highlighted (Met) and the sequence upstream was analyzed 
showing the ATG codon is in the correct reading frame to produce the putative 
Emerin protein. C) Emerin sequence obtained after sub-cloning the gene into 
pASl, was analyzed by the BLASTN (Basic Local Alignment Search Tool Nucleotide) 
for nucleotide homology. Distribution of 13 BLAST hits shows 100% similarity of 
the query to the reported emerin gene (highest scores). 
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Figure 3.2 
A transcriptional activation assay was set up in Y190. Yeast were co-transformed 
with 0.5 |ig of the "empty" pASl vector and the pASl/BD-emerin construct using 
the lithium acetate transformation method, and .plated on agar plates containing 
different selective media to test for auto-activation of the RNA transcriptase 
activity in the yeast two-hybrid assay from the bait construct. 
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Figure 3.3 
p-galactosidase lift assay A. pASl-Emerin was co-transformed with full length 
emerin, lamin A, lannin B l and lannin C tagged to the activation domain of GAL4. 
Y190 was transformed using the lithium chloride method and grown on agar plates 
containing selective media. Yeast was grown for 4 days after transformation, 
when colonies were about 3 mm in diameter and streaked on plates containing 
selective media. After colonies appeared, the p-galactosidase lift assay was set up 
and color development stabilized at 2 hours. 
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Table 3.1 
A summary of the time course of p-galactosidase lift assay in the yeast two-hybrid 
experiment to assess the level of interaction between emerin and lamins. 0.5 \ig of 
each construct was co-transformed in the yeast strain Y190 using the lithium 
acetate transformation method. Time was recorded as soon as the filters were in 
touch with the reaction buffer containing X-gal. The strength of the color of the 
colonies is represented by V. 
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Time Emerin Emerin Emerin Emerin 
(h) Lamin A Lamin B1 Lamin B1Coil2 Lamin Bitail 
To 0 0 0 0 
To.5 V vv 0 W 
T 2 vv WW V WW 
T 3 WW V WW 
Table 3.1 
Figure 3.4 
p-galactosidase lift assay B. pASl BD-Emerin was co-transformed with full length 
lamin A and lamin B, and different deletions mutants of lamin 81 tagged to the 
activation domain of GAL4. Y190 was transformed using the lithium acetate method 
and growth on agar plates containing selective media. Yeast was grown for 2 - 4 
days after transformation, when colonies were about 3 mm in diameter and 
streaked on plates containing selective media. After colonies appeared, the p-
galactosidase lift assay was set up, and color development recorded at 2 hours. 
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Table 3.2 
Summary of the constructs used in the yeast two-hybrid experiments. Ye, Q. and 
Worman, H. J. (1995). 
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A C T I V A T I O N D O M A I N D G A D 4 2 4 B I N D I N G D O M A I N dAS1 
1 Lamin A (1-646 a. a) Emerin 
2 Lamin B1 (1-586 a. a) Emerin 
3 Lamin B1 Coil2 (241-394a. a) Emerin 
4 Lamin B1 Tail (395-586 a. a) Emerin 
5 Lamin 81 HC1a1b2 Emerin 
6 Lamin 81 HCIa lb Emerin 
7 Lamin 81 C l a l b Emerin 
8 Lamin 81 C1b2 Emerin 
Table 3.2 
Figure 3.5 
Liquid p-galactosidase assay. Y190 was co-transformed with pASIBD-Emerin and 
full length emerin, lamin A, lamin Bland lamin C, and the fragments lamin B1C2, 
lamin B l a l b and lamin B l tail fused to. the AD of GAL4. Transformants were 
grown ON at 30°C with constant shaking at 250 rpm in selective media, and yeast 
processed for the liquid assay. Samples were set up by triplicate. For the full 
length constructs, Lamin B l showed the strongest value of p-galactosidase 
activity, as in the lift assays A and B. The tail domain of lamin B l showed the 
strongest value between the fragments. 
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Figure 3.6 
Transfection of GFP-Lamin A (wild type) and DSRed2-lamin C (wild type) in Human 
Dermal Fibroblasts from a healthy donor and from an EDMD X-linked patient. Cells 
were transfected with 0.5 ng of the plasmid DNAs using the electroporation system 
from Eppendorf. 300 cells were counted and the number of aggregates recorded. 
The statistical significance was calculated using the Wilcoxon test. Both 
increments of aggregates were highly significant with p = 0.0001. 
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Figure 3.7 
Fibroblasts from a healthy donor and X-linked EDMD cell lines were transfected 
with GFP-laminA (wild type) and stained with anti-emerin antibody. Different 
distribution patterns of the exogenous protein were observed. In control 
fibroblasts, when GFP-LaminA was localized to the nuclear rim (GFP-laminA i, iii 
and v) , endogenous emerin showed a normal distribution (emerin i). Aggregation 
of the reporter protein in control fibroblasts (GFP-laminA ii) did not cause mis-
localization of endogenous emerin into aggregates (emerin ii). GFP-laminA formed 
"honeycomb" like structures in the patient fibroblasts (GFP-LaminA v). Panels iii -
vi) in the red channel showed no emerin expression in the patient cell lines. 
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Figure 3.8 
Fibroblasts from a healthy donor and X-linked EDMD cell lines were transfected 
with GFP-laminA (wild type) and stained with anti-lamin C antibody. Different 
patterns of distribution of the exogenous protein were observed. In control and X-
linked EDMD fibroblasts, when GFP-LaminA was localized to the nuclear rim (GFP-
laminA i, iii and v), endogenous lamin C showed a normal distribution (lamin C i, iii 
and v). Aggregation of the reporter protein (GFP-laminA ii, iv and vi) caused mis-
localization of endogenous lamin C into aggregates in control fibroblasts (lamin C 
ii), but only partial mis-localization in the patient cell lines (Lamin C iv and vi). 
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Figure 3.9 
Fibroblasts from a healthy donor and X-linked EDMD cell lines were transfected 
with GFP-laminA (wild type) and stained with anti-lamin Bl antibody. Different 
patterns of distribution of the exogenous protein were observed. In control and X-
linked EDMD fibroblasts, GFP-LaminA was localized to the nuclear rim (GFP-laminA 
i, iii and v), and into aggregates (GFP-LaminA ii, iv and vi). Endogenous lamin Bl 
localization at the nuclear rim was never affected by the distribution adopted by 
the reporter protein (LaminBI i - vi). Absence of lamin Bl from one pole of the 
nucleus co-localized with the absence of GFP-LaminA aggregates at the same 
area (Lamin 81 iv). 
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Figure 3.10 
Fibroblasts from a healthy donor and X-linked EDMD cell lines were transfected 
with DSRed2-LaminC (wild type) and stained with anti-emerin antibody. Different 
patterns of distribution of the exogenous protein were observed. In control 
fibroblasts, DSRedZ-LaminC was localized to the nuclear rim (DSRed2-LaminC i, iii 
and v) and into aggregates (DSRed2-LaminC ii, iv and vi). Endogenous emerin 
localization at the nuclear rim was not affected by the distribution adopted by the 
reporter protein in the control fibroblasts (Emerin i -ii). Panels iii - vi) in the green 
channel showed no emerin expression in the patient cell lines. 
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Figure 3.11 
Fibroblasts from a healthy donor and X-linked EDMD cell lines were transfected 
with DSRed2-LaminC (wild type) and stained with anti-lamin A antibody. Different 
patterns of distribution of the exogenous protein were observed. In control and X-
linked EDMD fibroblasts, DSRed2-LaminC was localized to the nuclear rim 
(DSRed2-LaminC i, iii and v), and into aggregates (DSRed2-LaminC ii, iv and vi). 
Endogenous Lamin A localization at the nuclear rim was not affected by the 
distribution adopted by the reporter protein in the control fibroblasts (Lamin A i -
ii), nor in the patient cell lines (Lamin A iv - vi). 
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Figure 3.12 
Fibroblasts from a healthy donor and X-linked EDMD cell lines were transfected 
with DSRed2-laminC (wild type) and stained with anti-laminBl antibody. Different 
patterns of distribution of the exogenous protein were observed. In control and X-
linked EDMD fibroblasts, DSRed2-LaminC was localized to the nuclear rim 
(DSRed2-LaminC i, iii and v), and into aggregates (DSRedZ-LaminC ii, iv and vi). 
Endogenous lamin Bl localization at the nuclear rim was not affected by the 
distribution adopted by the reporter protein neither in the control or patients 
fibroblasts (laminBl i - vi). 
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Figure 3.13 
Fibroblasts from a healthy donor and X-linked EDMD cell lines were transfected 
with GFP-Emerin (wild type) and stained with anti-laminA antibody. Different 
distribution patterns of the exogenous protein were observed. In control and X-
linked EDMD fibroblasts, when GFP-Emerin was localized to the nuclear rim (GFP-
Emerin i, iii and v), endogenous laminA showed a normal distribution (laminA i, iii 
and v). Aggregation of the reporter protein in control and patient fibroblasts did 
not cause miss-localization of endogenous laminA (lamin A ii, iv and vi) into 
aggregates. GFP-Emerin was often localized in the cytoplasm, either in a smooth 
distribution (GFP-Emerin ii, iii and vi) or into aggregates (GFP-Emerin iii and iv). 
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Figure 3.14 
Fibroblasts from a healthy donor and X-linked EDMD cell lines were transfected 
with GFP-Emerin (wild type) and stained with anti-lamin C antibody. Different 
distribution patterns of the exogenous protein were observed. In control 
fibroblasts, when GFP-Emerin was localized to the nuclear rim (GFP-Emerin i, iii 
and v), endogenous lamin C showed a normal distribution (lamin C i, iii and v). 
Aggregation of the reporter protein in control cells did cause miss-localization of 
endogenous lamin C (lamin C ii) into the nucleoplasm. In the patient cell lines, 
aggregation of the GFP-Emerin did not caused miss'-localization of the endogenous 
lamin C, but in this case, GFP-Emerin aggregates were localized mainly to the 
perinuclear space (GFP-Emerin iv and vi, lamin C iv and vi). GFP-Emerin was 
often localized in the cytoplasm, either in a smooth distribution (GFP-Emerin ii 
and vi) or into aggregates (GFP-Emerin iv and vi). 
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Figure 3.15 
Fibroblasts from a healthy donor and X-linked EDMD cell lines were transfected 
with GFP-Emerin (wild type) and stained with anti-lamin Bl antibody. Different 
patterns of distribution of the exogenous protein were observed. In control and X-
linked EDMD fibroblasts, GFP-Emerin was localized to the nuclear rim (GFP-Emerin 
i, iii and v), and into aggregates (GFP-Emerin ii, iv and vi). Endogenous lamin Bl 
localization at the nuclear rim was never affected by the distribution adopted by 
the reporter protein (LaminBl i - vi). GFP-Emerin was often localized in the 
cytoplasm, either in a smooth distribution (GFP-Emerin i and vi) or into 
aggregates (GFP-Emerin ii and vi). 
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Table 3.3 
Summary of the transfection/immunofluorecence results. Most relevant 
observations are highlighted. 
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4. Chapter Four - Changes in the distribution of nuclear and cytoplasmic 
proteins in Autosomal Dominant Emery- Dreifuss muscular 
dystrophy. 
4.1. Introduction 
Laminopathies are a group of diseases caused by underlying mutations in tlie 
genes encoding Lamins A and C or in their associated proteins (Cohen et al., 
2 0 0 1 ; Hutchison et al., 2001 ; Morris and Manilal, 1999). Positional cloning 
revealed that mutations in the gene encoding Lamin A/C (LMNA) or in the gene 
encoding Emerin (STA, also called EMD) give rise to Emery Dreifuss muscular 
dystrophy (EDMD). There are three forms of this disease: autosomal dominant 
or recessive (AD-EDMD and AR-EDMD) are both caused by mutations in LMNA. 
XL- EDMD caused by mutations in STA display similar phenotypes that are 
atypical of other muscular dystrophies (Emery, 2000; Morris, 2000). The disease 
starts with stiffness of joints in the neck, elbows and Achilles tendons. Muscle 
weakness progresses very slowly and the life threatening condition associated 
with this disease is a conduction block and progressive cardiomyopathy. Five 
other diseases are related to mutations in LMNA. These include Dilated 
Cardiomyopathy with Conduction System Disease (DCM-CD) (Brodsky et al., 
2000; Fatkin et al., 1999), Dunnigan-type Familial Partial Lipodystrophy (FPLD) 
(Cao and Hegele, 2000; Shackleton et al., 2000), a sub-set of Limb Girdle 
Muscular Dystrophy (type IB) (LGMDIB) (Muchir et al., 2000), Charcot-Marie-
Tooth disorder type 2 (AR-CMT2) (De Sandre-Giovannoli et al., 2002) and 
Mandibuloacral Dysplasia (MAD) (Novelli et al., 2002). Other recently described 
disorders involving mutations in the LMNA gene are Hutchinson-Gilford (Eriksson 
et al., 2003) and Werner syndrome (Chen et al., 2003). 
Lamins A/C and Emerin are components of the nuclear Lamina and the 
inner nuclear membrane (INM) respectively. Emerin is a type I I integral 
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membrane protein (Ellis et a l . , 1997; Manilal et a l . , 1996; Nagano et 
a l . , 1996) that binds Lamins A/C and Bl (Clements et al., 2000; Vaughan et 
al., 2001), Barrier-to-Autointegration Factor (BAF) (Haraguchi et al., 2001), 
Splicing-Associated Factor YT521-B (Wilkinson et al., 2003), Nesprin l a 
(Mislow et al., 2002), Transcriptional Repressor Germ-Cell-Less (GCL) 
(Holaska et al., 2003) and Actin (Lattanzi et al., 2003; SEB-Symposia, 2003) 
and is anchored to the INM by its C-terminal domain (Yorifuji et a l . , 1997). 
Lamins A and C are members of the type V intermediate filament proteins 
(Fisher et al . , 1986; McKeon et a l . , 1986). They form part of the nuclear 
Lamina, a flattened filamentous structure lining the entire face of the INM 
(Aebi et al . , 1986; Hutchison, 2002) where they bind to chromatin (Glass 
et al., 1993), Emerin (Fairley et al., 1999; Vaughan et al., 2001), 
transcription and splicing factors (Dreger et al., 2002; Jagatheesan et al., 
1999; Markiewicz et al., 2002a), histones (Goldberg et al., 1999), Nesprin la 
(Mislow et al., 2002), Actin (Sasseville and Langelier, 1998) and other Lamina 
Associated Proteins (Hutchison et al., 2001). 
There is some debate concerning the mechanisms by which mutations in nuclear 
membrane proteins that are ubiquitously expressed give rise to tissue specific 
diseases (Hutchison et al., 2001; Muchir et al., 2000). Two models have been 
proposed to explain how disease phenotypes arise. The first, called the structural 
model, is based upon the fact that Lamins and their associated proteins form a 
filamentous nucleoskeleton that supports the NE (Hozak et al., 1995; Zhang et al., 
1996). It has been suggested that mutations in Emerin and Lamins A/C cause 
structural abnormalities within the Lamina and in turn this causes fragility in the NE 
particularly in contractile tissues such as skeletal and cardiac muscle (Fidzianska 
et al., 1999; Hutchison et al., 2001; Sullivan et al., 1999). In the second 
model, it has been suggested that mutations in Emerin and Lamins A/C cause 
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changes in gene expression, which ultimately promote the pathophysiology of the 
various diseases (Cohen et al., 2001; Hutchison, 2002). 
Recent support for the structural hypothesis has emerged in three separate 
studies using skin fibroblasts from Laminopathy patients. Fibroblasts from FPLD 
patients displayed characteristic alterations in the distribution of nuclear 
membrane proteins and Lamins together with "herniations" In the nuclear 
envelope. In addition, all Lamins displayed increased solubility properties in 
biochemical assays (VIgouroux et al., 2001). In a complementary investigation of 
fibroblasts from LGMDIB patients, which were null for Lamin A/C, nuclei were 
misshapen and contained multiple lobules. Lamin B l , the nuclear membrane 
protein LAP2P and the nucleoporin Nupl53 were all excluded from the lobules, 
whereas Emerin, while mainly located in the ER, was also concentrated in the 
lobules. The nuclear abnormalities were more apparent in early passage cultures 
and disappeared at late passages (Muchir A, 2002). A third report describes the 
solubility properties and localization of Lamins and Lamin Associated Proteins in 
fibroblasts from XL-EDMD patients. All Lamin sub-types displayed increased 
solubility properties in the absence of Emerin. In addition, Lamin C was 
redistributed from the nuclear envelope to the nucleoplasm, while the Lamin A/C 
binding protein LAP2a accumulated in "nuclear caps". However, herniations and 
lobules were not reported (Marklewicz et al., 2002b). Despite the differences in 
details between these three investigations, all indicate that mutations in Lamins or 
in Emerin can lead to structural weakness of the nuclear envelope. Given the very 
different clinical nature of these three diseases, the relevance of structural 
weakness to the disease etiologies must be questioned. 
The lack of experimental evidence to support the gene expression theory in EDMD 
as a main cause of the disease created a high level of scepticism between 
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researchers when first proposed, as it is still not understood how nuclear Lamins 
and/or inner nuclear membrane proteins could be involved in control of gene 
expression (Hutchison et al., 2001; Wilson, 2000). Although yet to be proved, it 
is clear that A-type Lamins must be in some way involved in the control of gene 
expression, considering the early reports of the appearance of A-type Lamins in 
differentiated cell types (Benavente et al., 1985; Lehner et al., 1987). Other 
sources of indirect evidence for the role of A-type Lamins in transcriptional 
regulation derived from other studies, where the C-terminal of the SIR4 protein in 
yeast, protein required for transcriptional silencing of the HM mating-type loci, 
showed a high similarity with a unique 43-aminoacid region of the coil lb domain 
of A-type Lamins (Diffley and Stillman, 1989). Other studies have shown that 
expression or changes of Lamin A occurs at differentiation, where certain genes are 
required to be expressed (Collard et al., 1992; Lourim and Lin, 1992; 
Muralikrishna et al., 2001). Current approaches involving powerful technologies 
like micro-arrays or proteomics may give rise to new insights in the specific set of 
genes under the control of A-type Lamins. 
Other aspect of great importance to be considered in the pathogenesis of 
muscular dystrophies is the heterogeneous genetic nature of this group of 
diseases. Focusing only on EDMD, mutations in the Emerin gene give rise to one 
phenotype, the XL form of EDMD, and up to six phenotypes are associated with 
mutations in the LMNA gene (AR and AD-EDMD, LGMDIB, DCM-CD, FPLD, AR-
CMT2 and MAD). Routine mutational analysis in patients with a classical EDMD 
phenotype revealed that only 40% were linked to mutations in the STA or LMNA 
gene. The other 60 % of the cases dearly indicates that further genes must be 
involved in EDMD (Gisele Bonne and al, 2003). The lack of large families or sufficient 
numbers of sib pairs have forced the functional candidate gene approach to be 
taken as a strategy for new linkage or association studies in order to identify other 
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genes involved in the development of the disease. Genes encoding proteins 
exclusively expressed in skeletal muscle and heart or those located in the nuclear 
membrane or Lamina that interact with Emerin or Lamin A/C or have structural 
similarities to these proteins have been considered as functional candidates, in 
particular: SMPX (small muscular protein), FLNC (filamin C), LMNBl (Lamin Bl ) , 
LMNB2 (Lamin B2), LBR (Lamin B receptor), LAPl (Lamina-Associated Peptide 1), 
LAP2 (Lamina-Associated Peptide 2), MANl (manl), NRM (nurim), BAF (Barrier-to-
Autointegration Factor), PSME3 (Proteasome Activator Subunit 3), DDX16 
(DEAD/H-box polypeptide). Monomorphic genes were excluded (SMPX, LMNB2, 
LAPl and BAF); intronic variation and frequent single nucleotide polymorphisms 
(SNPs) were considered not likely to cause the disease phenotype (MANl, LMNBl, 
PSME3, LBR were excluded). Partially unique exonic DNA-variations causing amino 
acid exchanges were found in the remaining genes: FLPC (filamin C), LAP2, NRM 
(nurim) and DDX16 (DEAD/H-box polypeptide) (Manfred Wehnert in (Gisele Bonne and 
al, 2003)). Other genes will need to be included in these studies like the newly 
described Actin-binding proteins Nesprins and/or Nuance, members of a giant 
gene family that will require an extensive experimental effort to analyze their 
entire sequences in order to find evidences for DNA variations in samples from 
EDMD patients. 
In this study, I investigated structural abnormalities in the nuclear envelopes of 
fibroblasts from AD-EDMD patients. I found that changes of the type described for 
FPLD, MAD and LGMDIB were observed in AD-EDMD fibroblasts but the frequency 
with which they were observed was dependent upon the conditions of fixation. In 
addition, these structural changes in the nuclear Lamina can be induced by serum 
starvation/re-stimulation and by over-confluence, which clearly indicates that re-
arrangements of the nuclear Lamina may be affected during the intriguing events 
following exit or re-entrance to the cell cycle, especially in the patients carrying 
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mutations in the LMNA gene. This raises further doubt as to whether the 
structural changes described are a primary cause of any Laminopathy. Rather 
they may reflect fundamental changes in Lamin-Lamin associations, which affect 
different cells in different ways, but may be increased in the nuclear Lamina of 
cell lines derived from patients where A-type Lamins are mutated. 
In search for new proteins involved in EDMD, I studied Nesprins and HSP70 
distribution, in EDMD cell lines. I confirmed the experimental evidences described 
in other studies that Nesprin 1 splicing isoforms, containing the original N-terminal 
region, might be involved in the interaction with Actin fibres (Zhang et al., 2002), 
an event that may be of special significance for natural and/or disease-induced 
process involving quiescence. The N-terminal of Nesprin l a has been shown to be 
able to bind full length Emerin (Mislow et al., 2002), which together with the 
putative interaction of Nesprin 1 N-terminal with a-S-Actin confirm the theoretical 
speculations that a macromolecular protein complex may exist in the nucleus that 
combine Emerin and Actin with other nuclear proteins (Katherine Wilson and Juliet 
Ellis in (SEB-Symposia, 2003)). I also describe here the re-distribution of HSP70 
protein in cells derived from EDMD patients under metabolic stress. 
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4.2. Results 
4.2.1. Distribution of Emerin and A and B-type Lamins 
revealed by methanol: acetone fixation. 
In previous investigations, LMNA mutations causing FPLD, LGMDIB and EDMD 
have been reported to promote abnormalities in the organization and distribution 
of Lamins and nuclear envelope proteins in fibroblasts (Muchir A, 2002; Vigouroux 
et al., 2001). Moreover, when mutant Lamin A or Lamin C are overexpressed as 
epitope-tagged proteins in model cell lines they may give rise to abnormal 
distributions of each protein, including the formation of intra-nudear aggregates 
(Ostlund et al., 2001; Raharjo et al., 2001). I therefore investigated the 
distribution of all Lamin sub-types as well as the nuclear envelope protein Emerin 
and nucleoporins in control and AD-EDMD fibroblasts. Initially, cells were fixed in 
methanol: acetone and co-stained with anti-Emerin and anti-Lamin C antibodies 
(Figure 4.1 A). In control cells the vast majority of nuclei were oval shaped. 
Emerin and all Lamin types displayed a uniform perinuclear staining pattern, in 
which each protein co-localized with the others (Figure 4.1Ai - Ci). In AD-EDMD 
cultures, Lamin C displayed a honeycomb like appearance typically orientated 
towards one pole in 15 - 20% of cells (Figure 4.1A 11 and iii Lamin C). The 
distribution of Lamin C in the remaining cells was identical to controls (Figure 4.1Ai 
Lamin C). Emerin was also present in the honeycomb structures (Figure 4.1Aii and 
iii Emerin) where it co-localized precisely with Lamin C (Figure 4.1Aii and iii 
Merged). 
Next I compared the distributions of Lamin C (green) and Lamin Bl (red). Once 
again Lamin C was organised into honeycomb structures, in as many as 20% of 
cells in AD-EDMD cultures (Figure 4.1Bii and iii Lamin C). Lamin Bl was relatively 
depleted from the honeycomb structures (Figure 4.IB ii and iii Lamin Bl ) , and 
therefore in these areas of the nucleus, Lamin C and Lamin Bl did not co-localise. 
119 
In contrast, in control fibroblasts (Figure 4.1Bi) and in AD-EDMD fibroblasts, which 
appeared normal (not shown), Lamin C and Lamin Bl co-localised throughout the 
nuclear envelope. Finally, I compared the distribution of Lamin B2 (green) and 
Lamin Bl (red) (Figure 4.1C). In all experiments, honeycomb structures were 
observed in ~20% of cells in AD-EDMD cultures. In all instances, there was 
complete co-localisation between the two B-type Lamins. Since Lamin C and Lamin 
Bl do not co-localise within the honeycomb I infer that within this structure A and 
B-type Lamins segregate away from each other. While the honeycomb structures 
observed in this study were superficially similar to those described in other studies 
(Vigouroux et al., 2001), under the conditions of fixation used here I rarely 
observed the associated "herniations" described in FPLD fibroblasts. In this study 
98% of cells in controls displayed a uniform perinuclear rim for all antibodies used. 
In 2% of cells, internal staining was observed corresponding to intra nuclear 
tubes. These are normal structures that have been described previously (Fricker et 
al., 1997). 
4.2.2. Distribution of Emerin and A and B-type Lamins 
revealed by Para-formaldehyde fixation. 
To further investigate structural abnormalities in AD-EDMD fibroblasts I performed 
double immunofluorescence on fibroblast cultures fixed in Para- formaldehyde 
(PFA) and permeabilized with Triton X-100. In control cultures, Emerin and all 
Lamin types were uniformly distributed at the nuclear periphery (Figure 4.2 Ai and 
ii Lamin C (double arrow) and Figures 4.2B - D). Under these conditions of 
fixation, the nuclear envelope was always defined more discretely than with 
methanol: acetone fixation, indicating better preservation of the structure. 
Honeycomb structures were detected in control (Figure 4.2 Ai and ii Lamin C 
single arrow) and AD-EDMD fibroblasts (Figure 4.2 Bii-iii Emerin and Lamin C, 
4.2 Cii-iii Nucleoporin and Lamin C, and 4.2 Dii-iii Nucleoporin and Lamin Bl) 
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fixed with PFA. However, the frequency at which they were observed was 
<5%. As with methanol: acetone fixation, Emerin (Figure 4.2 Bii-iii Emerin) 
and Lamin C (Figure 4.2 Bii-iii Lamin C) co-localised precisely within the 
honeycomb (Figure 4.2 Bii-iii Merged). B-type Lamins were reported to be 
absent from "honeycomb" structures in LGMDIB fibroblasts that were null for 
Lamins A/C and FPLD patients with missense mutations in the LMNA gene 
(Lattanzi et al., 2003; Muchir A, 2002). In the study on LGMDIB fibroblasts, the 
nucleoporin Nupl53 co-localised with Lamin B l and was consequently 
depleted from the honeycomb structure. To determine whether nucleoporin 
proteins were depleted from honeycomb structures in the AD-EDMD 
fibroblasts, cells were co-stained with anti-Lamin C and the XFXG nucleoporin 
antibody 414 or with anti-Lamin B l and 414. When the distribution of 
nucleoporins was compared to Lamin C there was less nucleopore protein 
within the honeycomb (Figure 4.2 Cii-iii Nucleoporin and Lamin C). When the 
distribution of nucleoporins was compared to Lamin B l , both types of protein 
were absent (Lamin B l ) or depleted (XFXG nucleoporins) from the honeycomb 
(Figure 4.2 Dii-iii Nucleoporin and Lamin B l ) . Thus the distribution and 
behaviour of proteins in AD-EDMD fibroblasts harbouring Lamin A/C mutations 
was similar if not identical to LGMDIB fibroblasts where Lamins A/C are null. 
To confirm these findings my study was extended to include six AD-EDMD 
fibroblast cell lines. Comparison of methanol: acetone fixation revealed a 
higher incidence of honeycombs in five patient cell lines compared to the 
control. Using PFA fixation, a higher incidence was observed in three out of six 
patient cell lines (Figure 4.3). To assess the statistical significance of the 
difference between the fixation methods, I used Wilcoxon-Mann-Whitney Z test 
for paired-samples using SPSS® 11,1 (for Windows®). All Z values were 
significant at p<0.001, except cell line AD-EDMD 4 (Z= -2.000), which was 
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significant at p < 0.05 (Table 4.1). Taken together, these results confirm that by 
using the strongest fixation method (methanol: acetone), a higher number of 
structural abnormalities can be displayed at the nuclear Lamina. 
4.2.3. Lamins expression and conformation in AD-EDMD. 
In this study, fibroblasts from four AD-EDMD patients with LMNA mutations were 
investigated. Two cell lines had mutations, one in the rod (R249Q) and the other 
one in the tail domain (R401C). I did not have the DNA sequencing data for the 
other two AD-EDMD cell lines at the time of writing this thesis. The two of them 
had been sent to our lab from Poland. 
In a previous investigation a LMNA mutation Y259X giving rise to LGMDIB was 
shown to promote haplo-insufficiency for Lamins A/C in the heterozygote and a 
null phenotype in the homozygote (Muchir et al., 2003). In order to investigate 
whether LMNA causing AD-EDMD had similar effects and honeycomb structures 
could arise from re-arrangements of the nuclear Lamina, I compared the level of 
expression of Lamins A/C in each patient cell line to an age-matched control under 
reduced and non-reduced conditions. Since one mutation introduced a cysteine 
residue into the tail domain (R401C), I investigated the possibility that this would 
permit aberrant disulphide bond formation between Lamin polypeptides or with 
other proteins. 
Therefore cell extracts were prepared from control and patient cell lines for 
immunoblotting, treated with the alkylating agent NEM to trap disulphide linked 
proteins and resolved on SDS-PAGE under reducing and non-reducing conditions. 
Levels of expression of Lamin C were similar in each cell line (Figure 4.4 A and B), 
while Lamin A was particularly expressed at a higher level in the cell line that 
presented the mutation in the rod domain (R249Q) of Lamin A (Figure 4.4 A, lanes 
2 and 8). When cell extracts were resolved under non-reducing conditions, there 
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was no evidence of cross-linking between Lamin polypeptides (Figure 4.4 A and B). 
As a positive control for cross-linking through cysteine residues, the same samples 
were probed with antibodies against the E.R. protein, PDI (Benham et al., 2000). 
Intermediate disulphide bonded complexes were clearly obtained under non-reducing 
conditions, as expected (Figure 4.4 C). 
While this evidence does not rule out the possibility that mutations introduce 
conformational changes in the Lamins, this data suggests that mutations 
introducing new cysteine do not lead to synthesis of unstable proteins and the 
residue does not permit unusual disulphide bond formation between Lamin 
polypeptides or with other proteins in the nuclei. 
4 .2 .4 . Lamina assembly may be affected in G l GO G l . 
Normal cells usually cease to proliferate in a cell-cycle-specific way. They arrest in 
Gl or enter a state of quiescence (GO) from Gl after depletion of serum or growth 
factors (Pardee, 1974; Temin, 1971) or nutrients (Prescott, 1976) or after cell 
crowding (Nilausen and Green, 1965; Zetterberg and Auer, 1970). Previous 
studies carried out in our lab have shown the dynamics of the nuclear Lamina 
in quiescence and re-stimulated normal human dermal fibroblasts (Dyer et 
a l . , 1997) . These studies have suggested that in cells induced to exit the cell cycle, 
the steady-state of the nuclear Lamina changes probably due to biochemical 
modifications or re-arrangements of A-type Lamins, evidenced by the change in 
availability of epitopes for monoclonal antibodies against Lamin A and/or C. 
Based on this evidence, I set up experiments to further investigate whether the 
honeycomb structures observed in the AD and XL-EDMD cell lines with different 
fixation methods were an artefact of the staining procedures or represented a real 
change in the nuclear Lamina, related to a particular stage of the cell cycle. 
Exponentially growing fibroblasts from a healthy donor (control HDF), AD and XL-
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EDMD patients were serum starved for 5 days and then re-stimulated with fresh 
media containing 10% NCS. After 30 hour, cells were fixed with 3.5% Para-
formaldehyde and stained with anti-Lamin A/C and anti-Emerin antibody at mid 
passages and late passages. AD-EDMD fibroblasts showed the higher amount of 
honeycombs compared to the control and XL-EDMD (Figure 4.5) 
At mid passages, in control and X-linked fibroblasts, the great majority of the 
nuclei presented normal staining for Lamin C (Figures 4.6 and 4.7 A - C i and iii), 
Emerin (Figures 4.14 and 4.16 A - C i and iii) or Lamin A/C (Figures 4.15 and 4.17 
A - C i and iii) at the nuclear rim, with honeycomb structures present at very low 
percentages (2-3%) in proliferative, quiescence and re-stimulated cultures. In 
contrast, the number of honeycomb structures in the AD-EDMD cell line was 
increasingly altered as cells progressed from proliferating to quiescent and back to 
a proliferating state with Lamin C (Figures 4.6 and 4.7 C ii), Emerin (Figures 4.14 
and 4.16 C ii) and Lamin A/C (Figures 4.15 and 4.17 C ii ). Other studies have 
shown that inducing quiescence by over-confluence also increases the amount of 
honeycomb structures in the nucleus of AD-EDMD cell lines in 3 fold (Chris ] . 
Hutchison, Personal Communication). In all cases, wherever a honeycomb structure 
was present, lack of chromatin was observed in the area, highlighted by the DAPI 
staining, as reported previously. 
Late passage cultures showed honeycomb structures as well when cells were 
stained with anti-Emerin or anti-Lamin A/C antibodies. But in this case, the 
amount of honeycombs in the AD-EDMD cultures was less than in the growth 
inhibition experiments (Figures 4.18 and 4.19 Band C). 
4.2.5. Indirect evidence for cytoskeleton re-organization: 
Heat Shock Proteins distribution. 
Diverse physiological stresses like heat, hemodynamics, mutant proteins and 
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oxidative injury, produce multiple changes in a cell that ultimately affect protein 
structure and function. Under these circumstances, molecular chaperons (for 
example heat shock proteins, HSPs) actively participate in a cascade of cellular 
events, including cytoprotection. I n . the case of disease states caused by 
expression of mutant proteins, elevated levels of misfolded or denatured proteins 
are potent inducers of HSPs gene expression (Ananthan J et al., 1986; Benjamin 
and DR, 1998). Conceivably, mutations in Lamins or other proteins might be 
considered as a source of stress in Laminopathies, so potentially heat shock 
proteins can be expressed or re-distributed. As metabolic stress is not known as a 
stimulus to induce heat shock proteins expression, I decided to test the 
distribution of some members of this family of, proteins in AD-EDMD fibroblast 
harbouring missense mutations in the rod and tail domain of the filaments, 
throughout exit and re-entrance to the cell cycle induced by serum starvation. 
Human dermal fibroblasts from a healthy donor, AD-EDMD (R401C) and XL-EDMD 
were used at mid passage. Proliferating cultures at 60% confluence were serum 
starved for 5 days using media containing 0.5% NCS. On day five, fresh media 
containing 10% NCS was added and cells were allowed to grow for 30 hours before 
fixation with 3.5 % PFA and staining with anti-HSP27 (green) and anti-Lamin C 
(red) antibodies. 
In proliferating cells (Figure 4.6 A), HSP27 was localized into a homogeneous 
pattern within the cytoplasm in all cell lines. No significant staining was observed 
in any nucleus. During quiescence, morphological changes in cell shape were 
accompanied by re-location of HSP27 into fibres throughout most of the 
cytoplasm, but a homogeneous pattern remained in the perinuclear space with no 
significant difference between cell lines. The nucleus remained partially negatively 
stained for HSP27 (Figure 4.6 B). Re-stimulation produced a re-distribution of 
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HSP27 to the homogeneous pattern observed in the proliferative stage, with an 
increased intensity in the signal for the heat shock protein (Figure 4.6 C). 
Other members of the family of the Heat Shock Proteins have been described to be 
altered in many diseases, including cardiovascular disorders. One of these 
members that have been studied in more details is HSP70 (Benjamin and DR, 
1998). To further analyze whether this protein is affected in EDMD patients and/or 
is involved in the re-arrangements of the nuclear Lamina observed in the EDMD 
cell lines, samples were double stained with anti-HSP70 (green) and anti-Lamin C 
(red) antibodies (Figure 4.7). Proliferating cultures showed a homogenous diffuse 
pattern of staining within the cytoplasm in all, cell lines (Figure 4.7 A). The 
nucleoplasm of AD-EDMD cells contained more HSP70 than the control or the XL-
EDMD samples (Figure 4.7 A ii). When cells were serum starved for 5 days (Figure 
4.7 B), morphological changes were accompanied with HSP70 redistributed 
strongly to the outer perinuclear space in 74% of the AD-EDMD cells (Figure 4.71 
B ii), while the control and the XL-EDMD cell lines showed a weak re-distribution in 
only 3 and 6 % respectively. The presence of nuclear HSP70 staining was reduced 
compared to proliferating cultures. Re-stimulated cells showed a re-location of 
HSP70 into the homogeneous pattern observed during proliferation (Figure 4.7 C), 
but 24 % of the XL-EDMD cells displayed perinuclear localization. HSP70 staining 
re-appeared in the nucleoplasm of AD-EDMD cells (Figure 4.7 C ii). 
Are HSP70 expression levels altered in AD-EDMD patients? To answer this 
question, I determined the levels of expression of HSP70 in proliferating cultures 
of AD-EDMD cell lines. Cell extracts were prepared from control and patient cell 
lines resolved on SDS-PAGE, transferred and immunoblotted (Figure 4.8). Levels 
of expression of HSP70 were almost identical in each cell line, suggesting that the 
increased levels of HSP70 in the quiescence AD-EDMD cultures might be due to re-
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location of its cytoplasmic pool into the nuclei or induction of HSP70 expression, 
rather than due to differences in protein content. 
It is well known that chaperones interact with several members of the cytoskeleton 
and influence their organization. During quiescence-induced metabolic stress, an 
abnormal re-arrangement of HSP70 to the Endoplasmic Reticulum (ER) occurred 
at the exit (AD-EDMD cells) or re-entrance (XL-EDMD cells) to the cell cycle, 
which resembled the rearrangement of Nesprin 2 (N-terminal) in cultures under 
metabolic stress. Taking together, this data implies that probably there is a stress 
response due to the mutations in the Lamins, Nesprins and/or others (it did not 
happen in the controls), where HSP70, but not HSP27 accumulates in the ER to 
execute a cytoprotective pathway at a critical cell cycle checkpoint in fibroblasts 
from EDMD patients. 
4.2.6. Nesprin 1 N-terminal co-localizes with the 
distribution of a-S-Actin fibres in skin dermal fibroblasts. 
The observed changes in the frequencies of occurrence of honeycomb structures 
in response to serum starvation or confluence indicated that honeycombs may 
arise as a result of stress. In addition, my early observation in skin dermal 
fibroblasts under a phase contrast microscope revealed a high frequency of very 
large and flattened cells derived from AD-EDMD and X-linked patients when 
compared to controls (Figure 4.9, arrows). In my very first Nesprin single staining 
in human fibroblasts, the anti-Nesprin 1 N5 antibody (specific for the N-terminal 
of Nesprin 1) produced a characteristic phenotype in a sub-population of cells 
resembling the distribution of a-S-Actin in other cell types. 
Together, these data indicate that EDMD fibroblasts may be subject to stress-
related responses which involve not only the nucleoskeleton but also the 
cytoskeleton. To investigate this possibility, I studied the distribution of Nesprins 
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1 and 2 in human fibroblasts. Nesprins were selected because they are giant 
spectrin-repeat proteins which link the nuclear Lamina to the Actin cytoskeleton 
(Zhang et al., 2001; Zhen et al., 2002); therefore they are potentially candidate 
markers for stress-related reorganization of nucleo-cytoskeleton in response to 
growth inhibition. With this in mind, I used double immunofluorescence with anti-
a-S-Actin and Nesprin 1 N5 antibody (specific for the N terminal of Nesprin 1) or 
Nesprin 2 GH3 antibody (specific for the N terminal of Nesprin 2) to investigate 
whether or not Nesprins and a-S-Actin where present in the same fibres. 
Skin dermal fibroblasts derived from a healthy donor, EDMD patient and rat were 
stained with anti-a-S-Actin (green) and anti-Nesprin 1 N5 antibodies (red) 
(Figure 4.10 A). Very large and flattened cells were observed in all cases, in 
which a-S-Actin perfectly co-localized with antibodies against the N terminal of 
Nesprin 1. Nesprin 1 labelled with this antibody showed a homogeneous-diffuse 
pattern in the nucleoplasm in normal spindle/shaped cells. Parallel samples were 
double stained with a-S-Actin (green) and anti-Nesprin 2 CHS antibodies (red) 
(Figure 4.10 B). Nesprin 2 CHS produced nuclear signal excluding nucleoli in 
human cells (Figure 4.10 B i - ii, Nesprin2 CHS). Rat nuclei presented a diffuse 
pattern through the nucleoplasm (Figure 4.10 B iii Nesprin2 CHS). In all cases, 
Nesprin 2 C-terminal never co-localized with a-S-Actin fibres when present in the 
cytoplasm. a-S-Actin positive cells always had a large flattened shape, resembling 
the phenotype of non-migrating senescent cells. 
Nesprin gene family was originally identified in search for Vascular Smooth Muscle 
Cell (VSMC) differentiation markers (Zhang et al., 2001). In association with a 
number of diseases, VSMC becomes functionally impaired, when made quiescent. 
To further investigate whether the distribution of Nesprin 1 fibres was related or 
not to the cell cycle, in particular to quiescence, human dermal fibrpblasts from a 
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healthy donor, AD-EDMD (R401C) and XL-EDMD were analyzed (Figure 4.11). 
Proliferating cultures at 60% confluence were serum starved for 5 days using 
media containing 0.5% NCS. On day five, fresh media was added and cells were 
allowed to grow for 30 hours before fixation with 3.5 % PFA and staining with a-S-
Actin (green) and Nesprin 1 N5 (red) antibodies. 
In proliferating cultures (Figure 4.11 A) heterogeneous patterns of Nesprin 1 and a-
S Actin positive cells were observed. In some cells, Nesprin 1 co-localized with a-
S-Actin stress fibres (Figure 4.11 A i and iii, single arrows). In other cells, stress 
fibres were absent and Nesprin 1 was distributed at the nuclear envelope and 
diffusely through the cytoplasm (Figure 4.11 i double arrows). In a third class of 
cells, Nesprin 1 partially co-localized with a-S-Actin stress fibres but was also 
concentrated in the nucleus. This third class of cells was found predominantly in 
the AD-EDMD cell line (Figure 4.11 A ii, triple arrows). 
Induction of quiescence by serum starvation caused almost all cells in control and 
AD-EDMD cultures to adopt shapes that were reminiscent of cells having a-S-Actin 
stress fibres in proliferating cultures. In contrast, a significantly high number of 
cells in XL-EDMD cultures maintained a bipolar shape. All cultures showed a 
dramatic re-distribution of Nesprin 1 towards the plasma membrane that co-
localized with re-distribution of a-S-Actin. In control and XL-EDMD cells, Nesprin 1 
re-location to the plasma membrane was independent of the expression of a-S-
Actin (Figure 4.11 B i and iii, arrows). In AD-EDMD cells, the vast majority of the 
cells were positive for Nesprin 1 and a-S-Actin, with both co-localising strongly 
towards the edge of the cells (Figure 4.11 B ii, arrows). After serum re-
stimulation, staining patterns for both a-S-Actin and Nesprin 1 antibodies 
reverted to the distributions reported previously for proliferating cultures (Figure 
4.11 C and see Figure 4.10 A and B). 
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Parallel samples from the same cultures were double stained with anti-a-S-Actin 
(green) and anti-Nesprin2 (N terminal) (red) antibodies (Figures 4.12 A - C). In 
all cases, Nesprin 2 N-terminal was always absent from a-S-Actin fibres. Its 
localization, as in previous experiments (Figure 4.10 B), was strong in the 
nucleus, but clearly absent in the nucleoli. 
In proliferating cultures (Figure 4.12 A), Nesprin 2 produced a diffuse cytoplasmic 
stain in all cell types. As cells became quiescent, there was a shift of cytoplasmic 
Nesprin 2 towards the perinuclear space in a high percentage of the AD-EDMD 
(Figure 4.12 B ii). In XL-EDMD cells (Figure 4.12 B iii), but not in the controls 
(Figure 4.12 B i), the shift appeared to occurs from the nucleoplasm, as the 
nucleoplasm staining was weaker. As in previous experiments, most of the AD-
EDMD cells showed a-S-Actin re-distributed to the edges of the plasma membrane 
and the shape of the cells was large and flattened. Some XL-EDMD fibroblasts 
remained resistant to change their shape (Figure 4.12 B iii). In all cell types, 
following re-stimulation of the cultures, Nesprin 2 relocated to the nucleus and to 
the cytoplasm as in proliferating cultures (weak background) (Figure 4.12 C). Cells 
recovered their original shape, but still the control and AD-EDMD cultures showed 
a higher fraction of a-S-Actin positive cells (Figure 4.12 C ii), which was absent in 
XL-EDMD fibroblasts (Figure 4.12 C iii). 
Since Nesprin 1 N-terminal clearly re-distributes in response to entry and exit 
from a quiescent state, I investigated whether this also happens during "natural" 
cell aging or senescence. Fibroblasts from a healthy donor and AD-EDMD patient 
(R401C) were grown through serial passage to generate senescent cells. Control 
fibroblasts became senescent at passage 40, while AD-EDMD fibroblasts became 
senescent at passage 45. Cultures were double labelled with anti-a-S-Actin 
(green) and anti-Nesprin 1 N5 (red) antibodies. In both cases, large and flattened 
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cells predominated in senescent cultures, with a higher percentage in the patient 
cell line. Senescent cells resembled both in shape and in the distribution of a-S-
Actin and Nesprin 1 those quiescent cells induced by serum starvation. The vast 
majority of the patient cells displayed double positive fibres for a-S-Actin and 
Nesprin 1 N-terminal (Figure 4.13 A i-ii). When senescent cells were co-stained 
with anti-a-S-Actin and Nesprin 2 (N terminal), there was no co-localization 
between the two antibodies. However, as in quiescent cells, cytoplasmic Nesprin 2 
became concentrated at the perinuclear space in AD-EDMD cells, and absent in 
the nucleoli (Figure 4.13 B i-ii). 
4.2.7. C-terminal of Nesprins during proliferation, 
quiescence and re-entrance to the cell cycle. 
To further investigate the significance of growth-related changes in Nesprin 
distribution, I performed immunofluorescence on human fibroblasts with 
antibodies specific for the C-terminal of Nesprins 1 and 2. As previously, 
proliferating cultures at 60% confluence were serum starved for 5 days using 
media containing 0.5% NCS. On day five, fresh media was added and cells were 
allowed to grow for 30 hours before fixation with 3.5 % PFA and staining with anti-
Emerin (green) and Nesprin 1 CI (C-terminal)(red) antibodies (Figure 4.14 A - C) 
or anti-Lamin A/C (green) and anti-Nesprin 1 CI (C-terminal)(red) antibodies 
(Figure 4.15 A-C). 
Nesprin 1 produced a heterogeneous weak-diffuse pattern in both the nucleus and 
the cytoplasm in the control (Figure 4.14 A - C i) and in the patient cell lines 
(Figure 4.14 A - C ii - iii). Nesprin 1 antibody never rendered fibre-like structures. 
A slightly stronger signal in the nucleus of the AD-EDMD cell line was observed 
(Figure 4.14 and 4.15 A ii). No cell-cycle dependent re-distribution occurred. 
Parallel cultures were double stained with anti-Emerin (green) and Nesprin 2 
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N2(C-terminal)(red) antibodies (Figure 4.16 A - C) or anti-Lamin A/C (green) and 
anti-Nesprin 2 N2 (C-terminal)(red) antibodies (Figure 4.17 A - C). The nuclear 
distribution pattern of Nesprin 2 C-terminal was not as evident as for Nesprin2 N-
terminal at different stages of the cell cycle. However, as with the N-terminal 
antibody, there was a relatively higher amount of Nesprin 2 C-terminal in the 
nucleus of the cell lines derived from EDMD patients (Figures 4.16 A ii-iii, 4.16 B 
ii-iii and 4.17 A ii-iii), compared to controls. 
Control and AD-EDMD fibroblasts were grown to late passages and double stained 
with anti-Emerin (green)/Nesprin 1 Cl(C-terminal)(red) antibodies (Figure 4.18 
B) or anti-Lamin A/C (green)/anti-Nesprin 1 CI (C-terminai)(red) antibodies 
(Figure 4.18 C). As in the previous experiments, the Nesprin 1 C-terminal 
antibody produced a diffuse staining pattern throughout the cell with some 
concentration of the signal in the patient cell line. Staining of stress fibres was not 
observed (Figures 4.18 B ii and 4.18 C ii). Almost identical results were obtained 
with antibody specific for Nesprin 2 C terminal (Figures 4.19 B - C). 
4.2.8. Expression of Nesprins in human fibroblasts. 
Next I investigated the expression pattern of Nesprin 1 in AD-EDMD cell lines on 
Western Blots. Similar experiments for Nesprin 2 were not set up due to the higher 
amount of isoforms recognised by anti-Nesprin 2 antibodies on Western Blots. 
Cell extracts from control and three AD-EDMD cell lines were used at mid and late 
passage. Extracts were resolved on 10% SDS-PAGE and blotted with either Nesprin 
1 C-terminal or Nesprin 1 N-terminal antibodies (Figure 4.20 A - B respectively). A 
complex pattern of staining was observed in each instance. With Nesprin C 
terminal antibody, bands with molecular weights of 250 KDa, 140 kDa, 95 kDa, 
52 kDa, 40kDa and 21 kDa were predominantly detected. The 140 kDa species 
(Figure 4.20 A * ) was only detected in mid passage AD-EDMD cultures. The 52 
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kDa species (Figure 4.20 +) was detected strongly in AD-EDMD cultures at mid 
and late passage. The 21 kDa species was detected in control and in AD-EDMD 
cultures at mid passage but was absent from all cultures at late passage. 
The predominant species detected by Nesprin 1 N terminal antibody migrated at ~ 
250 kDa, 240 kDa, 78 kDa, 60 kDa, 51 kDa 45 kDa and S5 kDa. Again differences 
in expression level between AD-EDMD and control were observed as well as 
differences between passage numbers. The ~78 kDa species (Figure 4.20 B *) was 
expressed more strongly in mutation R249Q than in any other cell line and was 
absent from late passage control cell line. In addition, the ~45 kDa (+) and ~35 
kDa (•) (Figure 4.20 B) were expressed more strongly in mid passage cultures of 
all cell lines compared to late passage cultures. 
4.2.9. Aging in AD-EDMD cultures. 
Data shown previously in this chapter has indicated that the expression and 
distribution patterns of Nesprin 1, normally associated with a senescent 
phenotype, occurs in mid passage culture of AD-EDMD fibroblasts. This may be 
explained if AD-EDMD fibroblast age prematurely in culture. To test this 
hypothesis, I established a simple experiment to compare the proliferation index 
of three AD-EDMD cultures with an age matched control through serial passage. 
Cells were grown from passage 14 onwards, and stained with the proliferation 
marker ki67. Two hundred cells were counted randomly in duplicate samples and 
in replicate experiments. Results were expressed in percentage of ki67 positive 
cells at each passage (Table 4.2). At passage 15, all cultures displayed indices of 
proliferation between 62 -82 %. The proliferation index of control cultures had 
declined to 10 % by passage 38. In contrast, two AD-EDMD cultures (R249Q and 
R45SW) had proliferation indices of 0% at passage 25. A third AD-EDMD culture 
(R401C) had a proliferation index of 40% at passage 45. Taken together, these 
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results might indicate that some AD-EDMD fibroblasts can enter a senescent state 
at twice the rate of age matched controls. 
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4.3. Discussion 
In this chapter, I reported changes in the distribution of lamins, nuclear 
membrane proteins, nucleoporins and cytoplasmic proteins in fibroblasts from AD 
and XL-EDMD patients. In the case of AD-EDMD cell lines, the presence of 
mutations in different regions of Lamin A/C apparently lead to haploinsufficiency 
or high expression of A-type Lamins since their levels were differentially 
expressed when compared to control fibroblasts. Apparently, mutations gave rise 
to similar changes in the distribution of Lamins, nuclear membrane proteins 
(Emerin) and nucleoporins in immunofluorescence. These changes resulted in the 
detection of A-type Lamins and Lamin binding proteins (Emerin) within a 
honeycomb structure orientated to one pole of the nucleus. B-type Lamins and 
nucleoporins were either absent or depleted from these structures. The 
appearance of the structures detected by immunofluorescence varied with fixation 
procedure but not with passage number, and they were induced by metabolic 
stress. 
Similar structures have been reported in two other diseases, which involve 
mutations in the LMNA gene, namely FPLD and DCM-CD (Muchir A, 2002; 
Vigouroux et al./ 2001). The variation in frequency of the structures with 
fixation procedure reported here reflects the extreme conditions of the 
methanol: acetone method compared to PFA. This must reflect underlying 
weakness in the nuclear Lamina and therefore a decreased resistance to 
chemical stress. Thus, in this study the use of harsh fixation procedures 
(methanol: acetone) generates the structures at a higher frequency than 
does by using mild fixation procedures (PFA). To my knowledge, this is the 
first study interconnecting critical changes in the distribution of Lamins, 
Nesprins and HSPs at the exit and re-entrance of the cell cycle, which might 
reflect the cell dynamics at early stages of the embryonic development in 
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AD-EDMD patients. 
4.3.1. The representation of different Lamins in honeycomb 
structures implies a disruption of Lamin-Lamin associations 
in the presence of LMNA mutations. 
One of the most striking features of this and previous studies (Vigouroux et a!., 
2001) is the segregation of A-type from B-type Lamins into different parts of the 
nuclear envelope in the presence of LMNA mutations. Depletion of B-type Lamins 
from one pole of the nuclear envelope also occurs in the complete absence of A-type 
Lamins (Muchir A, 2002). These changes in behaviour of Lamins have two 
important implications for Lamin associations in the nucleus. First the absence of 
B-type Lamins from the honeycomb implies that in the absence of A-type Lamins 
or in the presence of . mutant Lamins A or C, B-type Lamins may form closer 
associations with other structures in the nucleus or nuclear envelope (for example 
chromatin or NPCs). Presumably, these associations now determine the 
distribution of B-type Lamins in the nucleus. For example, it has been reported 
previously that chromatin is depleted from honeycomb structures in the nucleus 
(Muchir A, 2002). If the association of B-type Lamins and peripheral chromatin in 
Laminopathy fibroblasts is tighter than in normal fibroblasts, it is self evident that 
B-type Lamins will be observed in regions of the nucleus where chromatin is 
concentrated and absent from regions where chromatin is depleted. The co-
segregation of NPCs with B-type Lamins is expected because NPCs are anchored to 
Lamin filaments through interactions between the nucleoporin Nupl53 and B-type 
Lamins (Hutchison, 2002; Smythe et a l . , 2000; Walther et al . , 2001). 
A second implication of this and previous studies, is that LMNA mutations lead to 
an aberrant clustering of A-type Lamins in the absence of B-type Lamins. In 
previous studies it has been reported that A-type Lamins are normally 
incorporated into existing B-type Lamin filaments (Dyer et al., 1999; 
136 
Hutchison et al. , 2001). Within honeycombs, A-type Lamins are present in the 
absence of B-type Lamins. While it is an assumption these A-type Lamins are 
organized into filaments, the presence of the Lamin A/C binding protein 
Emerin in the honeycomb supports this assumption. These observations imply 
that mutations in the rod and tail domain abrogate the dependency for Lamins 
A/C to form filaments through association with B-type Lamins but do not 
disrupt Lamin-Emerin associations. At present I can only speculate as to the 
mechanism by which this occurs. The most obvious mechanism is that both 
types of mutation lead to weakened interactions between A-type and B-type 
Lamins, which causes them to polymerize independently. Alternatively, the 
mutations alter A-type Lamins-chromatin interactions, which may in turn 
promote the assembly of homotypic A-type Lamin filaments in areas of the 
nucleus depleted of chromatin. 
A third possibility might derive from the incorporation pathway of individual A-
type Lamins into the existing B-type Lamina after mitosis. The smallest soluble 
oligomers of intermediate filaments detected in vivo and in vitro were tetramers 
(Quinlan et al., 1984). If A-type Lamins incorporate as tetramers (or dimers) 
into the pre-assembled B-type Lamina, and if the mutation is heterozygous, 
one might expect a random mixture of normal A-type Lamins and their mutant 
counterparts in the oligomers. The heterozygosity of the A-type Lamins homo-
oligomers might then cause a change in the tertiary structure of the complexes 
that compromise its interaction with B-type Lamins polymers, segregating 
these subunits from a normal Lamina, and facilitating the formation of A-type 
Lamins homo-filaments and its accumulation in one pole of the nuclei. The co-
localization of ectopic-mutant Lamin A with endogenous-wild type Lamin C supports 
this hypothesis (Favreau et al., 2003). 
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4.3 .2 . Interconnecting cytoplasmic and nuclear 
abnormalities at the exit and re-entrance to the cell cycle in 
EDMD fibroblasts. 
The effect of serum deprivation on the cell cycle and the down-stream events 
regulating gene expression and protein concentration in Gl-> GO ^ G l has been 
well documented (Pardee, 1974; Temin, 1971). Serum starved and re-stimulated 
human fibroblasts have shown changes in the distribution of A-type Lamins, 
revealed by epitope masking at several points along the filament in quiescent and 
re-stimulated cells, as a result of protein phosphorylation, Lamin-Lamin or Lamin-
chromatin interactions, or specific binding to unidentified nuclear partners (Dyer et 
al., 1997). In this chapter I report structural changes at the exit/re-entrance to the 
cell cycle in AD-EDMD fibroblasts harbouring mutations in the LMNA gene that 
might be related to a nuclear checkpoint at these cell cycle events. 
The role of Nesprins during Go stage of the cell cycle it is one of the interesting 
findings of my study in normal and EDMD human skin dermal fibroblasts. 
Nesprins were originally isolated from a cDNA library of vascular smooth muscle 
cells (VSMCs) in search for a marker of differentiation (Zhang et al., 2001). The 
critical redistribution of Nesprin 1 (N-terminal) and its co-localization with a-S-
Actin, and redistribution of Nesprin 2 (N-terminal) during exit and entrance to the 
cell cycle in human dermal fibroblasts revealed the value of Nesprins as markers 
for differentiation not only in humans but as a conserved pathway in other 
species (rat). In addition, proliferating cultures of human fibroblasts harbouring 
mutations in the LMNA gene appeared to present a senescent phenotype in a 
higher percentage of cells compared to the controls, and an altered pattern of 
Nesprins expression, suggesting a possible implication of Nesprins in EDMD an 
revealing a possible involvement of an aging process in vitro. A recent 
investigation have demonstrated that Nesprin l a N-terminal binds Emerin and its 
C-terminal binds Lamin A (Mislow et al., 2002). 
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Compiling our experimental evidences in the cell cycle experiments, increased 
percentage of Nesprin 1 (N-terminal) fibres, co-localization of Nesprin 1 (N-
terminal) with a-S-Actin during quiescence, and re-distribution of the original pool 
of HSP70 and Nesprin 2 (N-terminal) towards the perinuclear space in cells derived 
from AD-EDMD patients might well be interconnected events, rather than isolated 
experimental records. These data might reflect underlying conveying processes 
that affect in some way the overall homeostasis of the early events involved in the 
development of the heart and skeletal muscle in patients carrying mutations in the 
LMNA gene, yet to be considered the main cause of the disease, or part of the 
plethora of cumulative genetic defects. 
I conclude that nuclear Lamina abnormalities described here in AD-EDMD 
fibroblasts but previously reported in FPLD, XL-EDMD, LGMD and MAD fibroblasts 
(Muchir A, 2002; Novelli et al., 2002; Vigouroux et al., 2001) might well reflect 
the steady-state of nuclear Lamins in EDMD patient cells in a proliferative state or 
G1^G0->G1, rather than artefacts due to the fixation methods. Defective Lamina 
(honeycomb structures) can be induced by serum starvation or over-confluence, 
both in vitro manipulations that end up in exit from the cell cycle to a Go stage, 
where critical interactions between nuclear proteins (Lamin-Lamins, Lamins-other 
partners, or Lamin-independent interactions) may affect key elements in the 
cellular program to re-enter the cell cycle at Gl . 
4.3.3. Implications for disease. 
The structural defects reported here (honeycomb structures) are similar to 
structural defects reported in other diseases caused by mutations in LMNA, namely 
FPLD and LGMDIB (Muchir A, 2002; Vigouroux et al., 2001). While LGMDIB shares 
certain pathophysiological features in common with EDMD, FPLD is distinctly 
different. Its major phenotype is an absence of white fat from the trunk. 
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deposition of white fat around the neck and secondary type I I diabetes. Given 
that FPLD mutations affect adipocytes, whereas EDMD and AD-EDMD mutations 
affect skeletal and cardiac muscle it seems unlikely that the structural changes in 
nuclear envelope morphology and organisation reported here are the primary 
causes of these diseases. The mechanical stress to which adipose tissue is 
exposed it is minimal compared to heart or skeletal muscle. As indicated above, 
the structural changes occur as a result of changes in the organisation and 
association of A-type and B-type Lamins in the cell. These changes give rise to 
structural weakness (as revealed in this study) and altered associations between 
Lamins and chromatin and Lamins and NPCs. Moreover, in a recent investigation of 
the organisation of nuclear envelope proteins in XL-EDMD fibroblasts, the 
formation of honeycomb structures was not an obvious feature; instead the major 
defect observed was a redistribution of Lamin C from the nuclear envelope to the 
nucleoplasm (Markiewicz et al., 2002b). 
The results of this study were very similar to the results reported in other studies. 
Munchir and co-workers also found that in XL-EDMD fibroblasts, the major change 
was a redistribution of A-type Lamins from the nuclear envelope to the 
nucleoplasm. They also reported that mutations in the tail domain promoted the 
formation of honeycomb structures and that B-type Lamins were absent from 
these structures. They did not report the presence of honeycomb structures in 
fibroblasts harbouring LMNA mutations in the rod domain. However, the mild 
fixation conditions (Para-Formaldehyde) used in their study might not reveal a 
honeycomb in these cells (Muchir et al., 2003). Since the phenotypes of the X-linked 
form of EDMD are almost identical to those of AD-EDMD, the current and previous 
findings (Markiewicz et al., 2002b) together with those of (Muchir A, 2002) 
suggests that the presence of honeycomb structures are indicative of underlying 
causes of disease rather being the primary cause. I propose that change in 
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Lamin-Lamin and Lamin-chromatin associations are promoted by all Laminopathy 
mutations. In skeletal muscle, evidence that weakness of the nuclear envelope 
leads to damage has been presented in XL-EDMD patients (Fidzianska et al., 1998; 
Markiewicz et al., 2002b) but is as yet missing in other tissues. The obvious 
explanation for physical weakness of the nuclear envelope promoting pathology in 
skeletal muscle is that in these cells, nuclei are close to the plasma membrane and 
are therefore more acutely subjected to the stress of muscle contractions. In 
adipocytes, nuclei are located centrally in the cell and the cells neither contract nor 
are they motile. Therefore weakness in the nuclear envelope may be 
inconsequential in adipocytes. 
Changes in Lamin-chromatin interactions are likely to affect gene expression 
(Hutchison, 2002). Again I propose that changes in Lamin-chromatin interactions 
are promoted by all Laminopathy mutations. I further propose that altered gene 
expression contribute to pathology in all Laminopathies. However, it seems likely 
that in some Laminopathies altered gene expression is the sole basis of the 
pathology (e.g. FPLD), whereas in other Laminopathies (e.g. EDMD) a 
combination of physical damage caused by a weak nuclear envelope together with 
altered patterns of gene expression both contribute to the pathology. Use of DNA 
expression profiling in model systems should help to address this hypothesis. 
Changes in Lamin-Lamin or Lamin-binding partners associations are likely to result 
in physical weakness of the NE in all EDMD cases but this weakness may only 
contribute to pathology in some cells. With this in mind, and considering the data 
obtained from the cell cycle experiments, I suggest that the physical weakness of 
the NE and the Lamina is particularly important during early differentiation events 
in skeletal and heart muscle during embryogenesis. At this stage, precise 
positioning of the Lamin filaments may orchestrate key control of gene expression 
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directly or indirectly, which may produce a general failure to maintain a 
homogeneous population of "healthy post-mitotic cells". This might be the 
beginning of a chain of events that ends in abnormal development of affected 
tissues in EDMD by the childhood. 
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Figures Chapter 4 
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Figure 4.1 
Exponentially growing cultures of fibroblasts were fixed in methanol: acetone 1:1 
(v/v). Dual labeled cells were imaged sequentially in the FITC and TRITC channels 
using a MicroRadiance 2000 confocal microscope (BioRad). Central sections were 
projected as Individual colors or as merged overlays (a, b and c merged). Control 
is shown in panel a, AD-EDMD fibroblasts are shown in panel b (R249Q) and c 
(R401C). The percentage, of cells displaying normal or honeycomb morphology 
was calculated by counting two hundred cells each on duplicate slides. Scale bar 
= 10 |im. 
A. Double staining with anti-emerin and anti-Lamin C antibodies 
B. Double staining with anti-Lamin C and anti-lamin Bl antibodies 
C. Double staining with anti-lamin B2 and anti-lamin Bl antibodies 
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Figure 4.2 
Exponentially growing cultures of fibroblasts were fixed in 4 % Para-
formaldehyde. Dual labeled cells were imaged sequentially in the FITC and TRITC 
channels using a MicroRadiance 2000 confocal microscope (BioRad). Central 
sections were projected as individual colors or as merged overlays (a, b and c 
merged). Control is shown in panel a, AD-EDMD fibroblasts are shown in panel b 
(R249Q) and c (R401C). The percentage of cells displaying normal or honeycomb 
morphology was calculated by counting two hundred cells each on duplicate 
slides. Scale bar = 10 ^m 
A. Exponentially growing cultures of normal human skin dermal fibroblasts 
were fixed in Para-formaldehyde and double stained with anti-ki67 and 
anti-Lamin C antibodies (a - b). Cells displaying honeycomb morphology 
(one arrow) are present at a very low percentage in normal cultures. 
Normal lamina is shown by a double arrow. 
B. Double staining with anti-emerin and anti-Lamin C antibodies 
C. Double staining with anti-nucleoporin and anti-Lamin C antibodies 
D. Double staining with anti-nucleoporin and anti-lamin Bl antibodies 
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Figure 4.3 
Honeycomb structures distribution in AD-EDMD cell lines. Cells were grown up to 
80% confluence, fixed in methanol: acetone or Para-formaldehyde and stained 
with anti-lamin A/C and lamin C antibodies. Two hundred cells were counted and 
lamins distribution in honeycomb like-structure was recorded as normal or 
honeycomb. 
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Table 4.1 
Proliferation index in EDMD cell lines. Cells were grown to mid passages in DMEM 
supplemented with 10 % NCS and seeded on glass coverslips for Para-
formaldehyde fixation followed by staining with anti-Ki67 antibody. Old passages 
were grown until passage 30 in DMEM supplemented with 10 % NCS. Afterwards, 
serial passages were maintained in DMEM supplemented with 5% NCS/5% FBS 
until a morphological change was observed under a phase contrast microscope. 
Data was recorded by counting 200 cells randomly from duplicate samples in 
duplicate experiments. 
147 
Mid passage 
Passage number % Ki67 + 
HDF 14 79.5 
R249Q 16 62 
R401C 15 82 
R453W 16 70.5 
Old passage (Senescent) 
Passage number % Ki67 + 
38 
25 
45 
25 
10 
0 
40 
0 
Table 4.1 
Figure 4.4 
Expression patterns for lamins A/C (A) and lamin C (B) in control and AD-EDMD 
fibroblasts. Comparison of lamins expression in control (lanes land 7) and AD-
EDMD fibroblasts (lanes 2 and 6: R249Q, lanes 3 and 9: R401C, lanes 4 and 10 
MA6G4 and lanes 5 and 11: TIOPR). Cell extracts were prepared from 
exponentially growing fibroblasts in the presence of NEM. Fifteen ng of total 
protein per lane were resolved on 12% SDS-PAGE, transferred to a membrane and 
immunoblotted with monoclonal antibody Jol2 (A). Samples were run under 
reducing and non-reducing conditions, to resolve intact S-S bonded complexes. As 
a control, parallel blots were probed with antibodies against the ER protein PDI, 
which is known to form disulphide bonded intermediates (C). Molecular weight 
markers are in kDa. 
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Figure 4.5 
Control (HDF), AD-EDMD (R401C) and X-linked cell lines were serum-starved, re-
stinnulated by adding serum to the culture after 5 days of starvation and stained 
after 30 hours of re-stimulation. Control and X-linked cell lines did not show any 
significant change in the amount of honeycomb structures, but AD-EDMD R401C 
showed an increasing amount as it went through proliferation, quiescence and re-
stimulation states. 
A. Control fibroblasts 
B. AD-EDMD R401C 
C. X-Linked-EDMD 
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Figure 4.6 
Human Dermal Fibroblasts from a healthy donor (i), AD-EDMD patient (ii) and X-
linked EDMD patient (ill) were grown until 80% confluence, fixed with 3.5 % para-
formaldehyde and double stained with anti-Lamin C (red) and anti-Heat Shock 
Protein 27 (HSP27) (green). DAPI-containing mounting media was used to label 
the DMA (blue). 
A. Cultures in proliferating state 
B. Cultures in quiescence state 
C. Cultures after 30 hours of serum re-stimulation 
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Figure 4.7 
Human Dermal Fibroblasts from a healthy donor (i), AD-EDMD patient (ii) and X-
linked EDMD patient (iii) were grown until 80% confluence, fixed with 3.5 % para-
formaldehyde and double stained with anti-Lamin C (red) and anti-Heat Shock 
Protein 70 (HSP70) (green). DAPI-containing mounting media was used to label 
the DNA (blue). 
A. Cultures in proliferating state 
B. Cultures in quiescence state 
C. Cultures after 30 hours of serum re-stimulation 
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Figure 4.8 
Expression patterns of HSP70 In proliferating human dermal fibroblasts from AD-
EDMD patients. Cell extracts were prepared from sub-confluent cultures in the 
presence of protein inhibitors cocktail (Sigma) and 5 g of total protein were loaded 
per well. Samples were separated in a 10% SDS-PAGE, transferred and immuno-
blotted with HSP70 antibody. Lane 1: control human dermal fibroblast. Lane 2: 
AD-EDMD mutation R249Q, Lane 3: AD-EDMD patient mutation R401C and Lane 4: 
AD-EDMD patient (unknown mutation). Molecular markers are in kDa. 
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Figure 4.9 
Phase contrast images of human dermal fibroblasts from a healthy donor (HDF, 
control), AD-EDMD and X-linked patients. Images were taken 48 hours after cells 
were seeded at 3xl0'*cells/ml in 60mm culture dishes. Flattened cells are shown 
by arrows. 
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Figure 4.10 
Nesprin 1 is in fibers, co-localizing with a-S-Actin in skin dermal fibroblasts from 
a healthy donor, EDMD patient and healthy rat. Cells were grown until 80% 
confluence, fixed with 3.5% Para-formaldehyde and double stained with anti-
alpha-S-actin (green) and anti-Nesprin 1 N5 antibodies (red) (A), or anti-a -S-
actin (green) and anti-Nesprin 2 CH3 antibodies (red) (B). Co-localization of 
Nesprin 1 (N-terminal) with a-S-Actin fibers, but not Nesprin 2 (N-terminal), is a 
common feature between these species. 
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Figure 4.11 
Human Dermal Fibroblasts from a healthy donor (i), AD-EDMD patient (ii) and X-
linked EDMD patient (lii) were grown until 80% confluence, fixed with 3.5 % 
Para-formaldehyde and double stained with a-S-Actin (green) and anti-nesprin 1 
N5 (N-terminal) (red) antibodies. DAPI-containing mounting media was used to 
label the DNA (blue). 
Cultures in proliferating stage. Control (25.5%) and X-linked EDMD (17.5%) 
fibroblasts presented Nesprin 1 fibers. Only 2.5% (control) and 4% (x-linked 
EDMD) of the cells remain co-expressing Nesprin 1 and a-S-actin. In contrast, 
33.5% of the AD-EDMD cells express Nesprin 1 in fibers and 21% of the total 
cultures co-express both proteins in fibers. 
A. Cultures in quiescent stage. Control (25%) and X-linked EDMD 
(21.5%) fibroblasts presented fibers either for Nesprin 1 or alpha-s-
actin. AD-EDMD dramatically presented all the cells with fibers, 95% of 
the culture co-expressing both proteins. Nesprin 1 relocated to the 
plasma membrane (thicker fibers), and the nucleoplasm in control 
fibroblasts, but no dramatic change was observed in the patient cell 
lines. X-linked EDMD cell line co-expressed both fibers in only 3% of the 
cells under these culture conditions. 
B. Cultures after 30 hours of serum re-stimulation. Control (2%) and X-
linked EDMD (2.5%) fibroblasts presented fibers either for Nesprin 1 or 
a-s-actin, resembling the distribution of fibers at the proliferating stage. 
AD-EDMD presented 12% of the cells co-expressing the fibers. Most of 
the cells in all three cell lines did not express any fiber. 
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Figure 4.12 
Human Dermal Fibroblasts from a healthy donor (i), AD-EDMD patient (ii) and X-
linked EDMD patient (iii) were grown until 80% confluence, fixed with 3.5 % Para-
formaldehyde and double stained with a-S-Actin (green) and anti-Nesprin 2 CHS 
(N-terminal) (red) antibodies. DAPI-containing mounting media was used to label 
the DNA (blue). 
A. Cultures in proliferating stage. Nesprin 2 labeled at the N-terminal had a 
nuclear localization, with diffuse cytoplasmic staining in all cell lines. 
Nuclear staining, was particularly stronger in X-linked EDMD cells. 
Nesprin 2 N-terminal was always absent in the nucleoli. 
B. Cultures in quiescent stage. Nesprin 2 re-organized in the perinuclear 
space in all cell lines (resembling HSP70 distribution?). In control and 
AD-EDMD fibroblast, the nuclear localization remained as in 
proliferating cells, but X-linked EDMD cells appeared, as less Nesprin 2 
was present in the nucleus. Nucleoli lack Nesprin 2. 
C. Cultures after 30 hours of serum re-stimulation. Nesprin 2 re-localized 
back to the cytoplasm and the strong signal was not yet present in the 
X-linked EDMD fibroblasts. 
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Figure 4.13 
Human dermal fibroblasts from a healthy donor and AD-EDMD patient were grown 
at late passages. Cells were grown in 10% NCS until passage 30, then were grown 
in 5%NCS / 5%FBS as far'as they were proliferating and the cells looked healthy. 
Cultures were split 1:3 every time they reached 80% confluence. Cells were 
cultured on 13mm glass coverslips, fixed with 3.5 % Para-formaldehyde and 
double stained with a-S-Actin (green) and Nesprin 1 N5 (red) (A) or Nesprin 2 
CH3 (B) antibodies. (N-terminal of Nesprins 1 and 2 respectively). 
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Figure 4.14 
Human Dermal Fibroblasts from a healthy donor (i), AD-EDMD patient (ii) and X-
linked EDMD patient (iii) were grown until 80% confluence, fixed with 3.5 % 
Para-formaldehyde and double stained with anti-emerin (green) and anti-Nesprin 
1 CI (C-terminal) (red) antibodies. DAPI-containing mounting media was used to 
label the DNA (blue). 
A. Cultures in proliferating state. Nesprin 1 did not form any fibers when 
stained with the, antibody specific for the C-terminal region. Control 
fibroblasts presented a very diffuse staining across the cell. AD-EDMD 
and X-linked cells presented more nucleoplasmic staining than the 
control. 
B. Cultures in quiescence state. Nesprin 1 re-locates to the nuclear ring 
and perinuclear space, in the control and the AD-EDMD cells but it 
stayed diffuse in the X-linked EDMD cell line. 
C. Cultures after 30 hours of serum re-stimulation. Nesprin 1 distributed 
in across the cell in control and X-linked EDMD fibroblasts but AD-EDMD 
cells still conserved the nuclear distribution. 
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Figure 4.15 
Human Dermal Fibroblasts from a healthy donor (I), AD-EDMD patient (ii) and X-
linked EDMD patient (ili) were grown until 80% confluence, fixed with 3.5 % 
Para-formaldehyde and double stained with anti-lamin A/C (green) and anti-
Nesprin 1 CI (C-terminal) (red) antibodies. DAPI-containing mounting media was 
used to label the DNA (blue). 
A. Cultures in proliferating state. Nesprin 1 did not form any fibers when 
stained with the antibody specific for the C-terminal region. Control 
fibroblasts presented a very diffuse staining across the cell. AD-EDMD 
and X-linked cells presented more nucleoplasmic staining than the 
control. 
B. Cultures in quiescent state. Nesprin 1 re-locates to the nuclear ring and 
perinuclear space, in the control and the AD-EDMD cells but it stayed 
diffuse in the X-linked EDMD cell line. 
C. Cultures after 30 hours of serum re-stimulation. Nesprin 1 distributed 
across the cell in control and X-linked EDMD fibroblasts but AD-EDMD 
cells still conserved the nuclear distribution. 
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Figure 4.16 
Human Dermal Fibroblasts from a healthy donor (i), AD-EDMD patient (ii) and X-
linked EDMD patient (ill) were grown until 80% confluence, fixed with 3.5 % Para-
formaldehyde and double stained with anti-emerin- (green) and anti-Nesprin 2 N2 
(C-terminal) (red) antibodies. DAPI-containing mounting media was used to label 
the DNA (blue). 
A. Cultures in proliferating state. Nesprin 2 labeled at the C-terminal 
presented a diffuse pattern of staining across the control cells, but in 
the patient cell lines the staining was stronger in the nucleus, with the 
X-linked cell line presenting the clearer nuclear localization. The absence 
of the C-terminal from the nucleoli was not as dramatic as the absence 
of the N-terminal. 
B. Cultures in quiescent state. Nesprin 2 C-terminal re-organized to the 
nucleus in all ceils, but still was stronger in the X-linked EDMD cell line. 
C. Cultures after 30 hours of serum re-stimulation. Nesprin 2 still 
remained in the nucleus, particularly in the X-linked .EDMD fibroblasts. 
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Figure 4.17 
Human Dermal Fibroblasts from a healthy donor (i), AD-EDMD patient (ii) and X-
linked EDMD patient (iii) were grown until 80% confluence, fixed with 3.5 % 
Para-formaldehyde and double stained with anti-lamin A/C (green) and anti-
Nesprin 2 N2 (C-terminal) (red) antibodies. DAPI-containing mounting media was 
used to label the DNA (blue). 
A. Cultures in proliferating state. Nesprin 2 labeled at the C-terminal 
presented a diffuse pattern of staining across the control cells, but in the 
patient cell lines, the staining was stronger in the nucleus, with the X-
linked cell line presenting the clearer nuclear localization. The absence 
of the C-terminal from the nucleoli was not as dramatic as the absence 
of the N-terminal. 
B. Cultures in quiescent state. Nesprin 2 C-terminal re-organized to the 
nucleus in all cells, but still was stronger in the X-linked EDMD cell line. 
C. Cultures after 30 hours of serum re-stimulation. Nesprin 2 still remained 
in the nucleus, particularly in the X-linked EDMD fibroblasts. 
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Figure 4.18 
Human dermal fibroblasts from a healthy donor and AD-EDMD patient were grown 
at late passages. Cells were grown in 10% NCS until passage 30, then they were 
grown in 5% NCS/ 5% FBS as far as they were proliferating and the cells looked 
healthy. Cultures were split 1:3 every time they reached 80% confluence. Cells 
were cultured on 13mm glass coverslips, fixed with 3.5 % Para-formaldehyde and 
double stained with: 
A. Anti-Ki67 (green) and nesprin 1 N5 (red) antibodies. 
B. Anti-emerin (green) and nesprin 1 CI antibodies. 
C. Anti-laminA-C (green) and nesprin 1 CI antibodies 
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Figure 4.19 
Human dermal fibroblasts from a healthy donor and AD-EDMD patient were grown 
at late passages. Cells were grown in 10% NCS until passage 30, then they were 
grown in 5% NCS / 5% FBS as far as they were proliferating and the cells looked 
healthy. Cultures were split 1:3 every time they reached 80% confluence. Cells 
were cultured on 13mm glass coverslips, fixed with 3.5 % Para-formaldehyde and 
double stained with: 
A. Anti-Ki67 (green) and Nesprin 2 CHS (red) antibodies. 
B. Anti-emerin (green) and Nesprin 2 N2 antibodies. 
C. Anti-laminA-C (green) and Nesprin 2 N2 antibodies 
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Figure 4.20 
Expression patterns for Nesprin 1 in control and AD-EDMD fibroblasts revealed. 
A. Cell extracts were prepared from sub-confluent cultures in the 
presence of protein inhibitors cocktail (Sigma) and 5 jig of total protein 
were loaded per well. Samples were separated in a 10% SDS-PAGE, 
transferred and immuno-blotted with anti-Nesprin 1 CI antibody (C-
terminal). Mid passage (20): Control (lanel), AD-EDMD patients (lanes 
2: R249Q, lane 3: R401C and lane 4: MA6G4). Late passage: Control 
(passage 38, lane 5) and AD-EDMD (passage 42, lane 6). Molecular 
markers are in KD. 
B. Cell extracts were prepared from non-confluence cultures in the 
presence of protein inhibitors cocktail (Sigma) and 5 |j.g of total protein 
were loaded per well. Samples were separated in a 10% SDS-PAGE, 
transferred and immuno-blotted with anti-Nesprin 1 N5 antibody (N-
terminal). Mid passage (20): Control (lanel), AD-EDMD patients (lanes 
2: R249Q, lane 3: R401C and lane 4: MA6G4). Late passage: Control 
(passage 38, lane 5) and AD-EDMD (passage 42, lane 6). Molecular 
markers are in KD. 
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Table 4.2 
Statistical analysis of honeycomb distribution with different fixation methods using 
Wilcoxon-Mann-Whitney Z test for paired-sample using SPSS® 11.1 (for 
Windows®). * represents significance at p<0.05. 
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Difference between 
AD-EDMD Variance Mean Standard Deviation PFA - M:A 
Cell Line PFA M:A PFA M:A PFA M:A Wiicoxon Test (Z) Significance 
HDF 0.0196 0.0385 0.02 0.04 0.14 0.196 (-2.828) 0.005 
R249Q 0.0196 0.138 0.02 0.165 0.14 0.371 (-7.616) 0.0001 
R401C 0.0338 0.147 0.035 0.18 0.184 0.384 (-7.616) 0.0001 
T10PR 0.0587 0.0942 0.0625 0.105 0.242 0.306 (-4.123) 0.0001 
MA6G4 0.0543 0.0861 0.0575 0.095 0.233 0.293 (-3.873) 0.0001 
F02/536 0 0.0099 0 0.01 0 0.099 (-2.000)* 0.046 
PK 0.04536 0.0092 0.0475 0.103 0.219 0.303 (-4.690) 0.0001 
Table 4.2 
5. Chapter five - ARMS- RT-PCR assay for AD-EDMD 
5.1. Introduction 
The importance for medical science of identifying the genetic basis underlying 
individual differences becomes obvious from the observation that individuals 
differ in their susceptibility to disease. The identification of gene variants 
predisposing to certain diseases allows assessment of risk and facilitates 
prevention. Similarly, genetic factors determine the reaction of individuals to 
therapeutic agents, by affecting drug metabolism or the predisposition to develop 
adverse reactions, or their interaction with the environment. Genetically 
determined individual differences are the result of polymorphisms in the genome, 
and complex processes, like susceptibility to most diseases, are often associated 
with variations in quantitative traits that are influenced by multiple gene loci. 
Quantitative trait loci must be polymorphic and their alleles must differ in their 
contribution to the quantitative trait (Rothenburg, Koch-Nolte et al. 2001). 
Considerable progress has been made in mapping quantitative trait loci, but it is 
very difficult to identify the mutations underlying a disease phenotype. Mutations 
with phenotypic consequences may be of two types: 1) mutation affecting coding 
regions, which may result in structural change in the gene product and lead to an 
altered function of the encoded protein. This is the easiest scenario to establish a 
causal link between the mutation and the disease phenotype; 2) mutations within 
non-coding regions, which are frequently more subtle in their effects as they lead 
to quantitative rather than qualitative variation of gene expression. Quantitative 
differences in gene expression are generally assumed to be due to mutations in 
regulatory sequences, such, as promoter or enhancer elements, which directly 
affect the ability of transcription factors to bind target sequences. 
Polymorphisms occurring in promoter regions upstream to the transcriptional 
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start site may potentially affect the process of transcription whereby RNA 
polymerases are recruited to the gene and the nascent mRNA synthesized. 
This complex process requires the coordinated action of multiple regulatory 
proteins through complex protein-DNA and protein-protein interactions 
(Orphanides and Reinberg 2002). Variation in the DNA sequence may potentially 
alter the affinities of existing protein-DNA interactions or, indeed, recruit new 
proteins to bind to the DNA, altering the specificity and kinetics of the 
transcriptional process (Tournamille, Colin et al. 1995; Buckley, Dean et al. 1999; 
Knight, Udalova et al. 1999; Udalova, Richardson et al. 2000). 
The most abundant source of polymorphisms in the mammalian genome is the 
presence of repetitive DNA sequences, due to defects in the DNA repairing 
machinery during nucleic acid replication, and Single Nucleotide Polymorphisms 
(SNPs). DNA repeats can modulate the role of regulatory sequences by 
different mechanisms like differential DNA methylation (Bird 1986; 
Rothenburg, Koch-Nolte et al. 2001) or left-handed Z-DNA formation 
(Schwartz, Rould et al. 1999). 
In diploid organisms, the vast majority of genes are expressed by both alleles, 
but mono-allelic expression has been reported in a growing number 
(Mostoslavsky and Bergman 1997; Ohisson, Tycko et al. 1998). In most of the 
instances investigated so far, the choice of which allele is expressed is 
determined either by the parental origin, as in genomic imprinting, or is 
stochastic, as in the allelic exclusion of the immuno-receptor genes (Chess, 
Simon et al. 1994; Held, Roland,et al. 1995; Nutt, Vambrie et al. 1999). Many 
biological processes are regulated by random selection of expressed alleles. In 
all instances, the choice for the activation or repression of a given allele is 
made at some point in the development of an ancestral cell and then passed on 
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to its descendants by clonal expansion (Ohisson, Tycko et al. 1998). Depending 
on the time-point of the activating or repressing event, this would result in 
fixation of the choice within a whole organism or in a given cell lineage. In the 
case of a disease phenotype, it is not difficult to imagine what the consequences 
for the patient can be if the allele chosen is altered by a polymorphism that 
affects the regulatory sequences. 
Many techniques are currently used for DNA polymorphism genotyping: Micro-
arrays, Real-Time PCR, Nucleotide extension. Cleavage, Ligation-Reaction product 
detection and display, each of them with its own advantages and disadvantages 
(Kirk, Feinsod et al. 2002). One of the simplest and most widely used SNP 
genotyping strategies is allele-specific PCR (AS-PCR). This DNA amplification 
method is based on positioning the 3' base of a PCR primer to match one of SNP 
allele and accurately extend only the correct matched primer under stringent 
conditions (Bottema, Sarkar et al. 1993). AS-PCR has the advantage of combining 
the amplification and detection events, with no additional probes or enzymes 
required. By using standard DNA primers, this approach generally produces false 
priming of certain nucleotides leading to inaccurate genotyping when G:T, C:A, 
A:C or T:G combinations are present if special care is not taken during the design 
process (Huang, Arnheim et al. 1992; Ayyadevara, Thaden et al. 2000). 
The specificity and reliability of DNA primers for AS-PCR have been improved by 
different approaches. Some strategies are based on the template or the primer like 
switching strand for analysis or incorporation of additional mismatches in the allele 
specific primer near the 3' end (Allelic Refractory Mutation Specific-Polymerase 
Chain Reaction: ARMS-PCR) (Newton, Graham et al. 1989). Others use biochemical 
approaches like titration of critical PCR reaction components to near-limiting levels 
(Bottema, Sarkar et al. 1993) or enrichment of target template by PCR prior to 
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adding allele-specific primer (Kaltenbock and Schneider 1998). Some use 
modifications like truncated Taq DNA polymerase (Stoffel fragment) lacking 5' and 
3' exonuclease activity (Lawyer, Stoffel et al. 1993) or nucleotide analogs to 
facilitate conversion at 3' mismatched sites (Day, Bergstrom et al. 1999). The latest 
approaches use apyrase to degrade dNTPs when reaction kinetics is slow at 
mismatched 3' ends (AMASE) (Ahmadian, Gharizadeh et al. 2001) or bidirectional 
Real-Time allele specific PCR with SYBR® Green fluorescent melt curve analysis of 
amplified products (Waterfall and Cobb 2002). Each of these AS-PCR optimization 
strategies has limitations. For example, inclusion of additional ARMS mismatches 
requires careful design, strand selection, and development that can create 
additional primer stability. Titration of reagents and target enrichment are time-
consuming and complicate primer multiplex design. The use of Stoffel fragment 
requires high concentration of enzyme and is not compatible with 5' exonuclease 
probe cleavage in Real-Time AS-PCR. The other variations require either more 
expenses via reagents (probe or enzymes) or specific instrumentation for 
detection analysis. 
Specificity and sensitivity of AS-PCR has recently increased by the introduction of 
a new modified nucleotide termed locked nucleic acid (LNA) at the 3' terminal 
position of the primers. LNA is a nucleic acid analog with a 2'-0, 4'-C methylene 
bridge (Kumar, Singh et al. 1998). This bi-cyclic structure locks the ribose moiety 
into a C3'-endo conformation, which generally increases hybrid Tm when an 
oligonucleotide containing LNA is hybridized with its complement (Nielsen, Singh et 
al. 1999). The use of this innovative family of nucleic acid analog does not restrict to 
AS-PCR, but to a series of applications including immobilized capture probes, 
micro-array analysis, and anti-sense and decoy oligonucleotide technologies 
(Nielsen, Singh et al. 1999; Orum, Jakobsen et al. 1999; Wahlestedt, Salmi et al. 
2000; Braasch and Corey 2001; Crinelli, Bianchi et al. 2002; Jacobsen, Bentzen et 
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al. 2002). 
Individual lamins and integral nuclear envelope proteins have been demonstrated 
to play a crucial role in maintaining the integrity and functionality of the cell 
nucleus, assessed by their involvement in several genetic disorders. Mutations in 
the STA gene (emerin) produce the X-linked form of EDMD, while point mutations 
in the gene encoding for A-type lamins have been linked up to six different clinical 
phenotypes so far (Gisele Bonne and al 2003). Interestingly, other patients with no 
mutation in the LMNA gene have been included within some of the same clinical 
classifications caused by point mutations in A-type lamins (e.g. cardiac, muscle 
involvement (Gisele Bonne and al 2003) and FPLD (Hegele, Yuen et al. 2001)). Despite 
the intensive research in the laminopathies field, focused on biochemical, cellular 
biology and human genetics approaches, no studies so far have been published to 
address the question whether non-coding mutations affecting regulatory elements 
in the LMNA gene or other candidates are involved in this group of muscular 
dystrophies. The biggest attempt to.find novel genes and mutations involved in 
the disease by a functional candidate gene approach has been focused in the 
coding region of candidate genes and has clearly discarded any intronic variations, 
short tandem repeats and frequent SNPs in non-coding regions (Gisele Bonne and 
al 2003). Other studies using genomic DNA sequencing approach found mutations in 
the coding and non- coding regions of LMNBl and LBR genes in FPLD patients 
whose LMNA gene sequence was normal (Hegele, Yuen et al. 2001). In contrast to 
studies by Wehnert et al (see (Gisele Bonne and al 2003)), the Hegele's study has 
considered LMNBl and LBR as potential candidates for FPLD in patients with no 
mutations in LMNA, and has suggested focused analyses on its promoter region. 
The genomic structure of the A-type lamins gene and its promoter region in 
humans, mice and rats has been determined (Lin and Worman 1993; Nakajima 
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and Abe 1995; Tiwari, Muralikrishna et al. 1998). The 5' promoter region have 
been analyzed and several regulatory elements have been found: a GC box that 
can bind to Spl and Sp3 transcription factors (Lin and Worman 1993; Tiwari, 
Muralikrishna et al. 1998; Muralikrishna and Parnaik 2001); a TATA box, and an AP-1 
motif that can bind to c-Jun and c-Fos, which play a key role in the activation of 
the lamin A promoter in Drosophila and Mouse embryonal carcinoma cells 
(Hass, Brach et al. 1991; Muralikrishna and Parnaik 2001); Lamin-Retinoic Acid 
Regulatory Element (L-RARE) (Okumura, Nakamachi et al. 2000) and DNasel 
hypersensitive sites (Nakamachi and Nakajima 2000). In addition, the LMNA locus 
is under the control of at least two promoters: a somatic cell-acting promoter 
(for lamins A and C) and a testis-specific promoter (for lamin C2). Expression 
of lamins A and C is controlled by differential selection of poly-A sites and lamin 
A-specific splicing (Nakajima and Abe 1995). It is well known that LMNA is a 
developmental regulated gene, which appears late in embryogenesis and it is 
up regulated when cells exit the cell cycle (Dyer, Kill et al. 1997). As described 
above, several regulatory elements are involved in this complex process, so it 
becomes obvious that mutations in regulatory elements would have an effect, 
subtle or dramatic, in the expression of A-type lamins, and might determine 
the disease phenotype. The effect of polymorphisms in susceptibility to 
diseases has been demonstrated (Knight, Udalova et al. 1999; Udalova, 
Richardson et al. 2000). 
Since the cell lines used in this study are heterozygous, two related question 
arose during the course of the experimental work: 1); are both alleles of the 
LMNA gene equally transcribed?; 2) is there any haplo-insufficiency at the 
protein levels of the mutant and the wild type A-type lamins as a result of any 
differential allelic transcription? The latter has been addressed in Chapter 
Four. 
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Here I describe the design, optimization and successful use of ARMS primers 
for RT-PCR to detect single nucleotide polymorphisms in cell lines derived from 
AD-EDMD patients with mutations in the rod (R249Q) and tail domain (R401C) 
of lamins A and C (Figure 5.1). Alternative primers design is given (LNA primers) 
in combination with powerful instrumental analysis (CEQ-8000). I found evidence 
for differential allelic expression, apparently not related to the mutations, for both 
lamin A and lamin C mRNA levels in the two cases analyzed. The different pattern 
of expression for the mutations studied may open more questions related to 
whether the disease-associated genetic variants linked to the LMNA gene in AD-
EDMD are functionally important or serve only as a genetic marker with the 
functional locus co-inherited on the polymorphic allele. 
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5.2. Results 
5.2.1. DNA primer design for ARMS-RT-PCR 
Originally, the analysis of the ARMS-PCR products was planned to be carried out 
using a CEQ-8000 genotyper (Beckman-Coulter), so the primers specific for the 
mutations (sense) were all labelled at the 5' end with different fluorescent probes 
in order to differentiate the wild type and mutant alleles on the same sample 
using a multiplex reaction. But technical difficulties with the CEQ-8000 made it 
impossible to separate the fragments by capillary electrophoresis, so the analysis 
had to be performed on agarose gels. The presence of the fluorescent probe at the 
5' end of the primers produced a predictable shift in the mobility of the fragments 
separated in 2% agarose gels. 
Amplification of specific point mutations restricts the strategies to design ARI^ IS-
PCR primers because the mutant base must be at the very 3' end of each primer 
and a mismatch at the second or third last base (Table 5.1). For example, in the 
case of the mutation R249Q (G746A) if the mutant sequence is: 
Mutant Sequence: 5 ' g a t g c g c t g c a g g a a c t g c i 
And the wild type sequence is: 
Wild type Sequence: 5 ' g a t g c g c t g c a g g a a c t g c 3 
Then the mutant primer for the mutant allele will be: 
Mutant Primer: 5 ' g a t g c g c t g c a g g a a c t i c i 
And the wild type primer for the wild type allele will be: 
Wild type Primer: 5 ' g a t g c g c t g c a g g a a c t H c S 
The same approach was used to design the ARMS-PCR primers for the mutation 
R401C (C1201T). With this in mind, using NetPrimer PCR online software I 
designed combinations of ARMS-PCR primers with the optimal theoretical 
parameters to ensure a successful assay. The coding region containing the 
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mutation R249Q (746 G^A) allowed designing of the best possible combination of 
primers for both lamin A and lamin C anti-sense specific probes. Melting points 
(Tm: theoretical temperature, based on the nucleotide composition, at which 50% 
of the primer molecules remain annealed to the template) were very similar 
between the sense and anti-sense primers, GC content was > 55% in all cases 
but not higher than 60%, and secondary structures were kept to the minimum 
(Hairpin, Dimer primers. Cross-linking, Palindromes) (Table 5.1). 
In the case of mutation R401C (1201C->T), the region where the mutation is only 
allowed designing sense primers with 5 - 10°C difference in the Tm regarding their 
anti-sense combinations for both lamin A and C, when keeping the secondary 
structures to the minimum. The high Tm reflects the elevated GC content of this 
region, forcing the design of primers with 70 - 75% of GC in their nucleotide 
composition. In the case of the combination of primers R401C (1201C^T) / Lamin 
C, a relative high number of cross-linking (4) (see Table 5.1) could account for the 
very high stability of this couple of primers at annealing temperatures above the 
Tm in the RT-PCR reaction (Figure 5.6 A - D). 
5.2.2. Annealing temperature optimization for mutations 
R249Q (746 G ->A) and R401C (1201 C->T) using ARMS 
primers 
Every PGR reaction requires optimization in some, if not all of its parameters 
before any Interpretation and conclusion is made out of the data obtained. The 
purpose of the ARMS-RT-PCR assay described in this chapter was to provide a fast, 
reliable and relatively cost effective assay that allows a large number of samples 
to be processed, In search for evidences of differential expression of the LMNA 
alleles in cell lines or clinical samples (blood, biopsies, etc) from heterozygous AD-
EDMD patient. 
Genotyping of mutation R249Q was optimized for both lamin A (Figure 5.2) and 
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Lamin C (Figure 5.3) specific mRNAs by using ARMS DNA primers. In both cases, 
the mutant allele was expressed at lower levels compared to the wild type during 
the entire gradient tested, even at the most stringent temperatures near the Tm. 
The design for the mutant primer proved to be optimum, considering it did not 
produce any amplification in the control mRNA. The combination of primers for the 
lamin C splicing variant produced a neater amplification when compared to the 
Lamin A on,e, where weak background fragments were observed between 500 and 
800 bp, but this should not affect the interpretation of the data. None of the 
primers produced any significant amount of secondary structures empirically 
(dimer primers, hairpins, cross-linking) as no bands were observed below 100 bp. 
PCR products were sequenced to confirm that the amplified fragments were 
specific for the region of interest. In both cases the sequence obtained 
corresponded to the wild type and mutant alleles as expected (data not shown). 
Although this was not a quantitative assay, it is important to note that at optimum 
annealing temperature for each combination of primers, the expression level of 
wild type lamins A and C transcripts was very similar to the control. In addition, 
the level of expression of lamin C transcripts was always higher when compared to 
lamin A. The primer specific for the mutation never produced any amplification in 
the control (Figures 5.2 and 5.3 A) and B) lanes 2 and 6). 
A pilot experiment was set up to analyze whether a multiplex RT-PCR reaction 
could differentiate between wild type and mutant allele using the CEQ-8000. 
Mutation R249Q (746 G^A) and control RNA were amplified for lamin C at 60°C and 
2 n\ of the products were mixed with Di-methylformamide. The mixture was 
injected in the CEQ-8000 and the fragments analyzed for molecular weight and 
fluorescent signal (Figure 5.4). The multiplex reaction did differentiate the wild 
type from the mutant allele, and the reduction pattern is similar to the signal 
obtained by Ethidium Bromide in the agarose gels (Figure 5.3 B, lanes 5 -8). The 
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ratio of wild type/mutant allele is not similar, due to the difference in quantum 
efficiency of the WellRed® D3 dye compared to D4. This should affect only the 
quantitative approach of the assay rather than the qualitative outcome. 
Amplification of the region containing mutation R401C was also successful. In 
contrast to the data obtained for mutation R249Q (lamin A), the combination of 
primers for lamin A and lamin C amplification in R401C produced a neat product in 
almost all the reactions. Lamin A specific primers showed a consistent differential 
amplification during the entire gradient, where the mutant allele in the patient cell 
line was always expressed at a higher level compared to the wild type, even at 
stringent conditions very near to the Tm (Figure 5.5 B) lanes 5 -8). 
Optimization of ARMS-RT-PCR for the combination of primers specific for lamin C 
transcripts in the R401C mutant was intriguing, as the primers produced PCR 
products at very high temperatures, above the Tm for the primers. For this 
combination of oligonucleotides, a first temperature gradient was set up, which 
produced a very slight difference in the level of expression between wild type and 
mutant alleles In the patient (Figure 5.6). When a second, more stringent 
gradient was assayed, a' clear differential pattern was obtained at critical 
temperatures, where the mutant allele was always present at higher level than the 
wild type (Figure 5.7 A - B), but still no inhibition of the annealing efficiency was 
observed. A third gradient was set up, to the maximum possible annealing 
temperature, and at a very stringent temperature (70°C), the same differential 
pattern of expression was observed. Only at 72°C, inhibition of the PCR reaction in 
both the control and the patient samples was observed (Figure 5.7 C - D). As in 
the case of the R249Q mutation, although the assay described here was not 
quantitative, all cases showed that the level of lamin A transcripts was lower than 
for lamin C, both in the control and In the patient. In addition, if the relative 
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amount of amplification products in the patient sample were put together both in 
lamin A and lamin C amplification, the levels were much lower in the patient than 
when compared to the control. A summary of all annealing temperature gradients 
tested are shown in Table 5.2. 
Multiplex reactions were set up to assess the performance of this assay when 
primers specific for the wild type and mutant alleles were present in the same RT-
PCR reaction, under the same conditions. At an optimum temperature (61 "C) 
(Figure 5.7 C lines 9 - 10), the multiplex RT-PCR produced results which were 
consistent with those obtained with separate primers at the same temperature 
(Figure 5.7 C lines 1 - 4), where an overall reduced amount of product was 
obtained. More stringent conditions (72°C) (Figure 5.6 D lines 9 - 1 0 ) affected the 
multiplex reaction in the same fashion as when separate primers were used at this 
temperature (Figure 5.7 D lines 5- 8). The primers specific for the mutation 
produced no amplification of lamin A or Lamin C in the control (Figures 5.5 and 5.6 
A-B and 5.7 A - D, lanes 2 and 6). 
In order to confirm the results using annealing temperature gradients, a final 
assay was set up including the optimum temperature at which no significant 
change in the intensity of the bands In the wild type and mutant alleles was 
obtained. Consistent results to those obtained in the optimization process were 
observed (Figure 5.8 A - B). Negative controls showed that the RNA samples used 
were free of any contaminants and p-Actin primers revealed the presence of an 
equal amount of mRNA in all samples (Figure 5.8 C). 
Another important observation from these data, showed consistently throughout 
the gradients (Figures 5.2 to 5.7), the confirmation assay (Figure 5.8) and the 
multiplex RT-PCR analyzed In the CEQ-8000 (Figure 5.4), is the lower overall 
amount of transcripts In the patients compared to the control, both for lamin A 
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and C. The simplest conclusion from this study is that fewer transcripts mean less 
protein for both lamin A and C, and therefore haploinsufficiency in these patients. 
5.2.3. Alternative primer modifications to detect Single 
Nucleotide Polymorphisms (SNPs) using the CEQ-
8000 series of genotypers. 
Technologies to detect known polymorphisms can be divided in two categories: 
hybridization-based or enzyme-based. Hybridization technologies include Micro-
arrays, Real-Time PCR and AS-PCR. Enzymatic technologies include Nucleotide 
Extension, Cleavage, Ligation Reaction product detection and display. As 
methodologies, all of them have their own advantages and disadvantages. Apart 
from the technical inconveniences, possibly the most limiting aspect of 
genotyping techniques is the elevated cost when a large number of samples are 
processed or when a genome wide scale approach is needed (Kirk, Feinsod et al. 
2002) . 
Optimization process is expensive, especially when genotyping technologies like 
ARMS-PCR (using labelled primers) demand a new primer design due to failure of 
the former primers to discriminate wild type from mutant alleles in heterozygous 
conditions. A new approach to increase the efficiency of primers to differentiate 
between wild type and mutant alleles in heterozygosis is the use of LNA primers 
(Latorra, Arar et al. 2003; Latorra, Campbell et al. 2003; Latorra, Hopkins et al. 
2003) . In addition, different fluorescent probes have been developed to be attached 
to the 5' end of primers. CEQ-8000 automatic DNA sequencers (Beckman- Coulter) 
use very accurate technology to separate labelled DNA fragments (using WellRed® 
dyes) based on size, but its advantage can be boosted if those DNA fragments are 
labelled with different fluorescent probes. Then it is possible to analyse different 
fragments at the same time, or what is more relevant in my case, it can 
differentiate the same fragment generated from different alleles in the same 
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heterozygous sample, With this in mind, and using the technologies available in 
the market, I designed a new generation of primers that allows high discrimination 
efficiency between mutant and wild type alleles in heterozygous samples, and time 
and cost saving during the primer design and optimization processes, by 
combining LNA and CEQ-8000 technologies. 
Using NetPrimer PCR, software online, I then designed primers that included a 
locked nucleic acid (LNA) at the 3' end for the mutant specific primer (at the 
position where the mutant base is in the mutant allele), and for the wild type 
specific primer (at the position where the wild type base Is In the wild type allele) 
(Table 5.3). Then, a different WellRed® fluorescent probe was assigned to each 
primer, so each end contained a marker with different functions: a fluorescent 
probe at the 5' end, which allows discrimination of fragments with very similar 
size (including the same size), and a locked nucleic acid at the 3' end to increase 
allelic specificity. A recent study using cystic fibrosis as a model has shown that 3" 
LNA residues in AS-PCR primers increases allelic specificity and maintains high 
sensitivity compared with DNA primers. Its effect is independent of the specific 
mismatch involved and has proved to work efficiently with plasmid and human 
genomic DNA, with single and multiplex targets and using agarose gel detection or 
Real-Time PCR (SYBR®green) (Latorra, Campbell et al. 2003). 
5.2.4. SNPs analysis in the regulatory elements of the LMNA 
genomic sequence: a bioinformatics approach 
The Nuclear Lamina have been under intense study for nearly 20 years, as an 
effort to understand its biochemical properties, its behaviour during the cell cycle 
and its role in every kind of cell were their presence have been reported. However, 
very little has been done so far to understand how the transcription and 
translation of this important family of type V Intermediate filaments is regulated. 
Since the finding that mutations in A-type lamins were linked to a disease 
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phenotype (AD-EDMD). (Bonne, Di Barletta et al. 1999), a very competitive field of 
research was set up in order to find the biochemical basis of these diseases. 
Although some advance have been made, it is still not clear how these mutations 
can cause the muscle wasting and heart failure observed in the patients and the 
broad range of phenotypes found due to nnutations in the LMNA gene. Most of the 
mutations described to produce laminopathies are heterozygous, and some 
patients presenting the same clinical features do not have mutations in the LMNA 
gene. Taking this evidence together with the unexpected results of the ARMS-RT-
PCR described in this chapter, a fertile ground was set up to formulate an obvious 
question: Are the point mutations in laminopathies. the actual cause of the disease 
phenotype, or they are just a genetic marker that co-segregates with the actual 
disease-causing mutation/s on the polymorphic allele? The complete lack of 
sequencing data in the promoter region of the LMNA gene in patients with any of 
the laminopathies drives one to this hypothesis. 
The first step to present this hypothesis was to analyze the regulatory elements 
contained in the human LMNA gene and map all known SNPs to this regions to 
check for overlap. A total of 99 SNPs were found, divided in 67% transitions and 
32 % transversions; 1.5% of the transitions produced a silent variation (H566H 
[1698C^T]) while 3.1 % of the transversions produced a missense variation 
(R624P [1871G^C]). Interestingly, the SNP at position 1698 G^C, although 
produces a silent amino acid change, it occurs at the last position of the poly-
histidine stretch on exon 10, changing the DNA sequence just at the splicing 
region for lamin C (Figure 5.1). Whether this affects the targeting of the splicing 
machinery and consequently alters the transcriptional ratio of lamin C has yet to 
be proved. 
The LMNA sequence analyzed included 32kb upstream of ATG and 14.5 Kb 
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downstream of the TAA (57.5 Kb in total). This sequence was divided in four 
parts: Promoter region extending for 32360 bp upstream the ATG, genomic 
sequence for the LMNA gene from ATG to TAA (24188bp), downstream sequence 
from codon TAA (Stop), extending for 1013 bp and Full sequence analyzed, 
57561 bp (Figure 5.9), where base's number starts at base number 1 relative to 
the sequence analyzed, not the actual position in chromosome 1. Four algorithms 
for promoter's analysis were used: GRAIL/Prom, TSSW/Prom, GENSCAN/Prom 
and FGenes/Prom. One algorithm analyzed for CgP islands (GRAIL/CpG) and one 
for Transcriptional Sites (Eponine) (Table 5.4). I mapped the predicted regulatory 
elements in the genomic sequence of the LMNA gene and Its SNPs reported to date 
relative to the actual position in chromosome 1, in a graphic representation to 
scale, and classified the regulatory elements as good predictions (Figure 5.10) and 
marginal predictions (Figure 5.11). 
In Figure 5.10 C, two DNA variations overlapped with two CpG islands upstream 
the ATG of LMNA gene. SNP 2502488 was inside the CpG Island 2502232 -
2502642 (at position -32054), and variation 2526065-2526066 was an AG 
deletion In the CpG Island 2526054 -2526282 (at position - 8477). None of the 
SNPs overlapped with any of the good promoters or transcriptional sites predicted 
by NIX analysis in the promoter region. CpG Island 2534300 - 2535000 extended 
from positions - 242 In the promoter region to + 458 into the first exon of LMNA 
gene (Figure 5.10 A and C) but no SNPs hit this region. LMNA genomic sequence 
contained a good predicted TATA (2547829) at intron 1, but no polymorphism was 
found in this area. Curiously, two SNPs were found in coding regions of the LMNA 
gene, specifically In exons 10 (2557366) and 11 (2558283). SNP in exon 10 
produced a silent change of H - H while variation in exon 11 produced a change 
R^P. The region downstream the stop codon of LMNA gene showed one good 
prediction for a TATA box (2559385) but again no SNPs affected this region. Eight 
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polymorphisms were contained up to position + 421 after the TAA codon (Figure 
5.10 D). Marginal .predictions comprised only promoters and they were 
concentrated in the promoter region of the LMNA gene and its introns. None of 
them was hit by any SNP (Figure 5.11 A and C). 
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5.3. Discussion 
In this chapter, two cell lines derived from AD-EDMD patients carrying mutations 
in the rod domain (R249Q/746G^A) and in the tail domain (R401C/1201C->T) of 
the A-type filaments were RNA extracted, together with a control cell line (HDF). 
RNAs were then used as templates to set up a one-step ARMS-RT-PCR assay 
using DNA primers including a mismatch at the third last base to increase 
specificity. The main results show that first, a differential allelic pattern of 
expression is, present and the parental alleles are affected randomly, and 
secondly, the overall amount of A-type lamins transcripts is lower in both patients 
compared to the control. The point mutations in the coding region of the LMNA 
gene in the AD-EDMD fibroblasts studied here may not directly play a critical role 
in the disease phenotype, but rather they could be genomic markers that co-
segregate with the polymorphic allele, with the true mutation/s not yet found, 
forming part of a haplptype not yet described. 
Since the genomic structure of the LMNA gene was published, some studies have 
demonstrated the presence of regulatory elements in the promoter region of this 
gene, including TATA and GC boxes, API motifs, L-RARE (Lamin-Retinoic Acid 
responsive Elements), CpG Islands, DNasel hypersensitive sites and separate 
promoters for tissue specific lamins. Some of these studies have demonstrated 
that these regulatory elements are active, and are involved in the regulation of 
the LMNA gene during different biological processes. Despite these published data, 
genetic studies in laminopathies have mainly focused on searching for mutations in 
the coding region of the LMNA gene, even though some patients presenting the 
disease phenotype do not present any mutation in this gene or any other. So 
where is the lost link? Only one study has included the promoter region in their 
experimental design, while another one suggests, that the promoter region should 
be analyzed. By coincidence, both studies were related to a lipodystrophy 
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phenotype 
5.3.1. Differential allele expression 
The results obtained in the ARMS-RT-PCR could be due to different mechanisms, 
but I will consider first they are due to the point mutations present in exon 10 
(746 G^A) and exon 11(1201 C^T) of the LMNA gene. In both cases, there was 
an overall reduction of the amount of transcripts (adding up the wild type and the 
mutant one) compared to the control. If the lamina self-regulates its levels of 
transcription by interacting with specific elements in the nucleus, then it is 
possible that the mutations affect the nature of these interactions, resulting in a 
reduced amount of transcripts. However, one could expect that this is a general 
mechanism affecting both alleles at the ,same level, unless there is a stochastic 
transcription of A-type lamins alleles. In the case of a general allelic effect, it is 
difficult to explain that mutation 746 G^A reduces more the level of transcription 
in the mutant allele than mutation 1201 C^T does. If the effect is random, so 
alleles are affected independently, how can mutations In the coding regions affect 
the levels of mRNA for each allele? It is unlikely that this observation can be 
explained by RNA stability. Other regulatory mechanisms should be acting 
independently on separate alleles, so the transcriptional ratio differs. 
5.3.2. Searching for the lost link 
Compiling and analyzing information contained in current public databases can 
produce important conclusions on different subjects. Analysis of regulatory 
elements and DNA polymorphisms not reported in the literature to date for the 
genomic sequence of the human LMNA gene revealed interesting results. First, a 
number of DNA variations (SNPs and small deletions) are present in the promoter 
region of the LMNA gene, even inside regulatory elements not. too far from the 
transcriptional site. Secondly, and probably more important at this point due to 
184 
clinical and experimental evidence, is the finding that 2 % (2 out of 99 SNPs) of 
the polymorphisms analyzed were present in coding regions of the LMNA gene. 
Fifty percent (1 out of 2 SNPs) were missense mutations (624R^P), and the other 
50% were silent (566H^H), but a DNA variation occurred at the splicing region for 
lamin C. The finding that naturally occurring DNA variations (SNPs) are present in 
the promoter, introns and exons of the LMNA gene acquire more importance since 
several recent studies have demonstrated that a single SNP could not be 
associated to a particular disease risk or, phenotype. Instead, the combination 
of several SNPs on a single chromosome, the haplotype, offered greater 
power to identify causative loci for a particular clinical feature (Drysdale, McGraw 
et al. 2000; Bader 2001; Judson and Stephens 2001). 
One of the most intensely studied regulatory mechanisms that can influence 
the ultimate impact of a given protein on its biological role is transcriptional 
regulation. SNPs within regulatory elements in the promoter region of different 
genes have been shown to affect transcriptional activity (Zhang, Ye et al. 1999; 
Zhang, Stroud et al. 1999; Harendza, Lovett et al. 2003). Functional studies in MMPs 
have determined that a SNP (G^A) at position -1575 influenced transcriptional 
activity: the -1575 G allele functioned as an enhancer, whereas the -1575A 
allele (SNP) reduced transcriptional activity significantly by affecting the 
binding of the estrogen receptor to this region (Harendza, Lovett et al. 2003). A 
number of naturally occurring DNA variants in human genes have been identified 
and found to be associated with susceptibility/progression of several diseases. 
For example SNPs in the matrix metalloproteinase (MMP) gene promoters 
have been associated to ovarian cancer (MMP-1, SNP -1607) (Rutter, Mitchell et 
al. 1998), coronary atherosclerosis (MMP-9, SNP -1562) (Zhang, Ye et al. 1999) 
and MMP-12, SNP -82 (Jormsjo, Ye et al. 2000)). Other regulatory mechanisms 
that can affect a given biological process act at translational level. 
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As mentioned above, one of the most intriguing observations in the 
laminopathies field is that some patients with clinical symptoms of AD-EDMD, 
Cardiomyopathy with Conduction Defects and Familial Lipodystrophy have no 
mutations in the LMNA gene or in the coding region of any other functional 
candidate protein. Where is the disease-causing factor then? Some authors 
have suggested that there must bei other genes involved In these genetically 
heterogeneous diseases, but the fact is that none has been found so far, despite 
the combined effort of different laboratories worldwide. Combining the results 
from the ARMS-RT-PCR with the SNPs analysis, or more explicitly, the differential 
allelic expression and reduced A-type lamins transcripts in AD-EDMD, together 
with the polymorphism's distribution in the human LMNA gene and Its regulatory 
elements, I demonstrated that this gene deserves more attention regarding the 
study of the events that regulate its transcription, and perhaps, its translation. It 
would be Interesting to test the possibility that the high-order array of the nuclear 
lamin and/or lamina subunits, tetramers or dimers control regulatory mechanisms 
of transcription or translation, like some members of the microtubule filaments 
system do, where tubulin monomers not bound to the filaments regulate their level 
of translation (Barlow, Gonzalez-Garay et al. 2002; Hari, Yang et al. 2003). 
However, to understand regulatory mechanisms, we first need to know very well 
the structural details of the Intermediate filaments structure. Current structural 
biology technologies have to be pushed to the limits and more innovative 
approaches have to be developed to unravel the biochemical dynamics of the 
assembly-disassembly processes of nuclear lamins in vitro and in vivo (Strelkov, 
Herrmann et al. 2003). Certainly, these findings may bring more insights to 
understand how subtle changes in the composition of the nuclear lamina can 
affect the assembly-disassembly processes in disease, and whether a subtle 
"defective" lamina unable to Interact with its putative binding-partners in vivo can 
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be the answer to the already intriguing laminopathies. 
The ARMS-RT-PCR design described in this chapter using DNA primers have 
proved to be a robust assay that can be used to easily screen a large number of 
patients to further statistically determine whether the differential allelic pattern of 
expression is a common feature in laminopathies, or whether it is a particular 
pattern in the AD-EDMD clinical phenotype. In addition, it showed the importance 
of testing mRNA as a template rather than genomic DNA when point mutations 
are present in the coding region of the affected genes, especially when the 
disease phenotype is not 100% linked to mutations. Extra analysis can be made 
to determine whether the mutation affects the levels of transcription, and which 
regulatory elements are affected, and ultimately translation, giving a deficiency or 
over-expression of a disease-related protein. 
Here I have described a preliminary set of data that may bring light to the 
increasing concern in the laminopathies research community regarding the multi-
factorial nature of this group of disorders. Nearly 60 different mutations in the 
LMNA gene have been reported so far, linked up to six different clinical phenotypes 
of muscle involvement, cardiomyopathy or lipodystrophy, plus an aging related 
disorder (Progeria). Only the latter one, where a large region in the tail domain 
specific for lamin A is affected, can explain the disease phenotype from a 
structural-biochemical point of view. Most of the other laminopathies involve point 
mutations along the filament, where biochemical studies have failed to 
demonstrate a dramatic disruption of putative protein-protein interaction of A-
type lamins with their binding partners, and/or direct involvement of lamins in 
gene expression. 
Finally, I consider it is important to highlight the potential use of LNA primers in 
Allelic-Specific RT-PCR including fluorescent probes at the 5' end. The analysis of 
187 
these amplification products, in a CEQ-8000 genotyper may give birth to a new 
high-throughput technology where mismatch combinations in genetic disorders 
can quickly be highly discriminated and semi-quantified, and bring back the 
reliability of the AS-PCR as a SNP genotyping technique (Latorra, Hopkins et al. 
2003). 
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Figures Chapter 5. 
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Figure 5.1 
mRNA and protein sequence for LMNA gene, showing the position of the mutations 
studied, relative to the exons and protein domains. 
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Table 5.1 
Summary of the DNA primers designed using NetPrimer software. 
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Figure 5.2 
ARMS-RT-PCR in one step for lamin A. R249Q (746G^A) AD-EDIVID cell line was 
grown until 80% confluent on 90 mm culture dishes and RNA was extracted. After 
treatment with DNase-RNase free, 0.1 \ig of total RNA was used to set up RT-PCR 
reactions. A temperature gradient was set up to standardize the optimal annealing 
temperature for the primers specific for the wild type and mutant Lamin A alleles. 
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Figure 5.3 
ARMS-RT-PCR in one step for lamin C. R249Q (746 G^A) AD-EDMD cell line was 
grown until 80% confluent on 90 mm culture dishes, and RNA was extracted. After 
treatment with DNase-RNase free, 0.1 ^g of total RNA was used to set up RT-PCR 
reactions. A temperature gradient was set up to standardize the optimal 
annealing temperature for the primers specific for the wild type and mutant 
alleles. 
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Figure 5.4 
Multiplex ARMS-RT-PCR was analyzed in the automatic DNA Sequencer CEQ-8000 
(Beckman-Coulter). PGR products were cleaned up using Qiagen's Clean Up 
System and 2 ml of each reaction were injected in the capillary system. A) Lamin 
C multiplex ARMS-RT-PCR for mutation R249Q (746 G^A). B) Control Human 
Dermal Fibroblasts. Legend: Blue line: wild type primer labelled with 
WellRed®D4; Green: mutant primer labelled with WellRed®D3. 
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Figure 5.5 
ARMS-RT-PCR in one step for lamin A. R401C (1201C^T) AD-EDMD cell line was 
grown until 80% confluent on 90 mm culture dishes, and RNA was extracted. After 
treatment with DNase-RNase free, 0.1 ng of total RNA was used to set up RT-PCR 
reactions. A temperature gradient was set up to standardize the optimal annealing 
temperature for the primers specific for the wild type and mutant alleles. 
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Figure 5.6 
ARMS-RT-PCR in one step for lamin C (Gradient 1). R401C (1201C^T) AD-
EDMD cell line was grown until 80% confluent on 90 mm culture dishes and 
RNA was extracted. After treatment with DNase-RNase free, 0.1 of total 
RNA was used to set up 25ix\ RT-PCR reactions. A temperature gradient was 
set up to standardize the optimal annealing temperature for the primers 
specific for the wild type and mutant alleles. 
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Figure 5.7 
ARMS-RT-PCR in one-step for lannin C. Gradient 2 (A and B) and Gradient 3 (C 
and D). R401C (1201C-^T) AD-EDMD cell line was grown until 80% confluent on 
90 mm culture dishes and RNA was extracted. After treatment with DNase-RNase 
free, 0.1 of total RNA was used to set up RT-PCR reactions. A temperature 
gradient was set up to standardize the optimal annealing temperature at higher 
values for the primers specific for the wild type and mutant alleles. 
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Table 5.2 
Summary of the gradients used to optimize the annealing temperatures in the 
ARMS-RT-PCR. 
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Annealing Temperature Gradients 
Mutation 
R249Q 
R249Q 
Primer 
Specific 
Lamin C 
Lamin A 
Gradient 
Number 
Temperature Gradient 
52.00 52.30 52.90 53.70 54.80 56.30 
50.00 50.30 51.10 52.00 53.40 55.20 
59.40 60.50 61.30 61.80 62.00 
57.20 58.90 60.20 61.10 61.80 62.00 
R401C Lamin C 
R401C Lamin A 
50.00 50.30 51.00 51.80 53.10 54.70 56.60 58.20 59.30 60.20 60.80 61 00 
62.00 62.20 62.70 63.30 64.30 65.50 66.80 68.00 68.80 69.40 69.90 70.00 
59.00 59.30 6 0 . 1 0 1 ^ 1 62.70 64.60 I H 68.60 H H 71.00 71.80 
55.00 55.30 55.90 56.70 57 80 59.30 61.00 62.40 63.50 54.30 64 80 65.00 
Legend: Temperatures used 
Table 5.2 
Figure 5.8 
Summary of ARMS- RT-PCR in one-step for lamins A and C in both patients 
studied using optimum annealing temperatures. R249Q (A) and R401C (B) AD-
EDIMD cell lines were grown until 80% confluent on 90 mm culture dishes, and 
RNA was extracted. After treatment with DNase-RNase free, 0.1 iig of total RNA 
was used to set up 25 i^l RT-PCR reactions. Optimum annealing temperatures 
were used, considering the results obtained with each gradient. p-Actin primers 
(C, lines 1-4) were used as a positive control to assess the equal amount of the 
mRNA in each PGR reaction and to monitor the high efficiency of the assays. 
Negative controls were used to confirm no contaminants were influencing the 
quality of the data (C, lines 5 - 8 ) . 
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Table 5.3 
Summary of the RT-PCR results in control and AD-EDMD cell lines. 
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Primers 
Cell Line LMNA Mutation Wild type Mutant 
Control HDF None OK No Reaction 
AD-EDMD 1 R249Q ff Ji 
AD-EDMD 2 R401C u ft 
Table 5.3 
Table 5.4 
Summary of the LNA primers designed using NetPrimer software. 
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Figure 5.9 
NIX analysis of DNA regulatory elements in the LMNA gene using the algorithms 
available at the Human Genome Mapping Project (HGMP), Cambridge, UK. LMNA 
gene was searched in the OMIM database at the National Centre for 
Biotechnology Information (NCBI, USA, www.ncbi.nlm.nih.gov ). LMNA sequence 
included 32kb upstream ATG and 14.5 Kb downstream the TAA, 57.5 Kb in total. 
Four algorithms for promoter's analysis were used: GRAIL/Prom, TSSW/Prom, 
GENSCAN/Prom and FGenes/Prom. One algorithm analyzed for CgP islands 
(GRAIL/CpG) and one for Transcriptional Sites (Eponine). Numbering of bases 
starts at base number 1 , regarding the sequence analyzed, not the position in 
chromosome 1. 
A. Promoter region extending for 32360 bp upstream the ATG 
B. Genomic sequence for the LMNA gene from ATG to TAA (24188bp) 
C. Downstream sequence to codon TAA (Stop), extending for 1013 bp 
D. Full sequence analyzed, 57561 bp. 
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Table 5.5 
NIX analysis summary. 
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Algorithm Statistical 
Value 
Prediction at: Strand Quality of 
prediction 
Absolute positon 
in Chromosome 1 
GrailEXP CpG islands 1 
2 
3 
ratio 0.79 
ratio 0.65 
ratio 0.84 
N/A 
N/A 
N/A 
positive 
positive 
positive 
good 
good 
excellent 
2502232-2502642 
2526054-2526282 
2534300-2534998 
Transcriptional Sites 1 
2 
score= 0.998 
score= 0.998 
2502354 
2534725 
positve 
positve 
good 
good 
2502354 
2534725 
Grail Promoter 1 score 73 N/A N/A good 2530728 
TSSW Promoter 1 LDF-16.46 2502428 positive good 2502428 
2 LDF-4 .47 2511068 positive marginal 2511068 
3 LDF - 4,62 2512338 positive marginal 2512338 
4 LDF-6 .27 2521818 positive marginal 2521818 
5 LDF - 8.74 2524884 positive marginal 2524884 
6 LDF-5.41 2527090 positive marginal 2527090 
7 LDF - 5.41 2527942 positive marginal 2527942 
8 LDF-4 .97 2530441 positive marginal 2530441 
9 LDF - 5.42 2530914 positive marginal 2530914 
10 LDF - 5.08 2533485 positive marginal 2533485 
11 LDF -13.65 2534301 positive good 2534301 
12 LDF-4.51 2538072 positive marginal 2538072 
13 LDF-4 .15 2541909 positive marginal 2541909 
14 LDF - 8.62 2543443 positive marginal 2543443 
15 L D F - 11.10 2547829 positive good 2547829 
16 LDF - 4.57 2548361 positive marginal 2548361 
17 LDF-4.41 2550729 positive marginal 2550729 
18 LDF - 12.07 2559385 positive good 2559385 
Genescan Promoter 1 score - 4.91 2534295 positive marginal 2534295 
Fgenes Promoter 1 score 0.67 2548331 positive marginal 2548331 
Table 5.5 
Figure 5.10 
SNPs mapping in the genomic sequence for the human LMNA gene, overlapping 
the regulatory elements with high scores (good or excellent only) analyzed in 
figure 5.9. Chromosome 1 full sequence (NT079487) was searched in the OMIM 
database at the National Centre for Biotechnology Information (NCBI, USA, 
www.ncbi.nlm.nih.gov;), and used to assign the actual position for each base in 
the genomic sequence of the LMNA gene analyzed (see Materials and Methods 
Chapter for methodology used). 
A. LMNA gene genomic sequence from ATG to TAA only 
B. Entire genomic sequence used for NIX analysis 
C. Promoter region analyzed 
D. 3' region analyzed 
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Figure 5.11 
SNPs mapping in the genomic sequence for the human LI^NA gene, overlapping 
the regulatory elements with high scores (marginal scores only) analyzed in figure 
5.9. Chromosome 1 full sequence (NT079487) was searched in the OMIM database 
at the National Centre for Biotechnology Information (NCBI, USA, 
www.ncbi .n lm.nih.gov). and used to assign the actual position for each base in 
the genomic sequence of the LMNA gene analyzed (see Materials and Methods 
Chapter for methodology used). 
A. LMNA gene genomic sequence f rom ATG to TAA only 
B. Entire genomic sequence used for NIX analysis 
C. Promoter region analyzed 
D. 3' region analyzed 
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6. C h a p t e r S i x - G e n e r a l D i s c u s s i o n 
6 .1 . O v e r v i e w 
The aims of this study were, f irst, to unravel the biochemical basis of the 
Emery-Dreifuss Muscular Dystrophy (EDMD), through the characterization of 
the interaction between emerin and lamins in vitro and in vivo, and secondly, 
to fur ther investigate the functional consequences of the missense mutations 
in the LMNA gene and the loss of Emerin in Autosomal Dominant and XL-
EDMD respectively. 
The molecular interaction between Emerin and lamins became evident only 
after mutations in the LMNA gene were linked to Autosomal Dominant EDMD 
(Bonne et al., 1999). Previously, mutations in the STA gene were strongly linked 
to a genetically di f ferent but clinically close disorder: the XL-EDMD (Bione et 
al., 1994). The direct interaction between Emerin and lamins was initially 
demonstrated using in vitro biochemical assays like bio-molecular interaction 
analysis (BIA) combined with the use of monoclonal antibodies (Clements et al., 
2000), overlay assays (Vaughan et al., 2001) and Yeast Two-Hybrid System 
(Sakaki etal . , 2001). 
To study the molecular basis of the clinically related EDMD phenotypes (AD and 
X-L), I used di f ferent approaches: f irst, a yeast two-hybr id assay and 
transfect ion exper iments using f luorescent-tagged proteins (Emerin and A-
type lamins) were used to fur ther characterize the molecular interaction 
between Emerin and lamins, second, in vivo functional studies using 
established EDMD patient cell lines to analyze the structural weakness of the 
nuclear lamina and the possible involvement of other proteins/mechanisms in 
the disease phenotype, and th i rd , a genomics-bioinformatics analysis of AD-
EDMD cell lines and the LMNA gene to investigate the functional role of the 
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missense mutat ions in muscular dystrophies and/or other laminopathies. 
6 . 2 . A n c h o r a g e of E m e r i n to t h e n u c l e a r e n v e l o p e a n d its 
s t r u c t u r a l a n d functional role. 
A classical yeast two-hybrid assay was set up using Emerin as a bait protein and a 
panel of lamin-deletion mutants (a kind gift from Dr. Howard Worman) that can be 
divided in different groups: Head-Coil, Coil-Tail or Tail. Head domain of lamins 
adopts a highly flexible conformation with low content of secondary structure and it 
is believed to play an important role in filament assembly (Herrmann, 1996). The 
rod domain forms a characteristic a-helix responsible for the coiled-coil associations 
(Stuurman et al., 1998) and the globular tail domain forms an Ig-like structure, 
where theoretical crystallographic data suggest it should be arranged in such a 
way that remains on the outside part of the core of the 10 -13 nm filament 
(Strelkovetal., 2003). 
Two different approaches of the yeast two-hybrid system were used in the current 
study: a qualitative (p-galactosidase lift assay) and a semi-quantitative assay 
(liquid p-galactosidase assay). Although the interaction between Emerin and 
lamins was demonstrated by other in vitro assays (Clements et.al., 2000; Sakaki et 
al., 2001; Vaughan et al., 2001), the interacting domain of lamins was not known and 
complementary methods were required to conclusively demonstrate the protein-
protein interaction between these proteins. The in vitro approach of the two 
versions of the yeast two-hybrid system showed that Emerin interacts with all 
lamins, but more strongly with lamin B l , and that the region of. interaction is the 
globular Tail domain. Transfection experiments using cell lines derived from XL-
EDMD patients (lacking Emerin) showed that lamin B l is stably localized with 
Emerin at the NE when A-type lamins are mislocalized to aggregates, which 
suggest that the retention of Emerin at the NE in fibroblasts may be due to its 
stable interaction with B-type lamins. This observation is different from what 
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happens in HeLa cells, where miss-localization of A-type lamins to aggregates 
causes retraction of Emerin to the ER (Vaughan et al., 2001). Previous studies 
suggested Emerin interacts preferentially with Lamin A (B-type lamins were not 
included in the study) (Clements et al., 2000) while interaction with lamin Bl is weaker 
(Fairley et al., 1999). Our previous study showed that lamin C interacts 
preferentially with Emerin in immuno-precipitation assays (Vaughan et al., 2001). 
Preferential interaction with Lamin A, specifically its globular tail domain, with Emerin 
was reported by (Sakaki et al., 2001), but they did not include B-type lamins in their 
study. Most probably, these results are a consequence of the biochemical nature of 
the assays used, and they represent a dynamic range of interactions between 
Emerin and lamins at different stages of the cell cycle and/or the presence of 
different multi-protein functional complexes between Emerin and A and B-type 
lamins during G1-S/G2 or quiescence. 
6 .3 . P a r a d i g m of t h e l a m i n a a s s e m b l y : W h o g o e s f i rs t? 
Previous studies showed that the presence of B-type lamins is obligatory for the 
correct alignment of A-type lamins at the lamina (Dyer et al., 1999). To our surprise, 
the AD-EDMD cell lines studied showed A-type lamins homo-filaments that 
segregated from B-type lamins, forming honeycomb-like structures, where 
Emerin, but not nuclear pores, co-localized. These structures were present in all 
cell lines studied, independently of the position of the mutation in the filament. 
These imply that mutations in the rod and tail domain abrogate the dependency 
for lamins A/C to form filaments through association with B-type lamins but do not 
disrupt A-type lamins-Emerin associations or probably with other lamin-associated 
proteins. I t is possible that both types of mutation lead to weakened interactions 
between A-type and B-type lamins, which causes them to polymerize 
independently. Alternatively, the mutations alter A-type lamins interaction with 
chromatin, which may in turn promote the assembly of homotypic A-type lamin 
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fi laments in areas of tine nucleus depleted of chromatin. Another possibility might 
be influenced by the heterotypic nature of the interactions at the lamina between 
A and B-type lamins, where A-type lamin dimers/tetramers, with a random 
mixture of wild type and mutant monomers, fail to produce the precise 
conformational arrangement to associate with the pre-determined B-type lamina 
and/or with other inner nuclear membrane or nucleoplasmic components. This 
failure drives now the segregation of A-type lamin homo-filaments into one pole of 
the nuclei, deprived of heterochromatin. As demonstrated by my data, 
honeycombs appearance depends on the fixation method used. The stronger the 
fixation method, the higher the amount of honeycombs observed. Accordingly the 
methanol: acetone fixation method revealed the higher amount of honeycombs. 
The most strikingly observation related to the weakness of the nuclear lamina in 
laminopathies is the fact that these abnormal structures (honeycombs) are only 
present in a subpopulation of cells, and they appear to be related to a certain 
nuclear checkpoint at the exit/re-entrance to the cell cycle, where A-type lamins 
and their associated partners fail to interact appropriately. I t seems these 
structures occur naturally, as honeycombs were observed in normal human 
fibroblasts (Figure 4.2 A) , and in XL-EDMD cell lines expressing ectopic wild type 
Lamin A (Figure 3.7 GFP-Lamin A v) . But after growth inhibition by serum 
starvation, and back to a proliferative state, AD-EDMD cultures showed an 
increase in the amount of this nuclear abnormality, which is morphologically 
different from the bubbling structures observed in other studies in that 
honeycombs always appear depleted in heterochromatin. 
Opposite to their cytoplasmic relatives, mutations in the nuclear intermediate 
fi laments do not appear to disrupt drastically the structures of the filaments. 
Immuno-labell ing experiments in biopsies and cell lines derived from X-L or AD-
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EDMD patients have failed to show dramatic changes in the structure of the 
nuclear lamina as mutations in the cytoplasmic intermediate filaments does to the 
cytoskeleton. Maybe this is a direct consequence of the difference in length of the 
lamins rod and tail domain compared to the intermediate filaments type I, I I I I I 
and IV, and the differential effect of the mutations in the thermodynamic 
properties of the different intermediate filament types, ultimately representing 
the different roles of each group of this family of proteins. 
6.4 . D i rec t e v i d e n c e of o t h e r ce l lu la r e v e n t s in EDMD. 
Although conclusive linkage studies have demonstrated that missense mutations in 
A-type lamins are associated to different laminopathies (X-L, AD and AR-EDMD, 
LGMDIB, CMD-CD, MAD), it has been systematically reported the presence of all 
these clinical phenotypes with no mutation in the LMNA gene. This observation 
reveals the genetic diversity of these conditions, and has lead researchers to 
search for new candidate genes. In this effort, several genes have been studied 
using a functional candidate approach, and partially unique exonic DNA-variations 
causing amino acid exchanges have been found in FLPC (filamin C), LAP2, NRM 
(nurim) and DDX16 (DEAD/H-box polypeptide) (Bonne G and al, 2003). 
Nesprins are a new family of spectrin-repeat proteins first reported in a search for 
markers of differentiation in vascular smooth muscle cells (VSMCs), and their 
pattern of distribution was revealed to be complex in the model cell lines studied 
(Zhang et al., 2001). In my study, dermal fibroblasts derived from AD-EDMD 
patient showed a high percentage of proliferating cells where Nesprin 1 (N-
terminus) co-localized with a-S-Actin fibres, compared to the controls (normal 
human and rat fibroblasts) and XL-EDMD fibroblasts. Additionally, Nesprin 1 
amino-terminal re-distributes during exit/re-entrance in normal cells towards the 
plasma membrane, but in AD-EDMD fibroblast, the Nesprin fibres are thicker 
than in control and XL-EDMD fibroblasts, while the latter ones resist redistribution 
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of Nesprin 1 amino-terminal in a significant sub-population of cells. In contrast, 
Nesprin 1 carboxy-terminal and Nesprin 2 (remained nucleoplasmic and absent in 
nucleoli) were never organized in any kind of fibre, but Nesprin 2 re-distributed to 
the perinuclear space in the same fashion than Heat Shock Protein 70 (HSP70) 
during metabolic stress. This observation was made on separate samples; hence I 
suggest that to establish co-localization of HSP70 and Nesprin 2 during 
quiescence and re-entrance to the cell cycle induced by serum deprivation, a 
double immuno-labelling experiment is needed. In addition, proliferating cultures 
of human fibroblasts harbouring mutations in the LMNA gene present a senescent 
phenotype compared to the controls, and an altered pattern of Nesprins 
expression, suggesting a possible implication of Nesprins in EDMD an revealing a 
possible involvement of an aging process in vitro. 
Recent investigations have demonstrated that Nesprin l a N-terminal binds 
Emerin and its C-terminal binds Lamin A in vitro (Mislow et al., 2002), and that they 
must interact in vivo (Muchir et al., 2003). Combining these published data, the re-
arrangement of Nesprins at the exit/re-entrance of the cell cycle in my study 
(particularly in AD-EDMD) and previous studies of lamins interaction with other 
proteins, the role of nucleoplasmic intermediate filaments in the nuclear 
metabolism appear to be very dynamic. More experimental evidence are 
"drawing" the picture of tertiary or quaternary complexes involving lamins and 
their interacting partners, where a diverse range of molecular arrangements of 
lamin filaments (dimers/tetramers/f i lament units) can ultimately define key 
nuclear processes, and could explain better the complex genetic background in 
laminopathies (Figure 6.1). New experimental approaches could be used to test 
for tert iary complexes involving lamins, for example the yeast-three hybrid 
system. 
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6 . 5 . L a m i n o p a t h i e s : O n e d i s e a s e a n d d i f ferent m e c h a n i s m s or 
d i f fe rent pathologies? 
About 50% of mutations affecting membrane receptors and macromolecular 
complexes are dominant, which may result from the absence of substantial activity 
from one allele at a given locus and suggest that half of the normal amount of 
active product is insufficient to maintain a normal phenotype (Jimenez-Sanchez et al., 
2001). This phenomenon is called haploinsufficiency (HI) , where most of the known 
examples are compatible with survival of the individual. Dominant negative effect 
is a different phenomenon that refers to cases where a mutant protein interferes 
with the action of the normal one. Both, HI and dominant negative effect are 
direct consequence of heterozygosity and play a dominant role. As a consequence 
of heterozygosity, an imbalance in the concentration of the subcomponents of a 
protein-protein complex can be deleterious by different biochemical mechanisms, 
which is called the balance hypothesis (Papp et al., 2003). 
Heterozygosity is the most common distribution pattern of mutations in the LMNA 
gene in laminopathies. ARMS-RT-PCR is able to detect imbalance in the relative 
amount of transcripts produced by the wild type and mutant alleles in AD-EDMD 
fibroblasts. Both cell lines studied show an overall transcript imbalance compared 
to the controls. In the case of the cell line with mutation R249Q, more transcripts 
from the wild type allele are present in proliferating cultures, while in the cell line 
harbouring the mutation R401C, the effect is the opposite. In both cases, lamina 
fi lament-units (dimers/tetramers) are assembled in such a way that for example, 
in the case of the dimers, at least 50% of the complexes will contain mutant 
monomers that could affect the higher assembly arrangements (tetramers, 
microfibrils, protofibrils, fi laments) of the nuclear lamina. I t is difficult to envision 
how missense mutations (leading to single point mutations) in the coding regions of 
any gene can give rise to the effect observed in the AD-EDMD cell lines. In the case 
of less mutant transcript, one could expect this can be due to mRNA degradation by 
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a process called nonsense-mediated decay (Frischmeyer and Dietz, 1999), like 
occurs in the intermediate filament associated protein Desmoplakin (OMIM125647) 
or collagens (OMIM120140). But in the other sample, where the mutant allele is 
expressed at a higher level compared to the wild type, mRNA stability can not be a 
possible explanation. However, both effects can be explained if unreported 
mutations affect the regulatory region/s of the LMNA gene. Before any further 
conclusions are drawn from these data, extended studies are needed. Firstly, more 
AD-EDMD and other laminopathies patients have to be tested to demonstrate that 
this is a dominant pattern produced by heterozygous conditions, and to support 
statistically any outcome. Secondly, a new primer design using LNA primers 
instead of the standard ARMS-primers, combined with a quantitative method 
would result in a more robust study. I propose that the fastest way to test clinical 
samples is isolating total RNA from blood after appropriate ethical approval. 
Accordingly, bioinformatics analysis in parallel to the ARMS-RT-PCR data indicates 
that naturally occurring DNA variations in the LMNA gene (Single Nucleotide 
Polymorphisms, SNPs or di-nucleotide deletions occurring in more than 1 % of the 
normal population) could affect its regulatory regions. The most surprising finding 
of this analysis is that, f irst, there are SNPs in or nearby the regulatory elements 
of the LMNA gene, which combined with intragenic variations can give rise to a 
defined haplotype (e.g. AD-EDMD, MAD, LGMDIB); second, 2% of the SNPs 
occurred in coding regions, where 50% were silent but affected the splicing region 
for lamin C, and the other 50% was missense, changing an arginine for a proline 
in exon 11 of the tail domain specific for Lamin A. While the ARMS-RT-PCR data 
was not conclusive, the bioinformatics approach is supporting the design of 
further experiments to first, determine whether an imbalance is a dominant 
pattern in laminopathies, secondly to search for mutations in the regulatory 
region of the LMNA gene, and third, to encourage new studies to unravel the 
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regulatory mechanisms that control transcription and translation of nuclear 
intermediate fi laments. 
6 .6 . S k i n D e r m a l F ib rob las t a s e x p e r i m e n t a l model to unrave l 
t h e ce l l b iology of muscular dystrophies. 
Skin Dermal Fibroblasts have delivered a valuable model to study the cellular and 
molecular mechanisms underlying laminopathies, and became the first tool to 
study the effect of single point mutations in the biology of non-cytoplasmic 
intermediate fi laments. But as any model has shown its own limitations, and has 
failed to explain the role of lamins in heart and skeletal muscle disorders. Not all 
laminopathies involve skin abnormalities from the pathological point of view (only 
MAD and the other progeria disorders), and sometimes it is difficult to extrapolate 
experimental data to the actual disease. New ethical approaches will need to be 
taken in order to investigate why A-type lamins, which are present in almost all 
known differentiated cells, are related to tissue-specific diseases, and whether 
they affect directly the patterns of gene expression, produce weakness of the 
nuclear envelope, or both. 
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Figures Chapter 6. 
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Figure 6.1. 
Cartoon summarizing the general hypothesis that considers multi-complexes of 
proteins involving lamins, emerin, nesprins, actin and others in the regulation of 
several cell processes including gene regulation or chromating re-organization 
that influence the final commitment of certain cell types towards a normal 
differentiation process or to a disease phenotype. 
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